

# 2018 HEDIS Aggregate Report for Michigan Medicaid

October 2018





# **Table of Contents**

| 1. | Executive Summary1-1                              |
|----|---|
|    | Introduction1-1                                   |
|    | Summary of Performance                            |
|    | Limitations and Considerations1-6                 |
| 2. | How to Get the Most From This Report2-1           |
|    | Introduction                                      |
|    | Michigan Medicaid Health Plan Names2-1            |
|    | Summary of Michigan Medicaid HEDIS 2018 Measures  |
|    | Data Collection Methods                           |
|    | Data Sources and Measure Audit Results2-5         |
|    | Calculation of Statewide Averages                 |
|    | Evaluating Measure Results                        |
|    | Interpreting Results Presented in This Report     |
|    | Measure Changes Between HEDIS 2017 and HEDIS 2018 |
| 3. | Child & Adolescent Care                           |
|    | Introduction                                      |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |
| 4. | Women—Adult Care4-1                               |
|    | Introduction                                      |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |
| 5. | Access to Care                                    |
| •  | Introduction                                      |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |
| 6. | Obesity   |
| U. | Introduction                                      |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |
| 7  |   |
| 7. | Pregnancy Care                                    |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |
| 0  |   |
| 8. | Living With Illness                               |
|    | Introduction                                      |
|    | Summary of Findings                               |
|    | Measure-Specific Findings                         |



| 9.  | Health Plan Diversity9-1                                      |
|-----|---|
|     | Introduction  |
|     | Summary of Findings   |
| 10. | Utilization   |
|     | Introduction  |
|     | Summary of Findings 10-1                                      |
|     | Measure-Specific Findings                                     |
| 11. | HEDIS Reporting Capabilities—Information Systems Findings     |
|     | HEDIS Reporting Capabilities—Information Systems Findings11-1 |
| 12. | Glossary  |
|     | Glossary  |
| Ap  | endix A. Tabular ResultsA-1                                   |
|     | Child & Adolescent Care Performance Measure Results           |
|     | Women—Adult Care Performance Measure Results                  |
|     | Access to Care Performance Measure Results                    |
|     | Obesity Performance Measure Results                           |
|     | Pregnancy Care Performance Measure Results                    |
|     | Living With Illness Performance Measure Results               |
|     | Health Plan Diversity and Utilization Measure Results         |
| Ap  | oendix B. Trend TablesB-1                                     |
| Ap  | oendix C. Performance Summary Stars C-1                       |
|     | Introduction  |
|     | Child & Adolescent Care Performance Summary Stars C-2         |
|     | Women—Adult Care Performance Summary StarsC-5                 |
|     | Access to Care Performance Summary Stars                      |
|     | Obesity Performance Summary Stars                             |
|     | Pregnancy Care Performance Summary Stars                      |
|     | Living With Illness Performance Summary Stars C-10            |
|     | Utilization Performance Summary Stars C-14                    |



## Introduction

During 2017, the Michigan Department of Health and Human Services (MDHHS) contracted with 11 health plans to provide managed care services to Michigan Medicaid enrollees. MDHHS expects its contracted Medicaid health plans (MHPs) to support claims systems, membership and provider files, as well as hardware/software management tools that facilitate valid reporting of the Healthcare Effectiveness Data and Information Set (HEDIS<sup>®</sup>)<sup>1-1</sup> measures. MDHHS contracted with Health Services Advisory Group, Inc. (HSAG), to calculate statewide average rates based on the MHPs' rates and evaluate each MHP's current performance level, as well as the statewide performance, relative to national Medicaid percentiles.

MDHHS selected HEDIS measures to evaluate Michigan MHPs within the following eight measure domains:

- Child & Adolescent Care
- Women—Adult Care
- Access to Care
- Obesity
- Pregnancy Care
- Living With Illness
- Health Plan Diversity
- Utilization

Of note, measures in the Health Plan Diversity and Utilization measure domains are provided within this report for information purposes only as they assess the health plans' use of services and/or describe health plan characteristics and are not related to performance. Therefore, most of these rates were not evaluated in comparison to national percentiles, and changes in these rates across years were not analyzed by HSAG for statistical significance.

The performance levels are based on national percentiles and were set at specific, attainable rates. MHPs that met the high performance level (HPL) exhibited rates that were among the top in the nation. The low performance level (LPL) was set to identify MHPs with the greatest need for improvement. Details describing these performance levels are presented in Section 2, "How to Get the Most From This Report."


<sup>&</sup>lt;sup>1-1</sup> HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA).



In addition, Section 11 ("HEDIS Reporting Capabilities—Information Systems Findings") provides a summary of the HEDIS data collection processes used by the Michigan MHPs and the audit findings in relation to the National Committee for Quality Assurance's (NCQA's) information system (IS) standards.<sup>1-2</sup>

## **Summary of Performance**

Figure 1-1 compares the Michigan Medicaid program's overall rates with NCQA's Quality Compass<sup>®</sup> national Medicaid HMO percentiles for HEDIS 2018, which are referred to as "national Medicaid percentiles" throughout this report.<sup>1-3</sup> For measures that were comparable to national Medicaid percentiles, the bars represent the number of Michigan Medicaid Weighted Average (MWA) measure indicator rates that fell into each national Medicaid percentile range.



<sup>&</sup>lt;sup>1-2</sup> National Committee for Quality Assurance. *HEDIS*<sup>®</sup> 2018, *Volume 5: HEDIS Compliance Audit<sup>TM</sup>: Standards, Policies and Procedures.* Washington D.C.

<sup>&</sup>lt;sup>1-3</sup> Quality Compass<sup>®</sup> is a registered trademark for the National Committee for Quality Assurance (NCQA).



Of the 59 reported rates that were comparable to national Medicaid percentiles, none of the MWA rates fell below the national Medicaid 25th percentile. Most MWA rates (about 80 percent) ranked at or above the national Medicaid 50th percentile, indicating high performance statewide compared to national standards. A summary of MWA performance for each measure domain is presented on the following pages.

## Child & Adolescent Care

For the Child & Adolescent Care domain, six of 18 (33.3 percent) MWA rates demonstrated significant increases from HEDIS 2017 to HEDIS 2018. Of note, three of the six rates that increased were *Childhood Immunization Status* measure indicators (*Combinations 7, 9,* and *10*), and the rate increases were due primarily to relatively small increases in the rotavirus and hepatitis A vaccination rates. Nearly all MWA rates (83 percent) ranked at or above the national Medicaid 50th percentile, with two rates ranking at or above the national Medicaid 75th percentile. The *Well-Child Visits in the First 15 Months of Life* measure was an area of strength in this domain, as the MWA was both above the 75th percentile and demonstrated a significant increase. Of note, the *Appropriate Testing for Children With Pharyngitis* rate had a significant increases.

Conversely, the MWA rates for *Appropriate Treatment for Children With Upper Respiratory Infection* and *Follow-Up Care for Children Prescribed ADHD Medication* fell below the national Medicaid 50th percentile, suggesting opportunities for improvement. However, caution should be used when comparing the HEDIS 2018 rates for the *Follow-Up Care for Children Prescribed ADHD Medication* measure indicators to national Medicaid percentiles and prior years' rates due to changes to the technical specifications for this measure for HEDIS 2018.

#### Women—Adult Care

For the four MWA rates in the Women—Adult Care domain that could be compared to national Medicaid percentiles or prior years' rates, *Cervical Cancer Screening* and *Chlamydia Screening in Women—Ages 16 to 20 Years* demonstrated a significant improvement from HEDIS 2017 to HEDIS 2018. Further, all four MWA rates ranked at or above the national Medicaid 50th percentile, with three of the rates ranking at or above the national Medicaid 75th percentile, indicating overall positive performance in the areas of cervical cancer and chlamydia screenings for women.

#### Access to Care

For the Access to Care domain, two of nine (22.2 percent) measure indicators, *Adults' Access to Preventive/Ambulatory Health Services—Ages 65+ Years* and *Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis*, demonstrated significant increases from HEDIS 2017 to HEDIS 2018. Of note, the *Adults' Access to Preventive/Ambulatory Health Services—Ages 65+ Years* measure indicator demonstrated an area of strength in this domain, with the MWA rate ranking above the national



Medicaid 75th percentile and three MHPs demonstrating significant increases from HEDIS 2017 to HEDIS 2018. Additionally, seven of nine (77.8 percent) MWA rates ranked at or above the national Medicaid 50th percentile, indicating positive performance in the area of Access to Care compared to national standards.

Conversely, six of nine (67 percent) MWA rates within the Access to Care domain demonstrated significant decreases from HEDIS 2017 to HEDIS 2018. Of note, the MWA rates for *Children and Adolescents' Access to Primary Care Practitioners*—*Ages 12 to 24 Months* and *Adults' Access to Preventive/Ambulatory Health Services*—*Ages 20 to 44 Years* fell below the national Medicaid 50th percentile and demonstrated significant decreases. In addition, 10 of 11 (90.9 percent) MHPs' rates and the MWA demonstrated significant decreases from HEDIS 2017 to HEDIS 2018 for the *Adults' Access to Preventive/Ambulatory Health Services*—*Ages 20 to 44 Years* and *Total* measure indicators. These declines in performance suggest opportunities for improving access to preventive/ambulatory services for adults ages 20 to 64 years and access to primary care physicians for children and adolescents.

## **Obesity**

The four MWA rates included in the Obesity domain demonstrated a significant improvement from HEDIS 2017 to HEDIS 2018. Additionally, all four MWA rates ranked at or above the national Medicaid 50th percentile, demonstrating overall positive performance related to obesity. Of note, the MWA rate for *Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total* ranked at or above the national Medicaid 75th percentile, and the MWA rate for *Adult BMI Assessment* ranked at or above the national Medicaid 90th percentile.

## **Pregnancy Care**

One of the two measure indicators in the Pregnancy Care domain, *Prenatal and Postpartum Care*—*Postpartum Care*, ranked at or above the national Medicaid 50th percentile. For the *Prenatal and Postpartum Care*—*Timeliness of Prenatal Care* measure, the MWA rate fell below the national Medicaid 50th percentile and demonstrated a significant decline from HEDIS 2017 to HEDIS 2018, indicating opportunities for improvement in prenatal care.

## **Living With Illness**

For the Living With Illness domain, 11 of 21 (52.4 percent) MWA rates that could be compared to national Medicaid percentiles or prior years' rates demonstrated significant improvement from HEDIS 2017 to HEDIS 2018. Of note, four MHPs and the MWA demonstrated significant improvement of more than 5 percentage points for the *Antidepressant Medication Management* measure indicators. Please note, caution should be used when comparing the 2018 rates for *Antidepressant Medication Management* to national Medicaid percentiles and prior years' rates due to changes to the technical measure specifications for HEDIS 2018.



Additionally, 16 of 21 (76.2 percent) MWA rates ranked at or above the national Medicaid 50th percentile, with nine MWA rates ranking at or above the national Medicaid 75th percentile. The following nine rates demonstrated positive performance: *Comprehensive Diabetes Care—Eye Exam* (*Retinal*) *Performed* and *Medical Attention for Nephropathy*; *Medication Management for People With Asthma—Medication Compliance 50%—Total* and *Medication Compliance 75%—Total*; *Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit* and *Discussing Cessation Medications*; *Antidepressant Medication Management—Effective Acute Phase Treatment* and *Effective Continuation Phase Treatment*; and *Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications*.

Conversely, only one MWA rate, *Comprehensive Diabetes Care—HbA1c Poor Control* (>9.0%), demonstrated a significant decline in performance from HEDIS 2017 to HEDIS 2018. Further, the MWA rates for *Asthma Medication Ratio—Total*, *Diabetes Monitoring for People With Diabetes and Schizophrenia*, *Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia*, and *Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARBs* and *Diuretics* fell below the national Medicaid 50th percentile, indicating opportunities for improvement for these measures.

#### Health Plan Diversity

Although measures under this domain are not performance measures and are not compared to national Medicaid percentiles, changes observed in the results may provide insight into how select member characteristics affect the MHPs' provision of services and care. The *Race/Ethnicity Diversity of Membership* measure shows that the HEDIS 2018 statewide rates for different racial/ethnic groups were fairly stable across years, with less than 1 percentage point difference between HEDIS 2017 and HEDIS 2018 rates for all racial/ethnic groups.

For the *Language Diversity of Membership* measure, HEDIS 2018 rates remained similar to prior years, with Michigan members reporting that they used English as the preferred spoken language for healthcare and preferred language for written materials, with less than 1 percentage point difference between HEDIS 2017 and HEDIS 2018.

#### Utilization

For the *Emergency Department Visits—Total* and *Outpatient Visits—Total* indicators, the Michigan average remained steady from HEDIS 2016 to HEDIS 2018 for the number of visits per 1,000 member months.<sup>1.4</sup> Because the measure of outpatient visits is not linked to performance, the results for this measure are not comparable to national Medicaid percentiles.

<sup>&</sup>lt;sup>1-4</sup> For the *Emergency Department Visits* indicator, a lower rate indicates better performance (i.e., low rates of emergency department visits suggest more appropriate service utilization).



## **Limitations and Considerations**

Due to changes in Michigan's managed care program in 2016, HAP Midwest Health Plan's (MID's) eligible population decreased substantially. Therefore, HSAG suggests that caution be exercised when comparing MID's HEDIS 2018 rates to prior years' results.



## 2. How to Get the Most From This Report

# Introduction

This reader's guide is designed to provide supplemental information to the reader that may aid in the interpretation and use of the results presented in this report.

## **Michigan Medicaid Health Plan Names**

Table 2-1 presents a list of the Michigan MHPs discussed within this report and their corresponding abbreviations.

| MHP Name                         | Abbreviation |
|----------------------------------|--------------|
| Aetna Better Health of Michigan  | AET          |
| Blue Cross Complete of Michigan  | BCC          |
| Harbor Health Plan               | HAR          |
| McLaren Health Plan              | MCL          |
| Meridian Health Plan of Michigan | MER          |
| HAP Midwest Health Plan          | MID          |
| Molina Healthcare of Michigan    | MOL          |
| Priority Health Choice, Inc.     | PRI          |
| Total Health Care, Inc.          | THC          |
| UnitedHealthcare Community Plan  | UNI          |
| Upper Peninsula Health Plan      | UPP          |

#### Table 2-1—2018 Michigan MHP Names and Abbreviations

## **Summary of Michigan Medicaid HEDIS 2018 Measures**

Within this report, HSAG presents the Michigan Medicaid Weighted Average (MWA) (i.e., statewide average rates) and MHP-specific performance on HEDIS measures selected by MDHHS for HEDIS 2018. These measures were grouped into the following eight domains of care: Child & Adolescent Care, Women—Adult Care, Access to Care, Obesity, Pregnancy Care, Living With Illness, Health Plan Diversity, and Utilization. While performance is reported primarily at the measure indicator level, grouping these measures into domains encourages MHPs and MDHHS to consider the measures as a whole rather than in isolation and to develop the strategic and tactical changes required to improve overall performance.



Table 2-2 shows the selected HEDIS 2018 measures and measure indicators as well as the corresponding domains of care and the reporting methodologies for each measure. The data collection or calculation method is specified by NCQA in the *HEDIS 2018 Volume 2 Technical Specifications*. Data collection methodologies are described in detail in the next section.

| Performance Measures   | HEDIS Data Collection<br>Methodology |
|--|--------------------------------------|
| Child & Adolescent Care  |                                      |
| Childhood Immunization Status—Combinations 2–10  | Hybrid                               |
| Well-Child Visits in the First 15 Months of Life—Six or More Visits  | Hybrid                               |
| Lead Screening in Children   | Administrative                       |
| Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life   | Hybrid                               |
| Adolescent Well-Care Visits  | Hybrid                               |
| Immunizations for Adolescents—Combination 1 (Meningococcal, Tdap)  | Hybrid                               |
| Appropriate Treatment for Children With Upper Respiratory Infection  | Administrative                       |
| Appropriate Testing for Children With Pharyngitis  | Administrative                       |
| Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase<br>and Continuation and Maintenance Phase  | Administrative                       |
| Women—Adult Care   |                                      |
| Breast Cancer Screening  | Administrative                       |
| Cervical Cancer Screening  | Hybrid                               |
| Chlamydia Screening in Women—Ages 16 to 20 Years, Ages 21 to 24 Years, and Total   | Administrative                       |
| Access to Care   |                                      |
| Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 24<br>Months, Ages 25 Months to 6 Years, Ages 7 to 11 Years, and Ages 12 to 19 Years   | Administrative                       |
| Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years,<br>Ages 45 to 64 Years, Ages 65 Years and Older, and Total  | Administrative                       |
| Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis  | Administrative                       |
| Obesity  |                                      |
| Weight Assessment and Counseling for Nutrition and Physical Activity for<br>Children/Adolescents—BMI Percentile Documentation—Total, Counseling for<br>Nutrition—Total, and Counseling for Physical Activity—Total | Hybrid                               |
| Adult BMI Assessment   | Hybrid                               |

#### Table 2-2—Michigan Medicaid HEDIS 2018 Required Measures



| Performance Measures  | HEDIS Data Collection<br>Methodology |
|---|--------------------------------------|
| Pregnancy Care  |                                      |
| Prenatal and Postpartum Care—Timeliness of Prenatal Care and Postpartum Care  | Hybrid                               |
| Living With Illness   |                                      |
| Comprehensive Diabetes Care—Hemoglobin A1c (HbA1c) Testing, HbA1c Poor<br>Control (>9.0%), HbA1c Control (<8.0%), Eye Exam (Retinal) Performed,<br>Medical Attention for Nephropathy, and Blood Pressure Control (<140/90 mm<br>Hg) | Hybrid                               |
| Medication Management for People with Asthma—Medication Compliance<br>50%—Total and Medication Compliance 75%—Total   | Administrative                       |
| Asthma Medication Ratio—Total   | Administrative                       |
| Controlling High Blood Pressure   | Hybrid                               |
| Medical Assistance With Smoking and Tobacco Use Cessation—Advising<br>Smokers and Tobacco Users to Quit, Discussing Cessation Medications, and<br>Discussing Cessation Strategies   | Administrative                       |
| Antidepressant Medication Management—Effective Acute Phase Treatment and Effective Continuation Phase Treatment   | Administrative                       |
| Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are<br>Using Antipsychotic Medications   | Administrative                       |
| Diabetes Monitoring for People With Diabetes and Schizophrenia  | Administrative                       |
| Cardiovascular Monitoring for People With Cardiovascular Disease and<br>Schizophrenia   | Administrative                       |
| Adherence to Antipsychotic Medications for Individuals With Schizophrenia   | Administrative                       |
| Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARBs, Diuretics, and Total   | Administrative                       |
| Health Plan Diversity   |                                      |
| Race/Ethnicity Diversity of Membership  | Administrative                       |
| Language Diversity of Membership—Spoken Language Preferred for Health<br>Care, Preferred Language for Written Materials, and Other Language Needs   | Administrative                       |
| Utilization   |                                      |
| Ambulatory Care—Total (Per 1,000 Member Months)—Emergency Department<br>Visits—Total and Outpatient Visits—Total  | Administrative                       |
| Inpatient Utilization—General Hospital/Acute Care   | Administrative                       |
| Use of Opioids From Multiple Providers (Per 1,000 Members)—Multiple<br>Prescribers, Multiple Pharmacies, and Multiple Prescribers and Multiple<br>Pharmacies  | Administrative                       |
| Use of Opioids at High Dosage (Per 1,000 Members)   | Administrative                       |



# **Data Collection Methods**

#### Administrative Method

The administrative method requires that MHPs identify the eligible population (i.e., the denominator) using administrative data, derived from claims and encounters. In addition, the numerator(s), or services provided to the members in the eligible population, are derived solely using administrative data collected during the reporting year. Medical record review data from the prior year may be used as supplemental data. Medical records collected during the current year cannot be used to retrieve information. When using the administrative method, the entire eligible population becomes the denominator, and sampling is not allowed.

#### **Hybrid Method**

The hybrid method requires that MHPs identify the eligible population using administrative data and then extract a systematic sample of members from the eligible population, which becomes the denominator. Administrative data are used to identify services provided to those members. Medical records must then be reviewed for those members who do not have evidence of a service being provided using administrative data.

The hybrid method generally produces higher rates because the completeness of documentation in the medical record exceeds what is typically captured in administrative data; however, the medical record review component of the hybrid method is considered more labor intensive. For example, the MHP has 10,000 members who qualify for the *Prenatal and Postpartum Care* measure and chooses to use the hybrid method. After randomly selecting 411 eligible members, the MHP finds that 161 members had evidence of a postpartum visit using administrative data. The MHP then obtains and reviews medical records for the 250 members who did not have evidence of a postpartum visit using administrative data. Of those 250 members, 54 were found to have a postpartum visit recorded in the medical record review. Therefore, the final rate for this measure, using the hybrid method, would be (161 + 54)/411, or 52.3 percent, a 13.1 percentage point increase from the administrative only rate of 39.2 percent.

#### **Understanding Sampling Error**


Correct interpretation of results for measures collected using HEDIS hybrid methodology requires an understanding of sampling error. It is rarely possible, logistically or financially, to complete medical record review for the entire eligible population for a given measure. Measures collected using the HEDIS hybrid method include only a sample from the eligible population, and statistical techniques are used to maximize the probability that the sample results reflect the experience of the entire eligible population.

For results to be generalized to the entire eligible population, the process of sample selection must be such that everyone in the eligible population has an equal chance of being selected. The HEDIS hybrid method prescribes a systematic sampling process selecting at least 411 members of the eligible



population. MHP may use a 5 percent, 10 percent, 15 percent, or 20 percent oversample to replace invalid cases (e.g., a male selected for *Postpartum Care*).

Figure 2-1 shows that if 411 members are included in a measure, the margin of error is approximately  $\pm$  4.9 percentage points. Note that the data in this figure are based on the assumption that the size of the eligible population is greater than 2,000. The smaller the sample included in the measure, the larger the sampling error.





As Figure 2-1 shows, sample error decreases as the sample size gets larger. Consequently, when sample sizes are very large and sampling errors are very small, almost any difference is statistically significant. This does not mean that all such differences are important. On the other hand, the difference between two measured rates may not be statistically significant but may, nevertheless, be important. The judgment of the reviewer is always a requisite for meaningful data interpretation.

## **Data Sources and Measure Audit Results**

MHP-specific performance displayed in this report was based on data elements obtained from the Interactive Data Submission System (IDSS) files supplied by the MHPs. Prior to HSAG's receipt of the MHPs' IDSS files, all of the MHPs were required by MDHHS to have their HEDIS 2018 results examined and verified through an NCQA HEDIS Compliance Audit.



Through the audit process, each measure indicator rate reported by an MHP was assigned an NCQAdefined audit result. HEDIS 2018 measure indicator rates received one of seven predefined audit results: *Reportable (R), Small Denominator (NA), Biased Rate (BR), No Benefit (NB), Not Required (NQ), Unaudited (UN),* and *Not Reported (NR).* The audit results are defined in Section 12.

Rates designated as *NA*, *BR*, *NB*, *NQ*, *UN*, or *NR* are not presented in this report. All measure indicator rates that are presented in this report have been verified as an unbiased estimate of the measure. Please see Section 11 for additional information on NCQA's Information System (IS) standards and the audit findings for the MHPs.

# **Calculation of Statewide Averages**

For all measures, HSAG collected the audited results, numerator, denominator, rate, and eligible population elements reported in the files submitted by MHPs to calculate the MWA rate. Given that the MHPs varied in membership size, the MWA rate was calculated for most of the measures based on MHPs' eligible populations. Weighting the rates by the eligible population sizes ensured that a rate for an MHP with 125,000 members, for example, had a greater impact on the overall MWA rate than a rate for the MHP with only 10,000 members. For MHPs' rates reported as *NA*, the numerators, denominators, and eligible populations were included in the calculations of the MWA rate. MHP rates reported as *BR*, *NB*, *NQ*, *UN*, or *NR* were excluded from the MWA rate calculation. However, traditional unweighted statewide Medicaid average rates were calculated for utilization-based measures to align with calculations from prior years' deliverables.

# **Evaluating Measure Results**

## National Benchmark Comparisons

#### **Benchmark Data**

HEDIS 2018 MHP and MWA rates were compared to the corresponding national HEDIS benchmarks, which are expressed in percentiles of national performance for different measures. For comparative purposes, HSAG used the most recent data available from NCQA at the time of the publication of this report to evaluate the HEDIS 2018 rates: NCQA's Quality Compass national Medicaid HMO percentiles for HEDIS 2017, which are referred to as "national Medicaid percentiles" throughout this report. Of note, rates for the *Medication Management for People With Asthma—Medication Compliance 50%—Total* measure indicator were compared to the NCQA's Audit Means and Percentiles national Medicaid HMO percentiles for HEDIS 2017.

Additionally, benchmarking data (i.e., NCQA's Quality Compass and NCQA's Audit Means and Percentiles) are the proprietary intellectual property of NCQA; therefore, this report does not display any actual percentile values. As a result, rate comparisons to benchmarks are illustrated within this report using proxy displays.



#### **Figure Interpretation**

For each performance measure indicator presented in Sections 3 through 8 of this report, the horizontal bar graph figure positioned on the right side of the page presents each MHP's performance against the HEDIS 2018 MWA (i.e., the bar shaded gray); the high performance level (HPL) (i.e., the green shaded bar), representing the national Medicaid 90th percentile; the P50 bar (i.e., the blue shaded bar), representing the national Medicaid 50th percentile; and the low performance level (LPL) (i.e., the red shaded bar), representing the national Medicaid 25th percentile.

For measures for which lower rates indicate better performance, the 10th percentile (rather than the 90th percentile) and the 75th percentile (rather than the 25th percentile) are considered the HPL and LPL, respectively. An example of the horizontal bar graph figure for measure indicators reported administratively is shown below in Figure 2-2.




Figure 2-2—Sample Horizontal Bar Graph Figure for Administrative Measures



For performance measure rates that were reported using the hybrid method, the "ADMIN%" column presented with each horizontal bar graph figure displays the percentage of the rate derived from administrative data (e.g., claims data and supplemental data). The portion of the bar shaded yellow represents the proportion of the total measure rate attributed to medical record review, while the portion of the bar shaded light blue indicates the proportion of the measure rate that was derived using the administrative method. This percentage describes the level of claims/encounter data completeness of the MHP data for calculating a particular performance measure. A low administrative data percentage suggests that the MHP relied heavily on medical records to report the rate. Conversely, a high administrative data percentage indicates that the MHP's claims/encounter data were relatively complete for use in calculating the performance measure indicator rate. An administrative percentage of 100 percent indicates that the MHP did not report the measure indicator rate using the hybrid method. An example of the horizontal bar graph figure for measure indicators reported using the hybrid method is shown in Figure 2-3.




Figure 2-3—Sample Horizontal Bar Graph Figure for Hybrid Measures



#### **Percentile Rankings and Star Ratings**

In addition to illustrating MHP and statewide performance via side-by-side comparisons to national percentiles, benchmark comparisons are denoted within Appendix B of this report using the percentile ranking performance levels and star ratings defined below in Table 2-3.

| Star Rating   | Performance Level   |  |
|---|---|--|
| Star Nating   |   |  |
| ****  | At or above the national Medicaid 90th percentile   |  |
| <b>At or above the national Medicaid 75th percentile but below the national Medicaid 90th percentile</b>                  |   |  |
| ***   | At or above the national Medicaid 50th percentile but below the national Medicaid 75th percentile |  |
| <b>At or above the national Medicaid 25th percentile but below the national Medicaid 50th percentile</b>                  |   |  |
| ★ Below the national Medicaid 25th percentile   |   |  |
| NA NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate. |   |  |

| Table 2-3—Percentile | Ranking | Performance Levels |
|----------------------|---------|--------------------|
|                      | nanning |                    |

Measures in the Health Plan Diversity and Utilization measure domains are designed to capture the frequency of services provided and characteristics of the populations served. With the exception of *Ambulatory Care—Total (Per 1,000 Member Months)—Emergency Department Visits, Use of Opioids From Multiple Providers*, and *Use of Opioids at High Dosage*, higher or lower rates in these domains do not necessarily indicate better or worse performance. A lower rate for *Ambulatory Care—Total (Per 1,000 Member Months)—Emergency Department Visits* may indicate a more favorable performance since lower rates of emergency department services may indicate better utilization of services. Further, measures under the Health Plan Diversity measure domain provide insight into how member race/ethnicity or language characteristics are compared to national distributions and are not suggestive of plan performance.

For the *Ambulatory Care—Total (Per 1,000 Member Months)—Emergency Department Visits* measure, HSAG inverted the star ratings to be consistently applied to this measure as with the other HEDIS measures. For example, the 10th percentile (a lower rate) was inverted to become the 90th percentile, indicating better performance.

Of note, MHP and statewide average rates were rounded to the second decimal place before performance levels were determined. As HSAG assigned star ratings, an em dash (—) was presented to indicate that the measure indicator was not required and not presented in previous years' HEDIS deliverables; or that a performance level was not presented in this report either because the measure did not have an applicable benchmark or a comparison to benchmarks was not appropriate.



## Performance Trend Analysis

In addition to the star rating results, HSAG also compared HEDIS 2018 MWA and MHP rates to the corresponding HEDIS 2017 rates. HSAG also evaluated the extent of changes observed in the rates between years. Year-over-year performance comparisons are based on the Chi-square test of statistical significance with a *p* value <0.05 for MHP rate comparisons and a *p* value <0.01 for MWA rate comparisons. Note that statistical testing could not be performed on the utilization-based measures domain given that variances were not available in the IDSS files for HSAG to use for statistical testing. Further statistical testing was not performed on the health plan diversity measures because these measures are for information purposes only.

In general, results from statistical significance testing provide information on whether a change in the rate may suggest improvement or decline in performance. Throughout the report, references to "significant" changes in performance are noted; these instances refer to statistically significant differences between performance from HEDIS 2017 to HEDIS 2018. At the statewide level, if the number of MHPs reporting *NR* or *BR* differs vastly from year to year, the statewide performance may not represent all of the contracted MHPs, and any changes observed across years may need to take this factor into consideration. Nonetheless, changes (regardless of whether they are statistically significant) could be related to the following factors independent of any effective interventions designed to improve the quality of care:

- Substantial changes in measure specifications. The "Measure Changes Between HEDIS 2017 and HEDIS 2018" section below lists measures with specification changes made by NCQA.
- Substantial changes in membership composition within the MHP.

#### **Table and Figure Interpretation**

Within Sections 3 through 8 and Appendix B of this report, performance measure indicator rates and results of significance testing between HEDIS 2017 and HEDIS 2018 are presented in tabular format. HEDIS 2018 rates shaded green with one cross (<sup>+</sup>) indicate a statistically significant improvement in performance from the previous year. HEDIS 2018 rates shaded red with two crosses (<sup>++</sup>) indicate a statistically significant decline in performance from the previous year. The colors used are provided below for reference:

- Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.
- <sup>+</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.




Additionally, benchmark comparisons are denoted within Sections 3 through 8. Performance levels are represented using the following percentile rankings:

| Percentile Ranking and<br>Shading | Performance Level  |
|-----------------------------------|--|
| ≥90th                             | At or above the national Medicaid 90th percentile  |
| $\geq$ 75th and $\leq$ 89th       | At or above the national Medicaid 75th percentile but<br>below the national Medicaid 90th percentile |
| $\geq$ 50th and $\leq$ 74th       | At or above the national Medicaid 50th percentile but below the national Medicaid 75th percentile    |
| $\geq$ 25th and $\leq$ 49th       | At or above the national Medicaid 25th percentile but<br>below the national Medicaid 50th percentile |
| ≤25th                             | Below the national Medicaid 25th percentile  |

For each performance measure indicator presented in Sections 3 through 8 of this report, the vertical bar graph figure positioned on the left side of the page presents the HEDIS 2016, HEDIS 2017, and HEDIS 2018 MWAs with significance testing performed between the HEDIS 2017 and HEDIS 2018 MWAs. Within these figures, HEDIS 2018 rates with one cross (<sup>+</sup>) indicate a statistically significant improvement in performance from HEDIS 2017. HEDIS 2018 rates with two crosses (<sup>++</sup>) indicate a statistically significant decline in performance from HEDIS 2017. An example of the vertical bar graph figure for measure indicators reported is included in Figure 2-4.

#### Figure 2-4—Sample Vertical Bar Graph Figure Showing Statistically Significant Improvement





## **Interpreting Results Presented in This Report**

HEDIS results can differ among MHPs and even across measures for the same MHP.

The following questions should be asked when examining these data:

#### How accurate are the results?

All Michigan MHPs are required by MDHHS to have their HEDIS results confirmed through an NCQA HEDIS Compliance Audit. As a result, any rate included in this report has been verified as an unbiased estimate of the measure. NCQA's HEDIS protocol is designed so that the hybrid method produces results with a sampling error of  $\pm$  5 percent at a 95 percent confidence level.

To show how sampling error affects the accuracy of results, an example was provided in the "Data Collection Methods" section above. When an MHP uses the hybrid method to derive a *Postpartum Care* rate of 52 percent, the true rate is actually within  $\pm$  5 percentage points of this rate, due to sampling error. For a 95 percent confidence level, the rate would be between 47 percent and 57 percent. If the target is a rate of 55 percent, it cannot be said with certainty whether the true rate between 47 percent and 57 percent and 57 percent meets or does not meet the target level.

To prevent such ambiguity, this report uses a standardized methodology that requires the reported rate to be at or above the threshold level to be considered as meeting the target. For internal purposes, MHPs should understand and consider the issue of sampling error when evaluating HEDIS results.

#### How do Michigan Medicaid rates compare to national percentiles?

For each measure, an MHP ranking presents the reported rate in order from highest to lowest, with bars representing the established HPL, LPL, and the national HEDIS 2017 Medicaid 50th percentile. In addition, the HEDIS 2016, 2017, and 2018 MWA rates are presented for comparison purposes.

Michigan MHPs with reported rates above the 90th percentile (HPL) rank in the top 10 percent of all MHPs nationally. Similarly, MHPs reporting rates below the 25th percentile (LPL) rank in the bottom 25 percent nationally for that measure.

## How are Michigan MHPs performing overall?

For each domain of care, a performance profile analysis compares the 2018 MWA for each rate with the 2016 and 2017 MWA and the national HEDIS 2017 Medicaid 50th percentile.



## Measure Changes Between HEDIS 2017 and HEDIS 2018

The following is a list of measures with technical specification changes that NCQA announced for HEDIS 2018.<sup>2-1</sup> These changes may have an effect on the HEDIS 2018 rates that are presented in this report.

## Appropriate Treatment for Children With Upper Respiratory Infection

- Revised the episode date to allow for multiple diagnoses of URI and to exclude members who had other diagnoses on the same date of service.
- Clarified how to identify an ED visit or observation visit that resulted in an inpatient stay.

## Appropriate Testing for Children With Pharyngitis

- Revised the episode date to allow for multiple diagnoses of pharyngitis and to exclude members who had other diagnoses on the same date of service.
- Clarified how to identify an ED visit or observation visit that resulted in an inpatient stay.

#### Follow-Up Care for Children Prescribed ADHD Medication

- Added telehealth as eligible for one visit for the continuation and maintenance phase.
- Clarified that for the continuation and maintenance phase, visits must be on different dates of service.
- Note added: Do not count visits billed with a telehealth modifier (Telehealth Modifier Value Set) or billed with a telehealth place of service (POS) code (Telehealth POS Value Set).
- Clarification under Admin specifications: Replace the paragraph after the first two bullets with the following text:
  - Only one of the two visits (during days 31–300) may be a telephone visit (Telephone Visits Value Set) or a telehealth visit. Identify follow-up visits using the code combinations below. Then, identify telehealth visits by the presence of a telehealth modifier (Telehealth Modifier Value Set) or the presence of a telehealth POS code (Telehealth POS Value Set) on the claim.
- Added value sets: Add the following as the fifth and sixth bullets in the last paragraph:
  - Add Visits Group 1 Value Set with Telehealth POS Value Set
  - Add Visits Group 2 Value Set with Telehealth POS Value Set

#### **Breast Cancer Screening**

• Added digital breast tomosynthesis as a method for meeting numerator criteria.

<sup>&</sup>lt;sup>2-1</sup> National Committee for Quality Assurance. *HEDIS*<sup>®</sup> 2018, *Volume 2: Technical Specifications for Health Plans*. Washington, DC: NCQA Publication, 2016.



## Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

• Clarified how to identify an ED visit or observation visit that resulted in an inpatient stay.

## Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

• Clarified in the Notes that documentation related to a member's "appetite" does not meet criteria for the *Counseling for Nutrition* measure indicator.

#### Prenatal and Postpartum Care

- Updated the administrative numerator specification to indicate when codes must be on the same claim and when codes can occur on different dates of service.
- Revised Decision Rule 3 to allow **either** (rather than any) of the criteria where the practitioner type is a primary care provider (PCP).

## **Comprehensive Diabetes Care**

- Added bilateral eye enucleation to the Eye Exam (Retinal) Performed measure indicator.
- Revised the language in step 1 of the *BP Control* <140/90 mm Hg Numerator and added *Notes* clarifying the intent when excluding BP readings from the numerator.
- Clarified the medical record requirements for evidence of angiotensin converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) therapy (for the *Medical Attention for Nephropathy* measure indicator).
- Added "sacubitril-valsartan" to the description of Antihypertensive combinations in the ACE Inhibitor/ARB Medications List.
- Revised the Data Elements for Reporting table to reflect the removal of the Final Sample Size (FSS) when reporting using the hybrid methodology.
- Replaced a bullet under Admin Specifications for the eye exams numerator: Replaced the eighth bullet with the following text:
  - Two unilateral eye enucleations (Unilateral Eye Enucleation Value Set) with service dates 14 days or more apart. For example, if the service date for the first unilateral eye enucleation was February 1 of the measurement year, the service date for the second unilateral eye enucleation must be on or after February 15.

## Controlling High Blood Pressure

- Clarified that a diagnosis code for hypertension documented in the medical record may be used to confirm the diagnosis of hypertension.
- Clarified that the pregnancy optional exclusion should be applied to only female members.
- Revised the language in step 1 of the Numerator and added *Notes* clarifying the intent when excluding BP readings from the numerator.



- Replaced the bullet under hybrid specifications—Denominator: Replace the last bullet under the second paragraph with the following text:
  - A diagnosis code for essential hypertension (from the Essential Hypertension Value Set) documented in the medical record.

#### Antidepressant Medication Management

• Added telehealth and telehealth modifiers.

#### Annual Monitoring for Patients on Persistent Medications

- Removed the annual monitoring for members on digoxin rate.
- Added "sacubitril-valsartan" to the description of Antihypertensive combinations in the ACE Inhibitor/ARB Medications List.

#### **Ambulatory Care**

- Clarified how to identify an ED visit that resulted in an inpatient stay.
- Removed the Alcohol and Other Drug (AOD) Rehab and Detox Value Set from the required exclusions (exclusions will be identified based on a principal diagnosis of chemical dependency).
- Revised the data elements tables to indicate that rates are calculated for the Visits/1,000 Member Months/Years in the unknown category.

#### **Inpatient Utilization**

• Revised the data elements tables to indicate that rates are calculated for the Discharges/1,000 Member Months/Years in the unknown category.



# Introduction

The Child & Adolescent Care measure domain encompasses the following MDHHS measures:

- Childhood Immunization Status—Combinations 2–10
- Well-Child Visits in the First 15 Months of Life—Six or More Visits
- Lead Screening in Children
- Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life
- Adolescent Well-Care Visits
- *Immunizations for Adolescents—Combination 1 (Meningococcal, Tdap)*
- Appropriate Treatment for Children With Upper Respiratory Infection
- Appropriate Testing for Children With Pharyngitis
- Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase and Continuous and Maintenance Phase

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

## **Summary of Findings**

Table 3-1 presents the MWA performance for the measure indicators under the Child & Adolescent Care measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.



| Measure   | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|---|--|--|--|--|
| Childhood Immunization Status   |  |  |  |  |
| Combination 2   | 76.35%   | -0.60  | 1  | 2  |
| Combination 3   | 72.28%   | -0.56  | 0  | 1  |
| Combination 4   | 70.75%   | +0.32  | 0  | 1  |
| Combination 5   | 62.63%   | +0.90  | 0  | 0  |
| Combination 6   | 39.93%   | +0.09  | 0  | 0  |
| Combination 7   | 61.53%   | +1.48+   | 0  | 0  |
| Combination 8   | 39.56%   | +0.36  | 1  | 0  |
| Combination 9   | 35.85%   | +1.38+   | 1  | 0  |
| Combination 10  | 35.55%   | +1.57+   | 1  | 0  |
| Well-Child Visits in the First 15 Months of Life                          |  |  |  |  |
| Six or More Visits  | 71.89%   | +2.10+   | 1  | 0  |
| Lead Screening in Children  |  |  |  |  |
| Lead Screening in Children  | 80.55%   | -0.43  | 0  | 1  |
| Well-Child Visits in the Third, Fourth, Fifth, and Si                     | xth Years of Life  | 2  |  |  |
| Well-Child Visits in the Third, Fourth, Fifth,<br>and Sixth Years of Life | 75.19%   | -0.90++  | 0  | 1  |
| Adolescent Well-Care Visits   | <b>I</b>   |  | a  |  |
| Adolescent Well-Care Visits   | 56.75%   | +1.06+   | 1  | 1  |
| Immunizations for Adolescents   |  |  |  |  |
| Combination 1   | 85.14%   | -1.59++  | 0  | 1  |
| Appropriate Treatment for Children With Upper Res                         | spiratory Infectio   | pn   | 11   |  |
| Appropriate Treatment for Children With<br>Upper Respiratory Infection    | 88.83%   | -0.11  | 3  | 2  |
| Appropriate Testing for Children With Pharyngitis                         |  |  |  |  |
| Appropriate Testing for Children With Pharyngitis                         | 79.20%   | +8.29+   | 9  | 0  |
| Follow-Up Care for Children Prescribed ADHD Me                            | dication <sup>3</sup>                                      |  |  |  |
| Initiation Phase  | 43.86%   | +1.32  | 1  | 0  |
| Continuation and Maintenance Phase  | 53.56%   | -1.47  | 1  | 1  |

#### Table 3-1—HEDIS 2018 MWA Performance Levels and Trend Results for Child & Adolescent Care

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

|  | $\leq 25th$ | $\geq$ 25th and $\leq$ 49th | $\geq$ 50th and $\leq$ 74th | $\geq$ 75th and $\leq$ 89th | $\geq 90th$ |
|--|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|
|--|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

*Green Shading*<sup>+</sup> *Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.* 

*Red Shading*<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.

<sup>3</sup> Due to changes in the technical specifications for this measure, exercise caution when trending rates between 2018 and prior years.



Table 3-1 shows that for the Child & Adolescent Care domain, six of 18 (33.3 percent) MWA rates demonstrated significant increases from HEDIS 2017 to HEDIS 2018. Of note, three of the six rates that increased were *Childhood Immunization Status* measure indicators (*Combinations 7, 9,* and *10*), and the rate increases were due primarily to relatively small increases in the rotavirus and hepatitis A vaccination rates. Nearly all MWA rates (83 percent) ranked at or above the national Medicaid 50th percentile, with two rates ranking at or above the national Medicaid 75th percentile. The *Well-Child Visits in the First 15 Months of Life* measure was an area of strength in this domain, as the MWA was both above the 75th percentile and demonstrated a significant increase. Of note, the *Appropriate Testing for Children With Pharyngitis* rate had a significant increase by upwards of 8 percentage points, with nine of 11 plans (82 percent) demonstrating significant increases.


Conversely, the MWA rates for *Appropriate Treatment for Children With Upper Respiratory Infection* and *Follow-Up Care for Children Prescribed ADHD Medication* fell below the national Medicaid 50th percentile, suggesting opportunities for improvement. However, caution should be used when comparing the HEDIS 2018 rates for the *Follow-Up Care for Children Prescribed ADHD Medication* measure indicators to national Medicaid percentiles and prior years' rates due to changes to the technical specifications for this measure for HEDIS 2018.




## **Measure-Specific Findings**

#### Childhood Immunization Status—Combination 2

*Childhood Immunization Status—Combination 2* assesses the percentage of children 2 years of age who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; and one chicken pox.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 


Four MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 20 percentage points.



*Childhood Immunization Status—Combination 3* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; and four pneumococcal conjugate.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Four MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by nearly 30 percentage points.



*Childhood Immunization Status—Combination 4* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; and one hepatitis A.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.


|          |       |         |                    | POP    | ADMIN%  |
|----------|-------|---------|--------------------|--------|---------|
| PRI      |       |         | 79.56%             | 2,490  | 98.17%  |
| HPL      |       |         |                    |        |         |
| MER      |       |         | 72.02%             | 10,043 | 97.64%  |
| UNI      |       |         | 71.29%             | 4,547  | 98.63%  |
| 2018 MWA |       |         | 70.75%             |        |         |
| BCC      |       |         | 70.32%             | 2,400  | 100.00% |
| MOL      |       |         | 69.78%             | 6,708  | 100.00% |
| P50      |       |         |                    |        |         |
| MCL      |       |         | 68.86%             | 3,448  | 96.11%  |
| UPP      |       |         | 67.40%             | 887    | 99.64%  |
| THC      |       |         | 64.48%             | 822    | 100.00% |
| LPL      |       |         | 1                  |        |         |
| AET      |       | 56      | .69%               | 799    | 88.84%  |
| HAR      |       | 51.6.   | 3%                 | 154    | 98.73%  |
| MID      | NA    |         |                    | 24     |         |
|          | % 20% | 40% 60% | 6 <b>8</b> 0% 1009 | /      |         |

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.


Five MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by nearly 30 percentage points.



*Childhood Immunization Status—Combination 5* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; and two or three rotavirus.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.


Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Three MHPs fell below the LPL. MHP performance varied by over 30 percentage points.



*Childhood Immunization Status—Combination 6* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; and two influenza.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Four MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 35 percentage points.




*Childhood Immunization Status—Combination 7* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; one hepatitis A; and two or three rotavirus.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.


Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.



*Childhood Immunization Status—Combination 8* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; one hepatitis A; and two influenza.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Four MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




*Childhood Immunization Status—Combination 9* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; two or three rotavirus; and two influenza.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




*Childhood Immunization Status—Combination 10* assesses the percentage of children 2 years of age during the measurement year who received the following vaccines by their second birthday: four diphtheria, tetanus, and acellular pertussis; three polio; one measles, mumps, and rubella; three haemophilus influenzae type B; three hepatitis B; one chicken pox; four pneumococcal conjugate; one hepatitis A; two or three rotavirus; and two influenza.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Well-Child Visits in the First 15 Months of Life–Six or More Well-Child Visits

*Well-Child Visits in the First 15 Months of Life—Six or More Visits* assesses the percentage of members who turned 15 months old during the measurement year and who received six or more well-child visits with a PCP during their first 15 months of life.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Lead Screening in Children

*Lead Screening in Children* assesses the percentage of children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




*NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

Nine MHPs and the MWA ranked above the national Medicaid 50th percentile, and all MHPs with reportable rates fell between the HPL and the LPL. MHP performance varied by approximately 15 percentage points.




### Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life

*Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life* is a measure of the percentage of members who were 3, 4, 5, or 6 years old and received one or more well-child visits with a PCP during the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Six MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 20 percentage points.




#### Adolescent Well-Care Visits

*Adolescent Well-Care Visits* assesses the percentage of members who were 12 to 21 years of age and who had at least one comprehensive well-care visit with a PCP or an obstetrician/gynecologist (OB/GYN) during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Seven MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Immunizations for Adolescents—Combination 1 (Meningococcal, Tdap)

*Immunizations for Adolescents—Combination 1 (Meningococcal, Tdap)* assesses the percentage of adolescents 13 years of age who had the following by their 13th birthday: one dose of meningococcal vaccine and acellular pertussis vaccine (Tdap).



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Nine MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. No MHPs with reportable rates fell below the LPL. MHP performance varied by over 10 percentage points.


### Appropriate Treatment for Children With Upper Respiratory Infection

Appropriate Treatment for Children With Upper Respiratory Infection assesses the percentage of children 3 months to 18 years of age who were given a diagnosis of upper respiratory infection and were not dispensed an antibiotic prescription. Due to changes in the technical specifications for this measure indicator, exercise caution when trending rates between 2017 and prior years.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.

Six MHPs ranked above the national Medicaid 50th percentile but fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 10 percentage points.









### Appropriate Testing for Children With Pharyngitis

Appropriate Testing for Children With Pharyngitis assesses the percentage of children 3 to18 years of age who were diagnosed with pharyngitis, were dispensed an antibiotic, and received a group A streptococcus test for the episode.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 

Six MHPs and the MWA ranked above the national Medicaid 50th percentile, and all MHPs with reportable rates fell between the HPL and the LPL. MHP performance varied by over 15 percentage points.




#### Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase

*Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase* assesses the percentage of children 6 to 12 years of age who were newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication and who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase. Due to changes in the technical specifications for this measure, exercise caution when trending rates between 2018 and prior years.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs ranked above the national Medicaid 50th percentile but fell below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase

*Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase* assesses the percentage of children 6 to 12 years of age newly prescribed ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (nine months) after the initiation phase ended. Due to changes in the technical specifications for this measure, exercise caution when trending rates between 2018 and prior years.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.



*NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs ranked above the national Medicaid 50th percentile but fell below the HPL. Three MHPs fell below the LPL. MHP performance varied by over 25 percentage points.



## Introduction

The Women—Adult Care measure domain encompasses the following MDHHS measures:

- Breast Cancer Screening
- Cervical Cancer Screening
- Chlamydia Screening in Women-Ages 16 to 20 Years, Ages 21 to 24 Years, and Total

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

### **Summary of Findings**

Table 4-1 presents the Michigan MWA performance for the measure indicators under the Women— Adult Care measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.

#### Table 4-1—HEDIS 2018 MWA Performance Levels and Trend Results for Women—Adult Care

| Measure                              | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|--------------------------------------|--|--|--|--|
| Breast Cancer Screening <sup>3</sup> |  |  |  |  |
| Breast Cancer Screening              | 62.13%   | NC   | NC   | NC   |
| Cervical Cancer Screening            |  |  |  |  |
| Cervical Cancer Screening            | 66.19%   | +1.35+   | 1  | 1  |



| Measure                      | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|------------------------------|--|--|--|--|
| Chlamydia Screening in Women |  |  |  |  |
| Ages 16 to 20 Years          | 63.28%   | +1.01+   | 2  | 0  |
| Ages 21 to 24 Years          | 68.65%   | -0.24  | 1  | 0  |
| Total                        | 65.65%   | +0.42  | 1  | 0  |

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

| $\leq 25th$ | $\geq$ 25th and $\leq$ 49th | $\geq$ 50th and $\leq$ 74th | $\geq$ 75th and $\leq$ 89th | $\geq 90th$ |
|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|
|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

*Green Shading*<sup>+</sup> *Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.* 

*Red Shading*<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark.

Table 4-1 shows that for the four MWA rates in the Women—Adult Care domain that could be compared to national Medicaid percentiles or prior years' rates, *Cervical Cancer Screening* and *Chlamydia Screening in Women—Ages 16 to 20 Years* demonstrated a significant improvement from HEDIS 2017 to HEDIS 2018. Further, all four MWA rates ranked at or above the national Medicaid 50th percentile, with three of the rates ranking at or above the national Medicaid 75th percentile, indicating overall positive performance in the areas of cervical cancer and chlamydia screenings for women.


WOMEN—ADULT CARE




## **Measure-Specific Findings**

#### Breast Cancer Screening

*Breast Cancer Screening* assesses the percentage of women 50 to 74 years of age who had a mammogram to screen for breast cancer on or after October 1 two years prior to the measurement year.



Due to changes in the technical specifications in HEDIS 2018 for the *Breast Cancer Screening* measure, a comparison to prior year's results is not appropriate. The rate in the chart above is presented for information purposes only.




Due to changes in the technical specifications in HEDIS 2018 for the *Breast Cancer Screening* measure, a comparison to benchmarks is not appropriate. The rates in the chart above are presented for information purposes only. MHP performance varied by almost 15 percentage points.



#### **Cervical Cancer Screening**

*Cervical Cancer Screening* assesses the percentage of women 21 to 64 years of age who were screened for cervical cancer using either of the following criteria:

- Women ages 21 to 64 who had cervical cytology performed every three years.
- Women ages 30 to 64 who had cervical cytology/human papillomavirus co-testing every five years.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.


|                                      | Health Plan Ranking  |        |              |
|--------------------------------------|----------------------|--------|--------------|
|                                      |                      | POP    | ADMIN%       |
| MOL                                  | 72.34%               | 70,476 | 93.75%       |
| HPL                                  |                      |        |              |
| PRI 🔤                                | 68.85%               | 23,125 | 92.46%       |
| UNI 🗖                                | 67.88%               | 46,844 | 97.13%       |
| 2018 MWA 🕅                           | 66.19%               |        |              |
| MER                                  | 65.21%               | 97,876 | 96.27%       |
| UPP 🗖                                | 63.02%               | 9,251  | 97.68%       |
| MCL                                  | 61.80%               | 34,888 | 93.31%       |
| BCC                                  | 61.80%               | 33,038 | 95.28%       |
| AET 🗖                                | 60.26%               | 7,912  | 96.07%       |
| тнс                                  | 60.10%               | 10,044 | 96.36%       |
| P50                                  |                      |        |              |
| MID                                  | 52.93%               | 1,395  | 93.55%       |
| LPL                                  |                      |        |              |
| HAR                                  | 47.20%               | 1,189  | 95.36%       |
| 0%                                   | 20% 40% 60% 80% 100% | 5      | 2000,000,000 |
| POP = Eligible Pop<br>ADMIN% = Admin | HEDIS 2018 Rate      |        |              |
| MRR = Medical Re                     |                      |        |              |

Nine MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 25 percentage points.




#### Chlamydia Screening in Women—Ages 16–20 Years

*Chlamydia Screening in Women—Ages 16–20 Years* assesses the percentage of women 16 to 20 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




*NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

Nine MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 25 percentage points.




#### Chlamydia Screening in Women—21–24 Years

*Chlamydia Screening in Women*—21–24 Years assesses the percentage of women 21 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 20 percentage points.




#### Chlamydia Screening in Women–Total

*Chlamydia Screening in Women—Total* represents the percentage of women 16 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.



Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 20 percentage points.



## Introduction

The Access to Care measure domain encompasses the following MDHHS measures:

- Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 24 Months, Ages 25 Months to 6 Years, Ages 7 to 11 Years, and Ages 12 to 19 Years
- Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years, Ages 45 to 64 Years, Ages 65 and Older, and Total
- Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

## **Summary of Findings**

Table 5-1 presents the Michigan MWA performance for the measure indicators under the Access to Care measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.

| Measure  | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|--|--|--|--|--|
| Children and Adolescents' Access to Primary Care H | Practitioners  |  |  |  |
| Ages 12 to 24 Months                               | 95.16%   | <b>-0.90</b> ++  | 0  | 4  |
| Ages 25 Months to 6 Years                          | 87.89%   | -1.19++  | 0  | 7  |
| Ages 7 to 11 Years                                 | 91.13%   | -0.26  | 0  | 2  |
| Ages 12 to 19 Years                                | 90.42%   | -0.37++  | 0  | 2  |
| Adults' Access to Preventive/Ambulatory Health Ser | vices  |  |  |  |
| Ages 20 to 44 Years                                | 78.64%   | -3.04++  | 0  | 10   |
| Ages 45 to 64 Years                                | 87.57%   | -1.64++  | 0  | 9  |
| Ages 65+ Years                                     | 91.79%   | +1.53+   | 3  | 0  |
| Total  | 82.25%   | -2.48++  | 0  | 10   |

Table 5-1—HEDIS 2018 MWA Performance Levels and Trend Results for Access to Care



| Measure  | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |  |
|--|--|--|--|--|--|
| Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis    |  |  |  |  |  |
| Avoidance of Antibiotic Treatment in Adults<br>With Acute Bronchitis | 32.20%   | +2.97+   | 4  | 0  |  |

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

| $\leq 25th$ $\geq 25t$ | th and $\leq 49$ th $\geq 50$ th and | $\leq 74th$ $\geq 75th$ and $\leq 89th$ | $\geq 90th$ |
|------------------------|--------------------------------------|---|-------------|
|------------------------|--------------------------------------|---|-------------|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

*Green Shading*<sup>+</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.

*Red Shading*<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.

Table 5-1 shows that for the Access to Care domain, two of nine (22.2 percent) measure indicators, *Adults' Access to Preventive/Ambulatory Health Services—Ages 65+ Years* and *Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis*, demonstrated significant increases from HEDIS 2017 to HEDIS 2018. Of note, the *Adults' Access to Preventive/Ambulatory Health Services—Ages 65+ Years* measure indicator demonstrated an area of strength in this domain, with the MWA rate ranking above the national Medicaid 75th percentile, and three MHPs demonstrating significant increases from HEDIS 2017 to HEDIS 2018. Additionally, seven of nine (77.8 percent) MWA rates ranked at or above the national Medicaid 50th percentile, indicating positive performance in the area of Access to Care compared to national standards.


Conversely, six of nine (67 percent) MWA rates within the Access to Care domain demonstrated significant decreases from HEDIS 2017 to HEDIS 2018. Of note, the MWA rates for *Children and Adolescents' Access to Primary Care Practitioners*—*Ages 12 to 24 Months* and *Adults' Access to Preventive/Ambulatory Health Services*—*Ages 20 to 44 Years* fell below the national Medicaid 50th percentile and demonstrated significant decreases. In addition, 10 of 11 (90.9 percent) MHPs' rates and the MWA demonstrated significant decreases from HEDIS 2017 to HEDIS 2018 for the *Adults' Access to Preventive/Ambulatory Health Services*—*Ages 20 to 44 Years* and *Total* measure indicators. These declines in performance suggest opportunities for improving access to preventive/ambulatory services for adults ages 20 to 64 years and access to primary care physicians for children and adolescents.



## **Measure-Specific Findings**


### Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 24 Months

*Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 24 Months* assesses the percentage of members 12 to 24 months of age who had a visit with a PCP during the measurement year.



Rates with two crosses (++) indicate a significant decline in performance from the previous year.

# The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Three MHPs ranked above the national Medicaid 50th percentile but below the HPL. Five MHPs fell below the LPL. MHP performance varied by over 20 percentage points.






#### Children and Adolescents' Access to Primary Care Practitioners—Ages 25 Months to 6 Years

*Children and Adolescents' Access to Primary Care Practitioners—Ages 25 Months to 6 Years* assesses the percentage of members 25 months to 6 years of age who had a visit with a PCP during the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Four MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Six MHPs fell below the LPL. MHP performance varied by over 20 percentage points.




#### Children and Adolescents' Access to Primary Care Practitioners—Ages 7 to 11 Years

*Children and Adolescents' Access to Primary Care Practitioners—Ages 7 to 11 Years* assesses the percentage of members 7 to 11 years of age who had a visit with a PCP during the measurement year or the year prior to the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Four MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Three MHPs fell below the LPL. MHP performance varied by over 15 percentage points.




#### Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 19 Years

*Children and Adolescents' Access to Primary Care Practitioners—Ages 12 to 19 Years* assesses the percentage of members 12 to 19 years of age who had a visit with a PCP during the measurement year or the year prior to the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Five MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Three MHPs fell below the LPL. MHP performance varied by over 20 percentage points.




#### Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years

Adults' Access to Preventive/Ambulatory Health Services—Ages 20 to 44 Years assesses the percentage of members 20 to 44 years of age who had an ambulatory or preventive care visit during the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Four MHPs ranked above the national Medicaid 50th percentile but below the HPL. Three MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Adults' Access to Preventive/Ambulatory Health Services—Ages 45 to 64 Years

Adults' Access to Preventive/Ambulatory Health Services—Ages 45 to 64 Years assesses the percentage of members 45 to 64 years of age who had an ambulatory or preventive care visit during the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Seven MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 15 percentage points.




#### Adults' Access to Preventive/Ambulatory Health Services—Ages 65 Years and Older

Adults' Access to Preventive/Ambulatory Health Services—Ages 65 Years and Older assesses the percentage of members 65 years of age or older who had an ambulatory or preventive care visit during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




*NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 15 percentage points.




#### Adults' Access to Preventive/Ambulatory Health Services—Total

Adults' Access to Preventive/Ambulatory Health Services—Total assesses the percentage of members 20 years of age and older who had an ambulatory or preventive care visit during the measurement year.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Seven MHPs and the MWA ranked above the national Medicaid 50th percentile but below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 25 percentage points.

ACCESS TO CARE




#### Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis assesses the percentage of members 18 to 64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. Due to changes in the technical specifications for this measure indicator, exercise caution when trending rates between 2017 and prior years.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.



Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 15 percentage points.



## Introduction

The Obesity measure domain encompasses the following MDHHS measures:

- Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile Documentation—Total, Counseling for Nutrition—Total, and Counseling for Physical Activity—Total
- Adult BMI Assessment

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

## **Summary of Findings**

Table 6-1 presents the Michigan MWA performance for the measure indicators under the Obesity measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.

| Measure   | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|---|--|--|--|--|
| Weight Assessment and Counseling for Nutrition an | d Physical Activ   | ity for Children   | Adolescents/   |  |
| BMI Percentile Documentation—Total                | 84.40%   | +2.30+   | 2  | 2  |
| Counseling for Nutrition—Total                    | 74.50%   | +2.29+   | 0  | 1  |
| Counseling for Physical Activity—Total            | 67.49%   | +6.25+   | 3  | 1  |

#### Table 6-1—HEDIS 2018 MWA Performance Levels and Trend Results for Obesity



| Measure              | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|----------------------|--|--|--|--|
| Adult BMI Assessment |  |  |  |  |
| Adult BMI Assessment | 94.47%   | +1.61+   | 1  | 1  |

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

|  | $\leq 25th$ | $\geq$ 25th and $\leq$ 49th | $\geq$ 50th and $\leq$ 74th | $\geq$ 75th and $\leq$ 89th | $\geq 90th$ |
|--|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|
|--|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

*Green Shading*<sup>+</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.

*Red Shading*<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.


Table 6-1 shows that the four MWA rates included in the Obesity domain demonstrated a significant improvement from HEDIS 2017 to HEDIS 2018. Additionally, all four MWA rates ranked at or above the national Medicaid 50th percentile, demonstrating overall positive performance related to obesity. Of note, the MWA rate for *Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total* ranked at or above the national Medicaid 75th percentile, and the MWA rate for *Adult BMI Assessment* ranked at or above the national Medicaid 90th percentile.



## **Measure-Specific Findings**


### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile Documentation—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile Documentation—Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of BMI percentile documentation during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by 25 percentage points.




### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Nutrition— Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of counseling for nutrition during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

## The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, and all MHPs fell between the HPL and the LPL. MHP performance varied by over 15 percentage points.




### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Physical Activity—Total assesses the percentage of members 3 to 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of counseling for physical activity during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

## The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Seven MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 30 percentage points.




#### Adult BMI Assessment

*Adult BMI Assessment* assesses the percentage of members 18 to 74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the measurement year or the year prior to the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.



Nine MHPs ranked above the national Medicaid 50th percentile, with six MHPs and the MWA ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 25 percentage points.



## Introduction

The Pregnancy Care measure domain encompasses the following MDHHS measures:

• Prenatal and Postpartum Care—Timeliness of Prenatal Care and Postpartum Care

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section.

For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

## **Summary of Findings**

Table 7-1 presents the Michigan MWA performance for the measure indicators under the Pregnancy Care measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.

| Measure                      | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|------------------------------|--|--|--|--|
| Prenatal and Postpartum Care |  |  |  |  |
| Timeliness of Prenatal Care  | 80.23%   | -1.34++  | 1  | 3  |
| Postpartum Care              | 67.27%   | <b>-1.69</b> ++  | 1  | 0  |

#### Table 7-1—HEDIS 2018 MWA Performance Levels and Trend Results for Pregnancy Care

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

| $\leq 25th$ | $\geq$ 25th and $\leq$ 49th | $\geq$ 50th and $\leq$ 74th | $\geq$ 75th and $\leq$ 89th | $\geq 90th$ |
|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|
|-------------|-----------------------------|-----------------------------|-----------------------------|-------------|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

Green Shading<sup>+</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.

Red Shading<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.

PREGNANCY CARE




Table 7-1 shows that one of the two measure indicators in the Pregnancy Care domain, *Prenatal and Postpartum Care*—*Postpartum Care*, ranked at or above the national Medicaid 50th percentile. For the *Prenatal and Postpartum Care*—*Timeliness of Prenatal Care* measure, the MWA rate fell below the national Medicaid 50th percentile and demonstrated a significant decline from HEDIS 2017 to HEDIS 2018, indicating opportunities for improvement in prenatal care.



### **Measure-Specific Findings**


#### Prenatal and Postpartum Care—Timeliness of Prenatal Care

*Prenatal and Postpartum Care—Timeliness of Prenatal Care* assesses the percentage of deliveries that received a prenatal care visit as a member of the MHP in the first trimester or within 42 days of enrollment in the MHP.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

## The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Two MHPs ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Six MHPs fell below the LPL. MHP performance varied by over 55 percentage points.




### Prenatal and Postpartum Care—Postpartum Care

*Prenatal and Postpartum Care—Postpartum Care* represents the percentage of deliveries that had a postpartum visit on or between 21 and 56 days after delivery.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.



Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. Four MHPs fell below the LPL. MHP performance varied by over 25 percentage points.



## Introduction

The Living With Illness measure domain encompasses the following MDHHS measures:

- Comprehensive Diabetes Care—Hemoglobin A1c (HbA1c) Testing, HbA1c Poor Control (>9.0%), HbA1c control (<8.0%), Eye Exam (Retinal) Performed, Medical Attention for Nephropathy, and Blood Pressure Control (<140/90 mm Hg)
- Medication Management for People with Asthma—Medication Compliance 50%—Total and Medication Compliance 75%—Total
- Asthma Medication Ratio—Total
- Controlling High Blood Pressure
- Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit, Discussing Cessation Medications, and Discussing Cessations Strategies
- Antidepressant Medication Management—Effective Acute Phase Treatment and Effective Continuation Phase Treatment
- Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications
- Diabetes Monitoring for People With Diabetes and Schizophrenia
- Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia
- Adherence to Antipsychotic Medications for Individuals With Schizophrenia
- Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARBs, Diuretics, and Total

Please see the "How to Get the Most From This Report" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendices A, B, and C.

## **Summary of Findings**

Table 8-1 presents the Michigan MWA performance for the measure indicators under the Living With Illness measure domain. The table lists the HEDIS 2018 MWA rates and performance levels, a comparison of the HEDIS 2017 MWA to the HEDIS 2018 MWA for each measure indicator with trend analysis results, and a summary of the MHPs with rates demonstrating statistically significant changes from HEDIS 2017 to HEDIS 2018.



| Measure  | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|--|--|--|--|--|
| Comprehensive Diabetes Care  |  |  |  |  |
| Hemoglobin A1C (HbA1c) Testing   | 88.81%   | +1.02+   | 0  | 2  |
| HbA1c Poor Control (>9.0%)*  | 36.88%   | +0.81++  | 1  | 3  |
| HbA1c Control (<8.0%)  | 52.73%   | -0.43  | 0  | 2  |
| Eye Exam (Retinal) Performed   | 64.18%   | +1.33+   | 0  | 0  |
| Medical Attention for Nephropathy  | 91.94%   | +0.80+   | 0  | 0  |
| Blood Pressure Control (<140/90 mm Hg)   | 62.23%   | +0.50  | 0  | 2  |
| Medication Management for People With Asthma   |  |  | (  |  |
| Medication Compliance 50%—Total <sup>3</sup>   | 70.74%   | -0.59  | 3  | 2  |
| Medication Compliance 75%—Total  | 49.83%   | -0.13  | 4  | 2  |
| Asthma Medication Ratio  |  |  | (  |  |
| Total  | 62.06%   | -0.57  | 1  | 1  |
| Controlling High Blood Pressure  |  |  | 11   |  |
| Controlling High Blood Pressure  | 58.21%   | +1.46+   | 1  | 2  |
| Medical Assistance With Smoking and Tobacco Use  | e Cessation <sup>4</sup>                                   |  |  |  |
| Advising Smokers and Tobacco Users to Quit   | 80.59%   | +0.44+   | 0  | 0  |
| Discussing Cessation Medications   | 57.14%   | +1.19+   | 0  | 0  |
| Discussing Cessation Strategies  | 47.32%   | +1.43+   | 0  | 0  |
| Antidepressant Medication Management <sup>5</sup>  | /  |  |  |  |
| Effective Acute Phase Treatment  | 58.27%   | +5.55+   | 4  | 0  |
| Effective Continuation Phase Treatment   | 41.25%   | +5.22+   | 4  | 1  |
| Diabetes Screening for People With Schizophrenia<br>Medications  | or Bipolar Disor   | der Who Are Us   | sing Antipsychot   | ic   |
| Diabetes Screening for People With<br>Schizophrenia or Bipolar Disorder Who Are<br>Using Antipsychotic Medications | 84.31%   | +1.22+   | 3  | 0  |
| Diabetes Monitoring for People With Diabetes and   | Schizophrenia  |  |  |  |
| Diabetes Monitoring for People With<br>Diabetes and Schizophrenia  | 69.97%   | +0.96  | 0  | 0  |
| Cardiovascular Monitoring for People With Cardio   | vascular Disease   | and Schizophr  | enia   |  |
| Cardiovascular Monitoring for People With<br>Cardiovascular Disease and Schizophrenia                              | 76.86%   | +7.22  | 1  | 0  |
| Adherence to Antipsychotic Medications for Individ   | uals With Schize   | ophrenia   |  |  |
| Adherence to Antipsychotic Medications for<br>Individuals With Schizophrenia                                       | 63.18%   | +2.02+   | 3  | 1  |

#### Table 8-1—HEDIS 2018 MWA Performance Levels and Trend Results for Living With Illness



| Measure  | HEDIS 2018<br>MWA and<br>Performance<br>Level <sup>1</sup> | HEDIS 2017<br>MWA–<br>HEDIS 2018<br>MWA<br>Comparison <sup>2</sup> | Number of<br>MHPs With<br>Statistically<br>Significant<br>Improvement<br>in HEDIS 2018 | Number of<br>MHPs With<br>Statistically<br>Significant<br>Decline in<br>HEDIS 2018 |
|--|--|--|--|--|
| Annual Monitoring for Patients on Persistent Media | cations  |  |  |  |
| ACE Inhibitors or ARBs                             | 86.60%   | -0.40  | 3  | 2  |
| Diuretics  | 86.64%   | -0.44  | 2  | 1  |
| $Total^{6}$  | 86.62%   | NC   | NC   | NC   |

<sup>1</sup> 2018 performance levels were based on comparisons of the HEDIS 2018 MWA measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks. 2018 performance levels represent the following percentile comparisons:

|  | 74th $\geq$ 75th and $\leq$ 89th $\geq$ 90th |
|--|--|
|--|--|

<sup>2</sup> HEDIS 2017 MWA to HEDIS 2018 MWA comparisons were based on a Chi-square test of statistical significance with a p-value <0.01 due to large denominators.

*Green Shading*<sup>+</sup> *Indicates that the HEDIS 2018 MWA demonstrated a statistically significant improvement from the HEDIS 2017 MWA.* 

*Red Shading*<sup>++</sup> Indicates that the HEDIS 2018 MWA demonstrated a statistically significant decline from the HEDIS 2017 MWA.

<sup>3</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medication Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>4</sup> To align with calculations from prior years, the weighted average for this measure used the eligible population for the survey rather than the number of people who responded as being smokers.

<sup>5</sup> Due to changes in the technical specifications for this measure, exercise caution when trending rates between 2018 and prior years.

<sup>6</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

NC indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark.

\* For this indicator, a lower rate indicates better performance.

Table 8-1 shows that for the Living With Illness domain, 11 of 21 (52.4 percent) MWA rates that could be compared to national Medicaid percentiles or prior years' rates demonstrated significant improvement from HEDIS 2017 to HEDIS 2018. Of note, four MHPs and the MWA demonstrated significant improvement of more than 5 percentage points for the *Antidepressant Medication Management* measure indicators. Please note, caution should be used when comparing the 2018 rates for *Antidepressant Medication Management* to national Medicaid percentiles and prior years' rates due to changes to the technical measure specifications for HEDIS 2018.

Additionally, 16 of 21 (76.2 percent) MWA rates ranked at or above the national Medicaid 50th percentile, with nine MWA rates ranking at or above the national Medicaid 75th percentile. The following nine rates demonstrated positive performance: *Comprehensive Diabetes Care—Eye Exam* (*Retinal*) *Performed* and *Medical Attention for Nephropathy*; *Medication Management for People With Asthma—Medication Compliance 50%—Total* and *Medication Compliance 75%—Total*; *Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit* and *Discussing Cessation Medications*; *Antidepressant Medication Management—Effective Acute Phase Treatment* and *Effective Continuation Phase Treatment*; and *Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications*.

LIVING WITH ILLNESS



Conversely, only one MWA rate, *Comprehensive Diabetes Care—HbA1c Poor Control* (>9.0%), demonstrated a significant decline in performance from HEDIS 2017 to HEDIS 2018. Further, the MWA rates for *Asthma Medication Ratio—Total*, *Diabetes Monitoring for People With Diabetes and Schizophrenia*, *Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia*, and *Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARBs* and *Diuretics* fell below the national Medicaid 50th percentile, indicating opportunities for improvement for these measures.


LIVING WITH ILLNESS



## **Measure-Specific Findings**


### Comprehensive Diabetes Care—Hemoglobin A1c (HbA1c) Testing

*Comprehensive Diabetes Care—Hemoglobin A1c (HbA1c) Testing* assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had HbA1c testing.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Three MHPs fell below the LPL. MHP performance varied by over 15 percentage points.




### Comprehensive Diabetes Care—HbA1c Poor Control (>9.0%)

*Comprehensive Diabetes Care—HbA1c Poor Control* (>9.0%) assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had HbA1c poor control. For this measure, a lower rate indicates better performance.



*Rates with two crosses* (++) *indicate a significant decline in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly declined from HEDIS 2017.




Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




### Comprehensive Diabetes Care—HbA1c Control (<8.0%)

*Comprehensive Diabetes Care—HbA1c Control* (<8.0%) assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had HbA1c control (<8.0%).



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 25 percentage points.




### Comprehensive Diabetes Care—Eye Exam (Retinal) Performed

*Comprehensive Diabetes Care—Eye Exam (Retinal) Performed* assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had an eye exam (retinal) performed.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 30 percentage points.




### Comprehensive Diabetes Care—Medical Attention for Nephropathy

*Comprehensive Diabetes Care—Medical Attention for Nephropathy* assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had medical attention for nephropathy.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. One MHP ranked below the LPL. MHP performance varied by over 5 percentage points.




### Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg)

*Comprehensive Diabetes Care—Blood Pressure Control (<140/90 mm Hg)* assesses the percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had blood pressure control (<140/90 mm Hg).



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. Four MHPs fell below the LPL. MHP performance varied by over 35 percentage points.




### Medication Management for People with Asthma—Medication Compliance 50%—Total

*Medication Management for People with Asthma—Medication Compliance 50%—Total* assesses the percentage of members 5 to 64 years of age who were identified as having persistent asthma and were dispensed appropriate medications that they continued to take for at least 50 percent of their treatment period.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




<sup>1</sup> Quality Compass percentiles for this measure were not available; therefore, the rates for this measure indicator were compared to the NCQA Audit Means and Percentiles.

Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with four MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 30 percentage points.




#### Medication Management for People with Asthma—Medication Compliance 75%—Total

*Medication Management for People with Asthma—Medication Compliance 75%—Total* assesses the percentage of members 5 to 64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they continued to take for at least 75 percent of their treatment period.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with five MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 40 percentage points.




#### Asthma Medication Ratio—Total

Asthma Medication Ratio—Total assesses the percentage of patients 5 to 64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Four MHPs ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 45 percentage points.




#### Controlling High Blood Pressure

*Controlling High Blood Pressure* assesses the percentage of members 18 to 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled during the measurement year based on the following criteria: Members 18 to 59 years of age whose BP was <140/90 mm Hg; Members 60 to 85 years of age with a diagnosis of diabetes whose BP was <140/90 mm Hg; and Members 60 to 85 years of age without a diagnosis of diabetes whose BP was <150/90 mm Hg.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Five MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. Three MHPs fell below the LPL. MHP performance varied by over 40 percentage points.




#### Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit

*Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit* assesses the percentage of members 18 years of age and older who are current smokers or tobacco users and who received cessation advice during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 5 percentage points.




#### Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Medications

*Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Medications* assesses the percentage of members 18 years of age and older who are current smokers or tobacco users and who discussed or were recommended cessation medications during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eleven MHPs and the MWA ranked above the national Medicaid 50th percentile, with five MHPs ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 5 percentage points.




#### Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Strategies

*Medical Assistance With Smoking and Tobacco Use Cessation—Discussing Cessation Strategies* assesses the percentage of members 18 years of age or older who are current smokers or tobacco users and who discussed or were provided cessation methods or strategies during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eleven MHPs and the MWA ranked above the national Medicaid 50th percentile, with one MHP ranking above the HPL. No MHPs fell below the LPL. MHP performance varied by over 10 percentage points.




#### Antidepressant Medication Management—Effective Acute Phase Treatment

Antidepressant Medication Management—Effective Acute Phase Treatment assesses the percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment for at least 84 days (12 weeks). Due to changes in the technical specifications for this measure indicator, exercise caution when trending rates between 2018 and prior years.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 30 percentage points.




#### Antidepressant Medication Management—Effective Continuation Phase Treatment

Antidepressant Medication Management—Effective Continuation Phase Treatment assesses the percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment for at least 180 days (6 months). Due to changes in the technical specifications for this measure indicator, exercise caution when trending rates between 2018 and prior years.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Eight MHPs and the MWA ranked above the national Medicaid 50th percentile, with three MHPs ranking above the HPL. No MHP fell below the LPL. MHP performance varied by over 25 percentage points.




# Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

*Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications* assesses the percentage of members between 18 and 64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




Ten MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. One MHP fell below the LPL. MHP performance varied by over 15 percentage points.




### Diabetes Monitoring for People With Diabetes and Schizophrenia

*Diabetes Monitoring for People With Diabetes and Schizophrenia* assesses the percentage of members between 18 and 64 years of age with schizophrenia and diabetes, who had both a low-density lipoprotein cholesterol (LDL-C) test and an HbA1c test during the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




*NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

Five MHPs ranked above the national Medicaid 50th percentile but below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 20 percentage points.




### Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

*Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia* assesses the percentage of members between 18 and 64 years of age with schizophrenia and cardiovascular disease who had an LDL-C test during the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

No MHPs with reportable rates ranked above the HPL or national Medicaid 50th percentile. All MHPs with a reportable rate and the MWA fell below the national Medicaid 50th percentile but above the LPL. MHP performance varied by about 2 percentage points.




#### Adherence to Antipsychotic Medications for Individuals With Schizophrenia

Adherence to Antipsychotic Medications for Individuals With Schizophrenia assesses the percentage of members between 19 and 64 years of age with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.



*Rates with one cross* (+) *indicate a significant improvement in performance from the previous year.* 

# The HEDIS 2018 MWA rate significantly improved from HEDIS 2017.




*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 

Six MHPs and the MWA ranked above the national Medicaid 50th percentile, with two MHPs ranking above the HPL. Two MHPs fell below the LPL. MHP performance varied by over 30 percentage points. HSAG HEALTH SERVICES


#### LIVING WITH ILLNESS

#### Annual Monitoring for Patients on Persistent Medications—ACE Inhibitors or ARBs

Annual Monitoring for Patients on Persistent Medications–ACE Inhibitors or ARBs assesses the percentage of patients 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and had at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Three MHPs ranked above the national Medicaid 50th percentile but below the HPL. Four MHPs fell below the LPL. MHP performance varied by over 5 percentage points.




#### Annual Monitoring for Patients on Persistent Medications-Diuretics

Annual Monitoring for Patients on Persistent Medications—Diuretics assesses the percentage of patients 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for diuretics and had at least one serum potassium and a serum creatinine therapeutic monitoring test in the measurement year.



The HEDIS 2018 MWA rate did not demonstrate a significant change from 2017 to 2018.




Two MHPs ranked above the national Medicaid 50th percentile but below the HPL. Two MHPs fell below the LPL. MHP performance varied by over 5 percentage points.




### Annual Monitoring for Patients on Persistent Medications—Total

Annual Monitoring for Patients on Persistent Medications–Total assesses the percentage of patients 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for ACE inhibitors or ARBs, or diuretics during the measurement year and had at least one therapeutic monitoring event for the agent in the measurement year.



Due to changes in the technical specifications in HEDIS 2018 for the *Annual Monitoring for Patients on Persistent Medications—Total* measure indicator, a comparison to prior years' results is not appropriate. The rate in the chart above is presented for information purposes only.



Due to changes in the technical specifications in HEDIS 2018 for the *Annual Monitoring for Patients on Persistent Medications—Total* measure indicator, a comparison to benchmarks is not appropriate. The rates in the chart above are presented for information purposes only. MHP performance varied by over 5 percentage points.



## Introduction

The Utilization measure domain encompasses the following MDHHS measures:

- Race/Ethnicity Diversity of Membership
- Language Diversity of Membership

## **Summary of Findings**

Although measures under this domain are not performance measures and are not compared to national Medicaid percentiles, changes observed in the results may provide insight into how select member characteristics affect the MHPs' provision of services and care. The *Race/Ethnicity Diversity of Membership* measure shows that the HEDIS 2018 statewide rates for different racial/ethnic groups were fairly stable across years, with less than 1 percentage point difference between HEDIS 2017 and HEDIS 2018 rates for all racial/ethnic groups.

For the *Language Diversity of Membership* measure, HEDIS 2018 rates remained similar to prior years, with Michigan members reporting using English as the preferred spoken language for healthcare and preferred language for written materials, with less than 1 percentage point difference between HEDIS 2017 and HEDIS 2018.



### Race/Ethnicity Diversity of Membership

#### **Measure Definition**

*Race/Ethnicity Diversity of Membership* is an unduplicated count and percentage of members enrolled at any time during the measurement year, by race and ethnicity.

#### Results

Tables 9-1a and 9-1b show that the statewide rates for reported racial/ethnic groups remained consistent from HEDIS 2016 to HEDIS 2018.

#### Table 9-1a—MHP and MWA Results for Race/Ethnicity Diversity of Membership

| мнр            | Eligible<br>Population | White  | Black or<br>African<br>American | American<br>Indian or<br>Alaska Native | Asian | Native<br>Hawaiian and<br>Other Pacific<br>Islander |
|----------------|------------------------|--------|---------------------------------|--|-------|---|
| AET            | 57,443                 | 26.57% | 60.54%                          | 0.15%                                  | 0.65% | 0.06%   |
| BCC            | 262,751                | 45.03% | 34.27%                          | 0.44%                                  | 1.64% | 0.08%   |
| HAR            | 13,623                 | 27.17% | 51.38%                          | 0.12%                                  | 0.00% | 0.99%   |
| MCL            | 248,361                | 66.14% | 18.23%                          | 0.51%                                  | 0.65% | 0.07%   |
| MER            | 653,627                | 61.91% | 21.40%                          | 0.46%                                  | 0.70% | 0.05%   |
| MID            | 10,401                 | 47.76% | 35.71%                          | 0.00%                                  | 2.04% | 0.21%   |
| MOL            | 440,337                | 45.47% | 33.92%                          | 0.26%                                  | 0.32% | <0.01%  |
| PRI            | 159,208                | 62.18% | 14.10%                          | 0.55%                                  | 0.83% | 0.07%   |
| THC            | 67,951                 | 30.89% | 54.27%                          | 0.28%                                  | 1.15% | 0.06%   |
| UNI            | 319,389                | 51.27% | 30.28%                          | 0.25%                                  | 2.05% | 0.01%   |
| UPP            | 57,352                 | 87.26% | 1.54%                           | 2.30%                                  | 0.24% | 0.05%   |
| HEDIS 2018 MWA |                        | 54.36% | 27.37%                          | 0.43%                                  | 0.93% | 0.05%   |
| HEDIS 2017 MWA |                        | 53.98% | 27.55%                          | 0.45%                                  | 0.89% | 0.12%   |
| HEDIS 2016 MWA |                        | 54.01% | 28.00%                          | 0.49%                                  | 1.09% | 0.05%   |



| МНР            | Eligible<br>Population | Some Other<br>Race | Two or More<br>Races | Unknown | Declined | Hispanic or<br>Latino* |
|----------------|------------------------|--------------------|----------------------|---------|----------|------------------------|
| AET            | 57,443                 | 0.00%              | 0.00%                | 4.43%   | 7.61%    | 3.14%                  |
| BCC            | 262,751                | 7.17%              | 0.00%                | 8.24%   | 3.14%    | 5.49%                  |
| HAR            | 13,623                 | 3.96%              | 0.00%                | 16.38%  | 0.00%    | 3.96%                  |
| MCL            | 248,361                | 5.45%              | 0.00%                | 8.96%   | 0.00%    | 5.45%                  |
| MER            | 653,627                | 0.02%              | 0.00%                | 6.08%   | 9.38%    | 5.75%                  |
| MID            | 10,401                 | 2.72%              | 0.00%                | 11.57%  | 0.00%    | 2.72%                  |
| MOL            | 440,337                | < 0.01%            | <0.01%               | 20.02%  | 0.00%    | 6.70%                  |
| PRI            | 159,208                | 0.01%              | 0.00%                | 22.27%  | 0.00%    | 10.59%                 |
| THC            | 67,951                 | 2.63%              | 0.00%                | 10.72%  | 0.00%    | 2.63%                  |
| UNI            | 319,389                | 0.00%              | 0.00%                | 16.15%  | 0.00%    | 5.60%                  |
| UPP            | 57,352                 | 1.64%              | 0.00%                | 0.00%   | 6.96%    | 1.64%                  |
| HEDIS 2018 MWA |                        | 1.57%              | 0.00%                | 11.88%  | 3.40%    | 5.90%                  |
| HEDIS 2017 MWA |                        | 1.33%              | 0.00%                | 12.44%  | 3.25%    | 5.46%                  |
| HEDIS 2016 MWA |                        | 1.23%              | 0.00%                | 12.23%  | 2.89%    | 5.27%                  |

#### Table 9-1b—MHP and MWA Results for Race/Ethnicity Diversity of Membership (Continued)

\* Starting from HEDIS 2011, the rates associated with members of Hispanic origin were not based on the total number of members in the health plan. Therefore, the rates presented here were calculated by HSAG using the total number of members reported from the Hispanic or Latino column divided by the total number of members in the health plan reported in the MHP IDSS files.



### Language Diversity of Membership

#### **Measure Definition**

*Language Diversity of Membership* is an unduplicated count and percentage of members enrolled at any time during the measurement year by spoken language preferred for healthcare and the preferred language for written materials.

#### Results

Table 9-2 shows that the percentage of Michigan members using English as the preferred spoken language for healthcare remained consistent when compared to the previous years, with almost 90 percent of members reporting English as their preferred spoken language for healthcare at the statewide level.

| МНР            | Eligible<br>Population | English | Non-English | Unknown | Declined |
|----------------|------------------------|---------|-------------|---------|----------|
| AET            | 57,443                 | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| BCC            | 262,751                | 97.48%  | 2.46%       | 0.06%   | 0.00%    |
| HAR            | 13,623                 | 98.98%  | 0.99%       | 0.03%   | 0.00%    |
| MCL            | 248,361                | 95.62%  | 0.77%       | 3.61%   | 0.00%    |
| MER            | 653,627                | 98.62%  | 1.35%       | 0.03%   | 0.00%    |
| MID            | 10,401                 | 100.00% | 0.00%       | 0.00%   | 0.00%    |
| MOL            | 440,337                | 98.66%  | 1.27%       | 0.07%   | 0.00%    |
| PRI            | 159,208                | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| THC            | 67,951                 | 99.13%  | 0.87%       | 0.00%   | 0.00%    |
| UNI            | 319,389                | 95.63%  | 4.37%       | <0.01%  | 0.00%    |
| UPP            | 57,352                 | 99.95%  | 0.03%       | 0.02%   | 0.00%    |
| HEDIS 2018 MWA |                        | 88.48%  | 1.64%       | 9.88%   | 0.00%    |
| HEDIS 2017 MWA |                        | 88.52%  | 1.49%       | 10.00%  | 0.00%    |
| HEDIS 2016 MWA |                        | 88.26%  | 1.11%       | 10.63%  | 0.00%    |

#### Table 9-2—MHP and MWA Results for Language Diversity of Membership— Spoken Language Preferred for Healthcare



Table 9-3 shows that for each MHP over 95 percent of Michigan members who reported a language reported English as the language preferred for written materials. At the statewide level, English remained the preferred language for written materials for most (over 70 percent) Michigan members from HEDIS 2016 to HEDIS 2018.

|                |            | 0 0     |             |         |          |
|----------------|------------|---------|-------------|---------|----------|
|                | Eligible   |         |             |         |          |
| МНР            | Population | English | Non-English | Unknown | Declined |
| AET            | 57,443     | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| BCC            | 262,751    | 97.48%  | 2.46%       | 0.06%   | 0.00%    |
| HAR            | 13,623     | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| MCL            | 248,361    | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| MER            | 653,627    | 98.62%  | 1.35%       | 0.03%   | 0.00%    |
| MID            | 10,401     | 100.00% | 0.00%       | 0.00%   | 0.00%    |
| MOL            | 440,337    | 98.66%  | 1.27%       | 0.07%   | 0.00%    |
| PRI            | 159,208    | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| THC            | 67,951     | 99.13%  | 0.87%       | 0.00%   | 0.00%    |
| UNI            | 319,389    | 95.63%  | 4.37%       | <0.01%  | 0.00%    |
| UPP            | 57,352     | 99.95%  | 0.03%       | 0.02%   | 0.00%    |
| HEDIS 2018 MWA |            | 77.53%  | 1.55%       | 20.93%  | 0.00%    |
| HEDIS 2017 MWA |            | 77.72%  | 1.40%       | 20.88%  | 0.00%    |
| HEDIS 2016 MWA |            | 70.13%  | 1.08%       | 28.79%  | 0.00%    |

#### Table 9-3—MHP and MWA Results for Language Diversity of Membership— Preferred Language for Written Materials



Table 9-4 shows that over half of Michigan members reported English as their preferred language for other language needs, and slightly less than half of Michigan members had Unknown listed as their preferred language for other language needs. Please note that *Language Diversity of Membership—Other Language Needs* captures data collected from questions that cannot be mapped to any other category (e.g., What is the primary language spoken at home?).

| МНР            | Eligible<br>Population | English | Non-English | Unknown | Declined |
|----------------|------------------------|---------|-------------|---------|----------|
| AET            | 57,443                 | 99.13%  | 0.76%       | 0.11%   | 0.00%    |
| BCC            | 262,751                | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| HAR            | 13,623                 | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| MCL            | 248,361                | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| MER            | 653,627                | 98.62%  | 1.35%       | 0.03%   | 0.00%    |
| MID            | 10,401                 | 100.00% | 0.00%       | 0.00%   | 0.00%    |
| MOL            | 440,337                | 98.66%  | 1.27%       | 0.07%   | 0.00%    |
| PRI            | 159,208                | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| THC            | 67,951                 | 99.13%  | 0.87%       | 0.00%   | 0.00%    |
| UNI            | 319,389                | 0.00%   | <0.01%      | 100.00% | 0.00%    |
| UPP            | 57,352                 | 0.00%   | 0.00%       | 100.00% | 0.00%    |
| HEDIS 2018 MWA |                        | 52.99%  | 0.68%       | 46.33%  | 0.00%    |
| HEDIS 2017 MWA |                        | 54.13%  | 0.64%       | 45.23%  | 0.00%    |
| HEDIS 2016 MWA |                        | 52.71%  | 0.51%       | 46.78%  | 0.00%    |

| Table 9-4—MHP and MWA Results for Language Diversity of Membership—Other Language Needs      |
|--|
| Tuble 5 4 min and mit internessing for Language Diversity of membership Other Language meeus |



# Introduction

The Utilization measure domain encompasses the following MDHHS measures:

- Ambulatory Care—Total (Per 1,000 Member Months)
  - Emergency Department Visits—Total
  - Outpatient Visits—Total
- Inpatient Utilization—General Hospital/Acute Care
  - Total Inpatient—Discharges per 1,000 Member Months—Total
  - Total Inpatient—Average Length of Stay—Total
  - Maternity—Discharges per 1,000 Member Months—Total
  - Maternity—Average Length of Stay—Total
  - Surgery—Discharges per 1,000 Member Months—Total
  - Surgery—Average Length of Stay—Total
  - Medicine—Discharges per 1,000 Member Months—Total
  - Medicine—Average Length of Stay—Total
- Use of Opioids From Multiple Providers
  - Multiple Prescribers
  - Multiple Pharmacies
  - Multiple Prescribers and Multiple Pharmacies
- Use of Opioids at High Dosage
  - Use of Opioids at High Dosage

The following tables present the HEDIS 2018 MHP-specific rates as well as the Michigan Medicaid Average (MA) for HEDIS 2018, HEDIS 2017, and HEDIS 2016. To align with calculations from prior years, HSAG calculated traditional averages for measure indicators in the Utilization measure domain; therefore, the MA is presented rather than the Medicaid Weighted Average (MWA), which was calculated and presented for all other measures. All measures in this domain are designed to describe the frequency of specific services provided by MHPs and are not risk adjusted. Therefore, it is important to assess utilization supplemented by information on the characteristics of each MHP's population.

## **Summary of Findings**

As stated above, reported rates for the MHPs and MA rates for the Utilization measure domain did not take into account the characteristics of the population; therefore, HSAG could not draw conclusions on performance based on the reported utilization results. Nonetheless, combined with other performance



metrics, the MHP and MA utilization results provide additional information that MHPs and MDHHS may use to assess barriers or patterns of utilization when evaluating improvement interventions.

## **Measure-Specific Findings**

### Ambulatory Care—Total (Per 1,000 Member Months)

The Ambulatory Care—Total (Per 1,000 Member Months) measure summarizes use of ambulatory care for *Emergency Department Visits*—Total and Outpatient Visits—Total. In this section, the results for the total age group are presented.

#### Results

Table 10-1 shows *Emergency Department Visits—Total* and *Outpatient Visits—Total* per 1,000 member months for ambulatory care for the total age group.

| МНР           | Member Months | Emergency<br>Department<br>Visits—Total* | Outpatient<br>Visits—Total |
|---------------|---------------|--|----------------------------|
| AET           | 532,014       | 82.21                                    | 301.45                     |
| BCC           | 2,212,604     | 64.19                                    | 400.42                     |
| HAR           | 105,779       | 71.57                                    | 225.08                     |
| MCL           | 2,239,264     | 74.32                                    | 558.58                     |
| MER           | 5,889,136     | 73.23                                    | 396.18                     |
| MID           | 90,722        | 71.25                                    | 506.48                     |
| MOL           | 4,282,886     | 70.06                                    | 422.90                     |
| PRI           | 1,485,824     | 71.90                                    | 381.02                     |
| THC           | 628,430       | 70.05                                    | 336.34                     |
| UNI           | 3,019,347     | 69.56                                    | 380.46                     |
| UPP           | 533,773       | 61.07                                    | 339.03                     |
| HEDIS 2018 MA | —             | 70.86                                    | 386.18                     |
| HEDIS 2017 MA | _             | 74.37                                    | 389.30                     |
| HEDIS 2016 MA |               | 74.00                                    | 373.49                     |

#### Table 10-1—Ambulatory Care—Total (Per 1,000 Member Months) for Total Age Group

\* A lower rate may indicate more favorable performance for this measure indicator (i.e., low rates of emergency department services may indicate better utilization of services).

For the *Emergency Department Visits—Total* and *Outpatient Visits—Total* indicators, the Michigan average remained steady from HEDIS 2016 to HEDIS 2018 for the number of visits per 1,000 member months.



## Inpatient Utilization—General Hospital/Acute Care—Total

The Inpatient Utilization—General Hospital/Acute Care—Total measure summarizes use of acute inpatient care and services in four categories: Total Inpatient, Medicine, Surgery, and Maternity.

#### Results

Table 10-2 shows the member months for all ages and the *Total Discharges per 1,000 Member Months* for the total age group. The values in the table below are presented for information purposes only.

# Table 10-2—Inpatient Utilization—General Hospital/Acute Care: Total Discharges per 1,000 Member Months for Total Age Group

| МНР           | Member<br>Months | Total Inpatient | Maternity** | Surgery | Medicine |
|---------------|------------------|-----------------|-------------|---------|----------|
| AET           | 532,335          | 8.17            | 2.62        | 1.75    | 4.47     |
| BCC           | 2,212,604        | 7.55            | 2.75        | 1.73    | 3.68     |
| HAR           | 105,779          | 7.43            | 0.88        | 1.88    | 4.30     |
| MCL           | 2,239,264        | 8.84            | 2.66        | 2.16    | 4.71     |
| MER           | 5,889,136        | 7.55            | 3.16        | 1.71    | 3.57     |
| MID           | 90,722           | 12.18           | 1.19        | 2.94    | 8.52     |
| MOL           | 4,282,886        | 7.63            | 2.56        | 1.85    | 3.93     |
| PRI           | 1,485,824        | 6.80            | 2.95        | 1.57    | 3.17     |
| THC           | 628,430          | 10.34           | 2.40        | 2.08    | 6.44     |
| UNI           | 3,019,347        | 6.33            | 2.56        | 1.49    | 3.00     |
| UPP           | 533,773          | 6.26            | 2.42        | 1.81    | 2.65     |
| HEDIS 2018 MA |                  | 8.10            | 2.38        | 1.91    | 4.40     |
| HEDIS 2017 MA |                  | 8.68            | 2.36        | 2.30    | 4.48     |
| HEDIS 2016 MA |                  | 8.27            | 2.59        | 1.83    | 4.52     |

\*\* The Maternity measure indicators were calculated using member months for members 10 to 64 years of age.



Table 10-3 displays the *Total Average Length of Stay* for all ages and are presented for information purposes only.

|               |                  | IUI IUIAI Age UI | oup       |         |          |
|---------------|------------------|------------------|-----------|---------|----------|
| МНР           | Member<br>Months | Total Inpatient  | Maternity | Surgery | Medicine |
| AET           | 532,335          | 4.14             | 2.62      | 6.47    | 3.88     |
| BCC           | 2,212,604        | 3.98             | 2.61      | 6.22    | 3.72     |
| HAR           | 105,779          | 4.89             | 2.40      | 6.14    | 4.82     |
| MCL           | 2,239,264        | 4.44             | 2.24      | 5.96    | 4.69     |
| MER           | 5,889,136        | 3.99             | 2.58      | 6.38    | 3.74     |
| MID           | 90,722           | 5.80             | 3.03      | 8.07    | 5.25     |
| MOL           | 4,282,886        | 4.58             | 2.72      | 7.69    | 3.98     |
| PRI           | 1,485,824        | 3.62             | 2.65      | 4.48    | 3.85     |
| THC           | 628,430          | 4.58             | 2.69      | 7.05    | 4.32     |
| UNI           | 3,019,347        | 4.18             | 2.56      | 6.74    | 3.91     |
| UPP           | 533,773          | 3.98             | 2.77      | 5.67    | 3.66     |
| HEDIS 2018 MA |                  | 4.38             | 2.62      | 6.44    | 4.17     |
| HEDIS 2017 MA |                  | 4.02             | 2.61      | 5.91    | 3.67     |
| HEDIS 2016 MA |                  | 3.98             | 2.63      | 6.18    | 3.64     |

# Table 10-3—Inpatient Utilization—General Hospital/Acute Care: Total Average Length of Stay for Total Age Group



## Use of Opioids From Multiple Providers

The Use of Opioids From Multiple Providers is a first-year measure that summarizes use of prescription opioids received from four or more providers. Three rates are reported: Multiple Prescribers, Multiple Pharmacies, and Multiple Prescribers and Multiple Pharmacies.

## Results

Table 10-4 shows the HEDIS 2018 rate per 1,000 members receiving prescription opioids. The values in the table below are presented for information purposes only.

| МНР           | Use of Opioids<br>From Multiple<br>Providers—<br>Eligible<br>Population | Use of Opioids<br>From Multiple<br>Providers—<br>Multiple<br>Prescribers <sup>1</sup> | Use of Opioids<br>From Multiple<br>Providers—<br>Multiple<br>Pharmacies <sup>1</sup> | Use of Opioids<br>From Multiple<br>Providers—<br>Multiple<br>Prescribers<br>and Multiple<br>Pharmacies <sup>1</sup> |
|---------------|---|---|--|---|
| AET           | 3,131   | 230.92  | 107.31   | 60.36   |
| BCC           | 13,428  | 203.46  | 162.05   | 84.60   |
| HAR           | 447   | 255.03  | 337.81   | 241.61  |
| MCL           | 14,317  | 151.71  | 87.45  | 33.88   |
| MER           | 36,741  | 214.34  | 71.53  | 44.12   |
| MID           | 1,274   | 169.54  | 48.67  | 28.26   |
| MOL           | 28,275  | 224.19  | 86.93  | 59.06   |
| PRI           | 7,197   | 294.43  | 91.29  | 55.72   |
| THC           | 4,982   | 199.52  | 84.30  | 52.59   |
| UNI           | 16,940  | 184.59  | 1.36   | 0.83  |
| UPP           | 2,845   | 237.61  | 92.79  | 65.73   |
| HEDIS 2018 MA |   | 209.04  | 80.47  | 47.15   |
| HEDIS 2017 MA |   |   |  |   |
| HEDIS 2016 MA |   |   |  |   |

## Table 10-4—Use of Opioids From Multiple Providers (Per 1,000 Members)\*

\*For this measure, a lower rate indicates better performance.

<sup>1</sup> This measure is a first-year measure; therefore, the measure does not have an applicable benchmark.



## Use of Opioids at High Dosage

The Use of Opioids at High Dosage is a first-year measure that summarizes use of prescription opioids received at a high dosage.

## Results

Table 10-5 shows the HEDIS 2018 rate per 1,000 members receiving prescription opioids at a high dosage. The values in the table below are presented for information purposes only.

| МНР           | <b>Eligible Population</b> | Rate <sup>1</sup> |
|---------------|----------------------------|-------------------|
| AET           | 2,722                      | 18.37             |
| BCC           | 11,459                     | 72.08             |
| HAR           | 387                        | 5.17              |
| MCL           | 12,702                     | 23.70             |
| MER           | 32,247                     | 26.48             |
| MID           | 1,080                      | 0.00              |
| MOL           | 25,074                     | 21.38             |
| PRI           | 6,238                      | 39.28             |
| THC           | 4,435                      | 80.72             |
| UNI           | 15,030                     | 35.33             |
| UPP           | 2,549                      | 30.99             |
| HEDIS 2018 MA |                            | 33.20             |
| HEDIS 2017 MA |                            |                   |
| HEDIS 2016 MA | —                          |                   |

Table 10-5—Use of Opioids at High Dosage (Per 1,000 Members)\*

\* For this measure, a lower rate indicates better performance.

<sup>1</sup> This measure is a first-year measure; therefore, the measure does not have an applicable benchmark.



## 11. HEDIS Reporting Capabilities—Information Systems Findings

## **HEDIS Reporting Capabilities—Information Systems Findings**

NCQA's IS standards are the guidelines used by certified HEDIS compliance auditors to assess an MHP's ability to report HEDIS data accurately and reliably.<sup>11-1</sup> Compliance with the guidelines also helps an auditor to understand an MHP's HEDIS reporting capabilities. For HEDIS 2018, MHPs were assessed on six IS standards. To assess an MHP's adherence to the IS standards, HSAG reviewed several documents for the MHPs. These included the MHPs' final audit reports (FARs), IS compliance tools, and the IDSS files approved by their respective NCQA-licensed audit organization (LO).

All the Michigan MHPs contracted with the same LOs as they did in the prior year to conduct the NCQA HEDIS Compliance Audit<sup>TM</sup>.<sup>11-2</sup> The MHPs were able to select the LO of their choice. Overall, the Michigan MHPs consistently maintain the same LOs across reporting years.

For HEDIS 2018, all but one MHP contracted with an external software vendor for HEDIS measure production and rate calculation. HSAG reviewed the MHPs' FARs and ensured that these software vendors participated in and passed the NCQA's Measure Certification process. MHPs could purchase the software with certified measures and generate HEDIS measure results internally or provide all data to the software vendor to generate HEDIS measures for them. Either way, using software with NCQA-certified measures may reduce the MHPs' burden for reporting and help ensure rate validity. For the MHP that calculated its rate using internally developed source code, the auditor selected a core set of measures and manually reviewed the programming codes to verify accuracy and compliance with HEDIS 2018 technical specifications.

HSAG found that, in general, all MHPs' IS and processes were compliant with the applicable IS standards and the HEDIS determination reporting requirements related to the measures for HEDIS 2018. The following sections present NCQA's IS standards and summarize the audit findings related to each IS standard for the MHPs.

<sup>&</sup>lt;sup>11-1</sup> National Committee for Quality Assurance. *HEDIS*<sup>®</sup> 2017, *Volume 5: HEDIS Compliance Audit<sup>TM</sup>: Standards, Policies and Procedures.* Washington D.C.

<sup>&</sup>lt;sup>11-2</sup> NCQA HEDIS Compliance Audit<sup>TM</sup> is a trademark of the National Committee for Quality Assurance (NCQA).



# *IS* 1.0—Medical Service Data—Sound Coding Methods and Data Capture, Transfer, and Entry

This standard assesses whether:

- Industry standard codes are used and all characters are captured.
- Principal codes are identified and secondary codes are captured.
- Nonstandard coding schemes are fully documented and mapped back to industry standard codes.
- Standard submission forms are used and capture all fields relevant to measure reporting; all proprietary forms capture equivalent data; and electronic transmission procedures conform to industry standards.
- Data entry processes are timely and accurate and include sufficient edit checks to ensure the accurate entry of submitted data in transaction files for measure reporting.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 1.0, Medical Service Data—Sound Coding Methods and Data Capture, Transfer, and Entry.* The auditors confirmed that the MHPs captured all necessary data elements appropriately for HEDIS reporting. A majority of the MHPs accepted industry standard codes on industry standard forms. Any nonstandard code that was used for measure reporting was mapped to industry standard code appropriately. Adequate validation processes such as built-in edit checks, data monitoring, and quality control audits were in place to ensure that only complete and accurate claims and encounter data were used for HEDIS reporting.

## IS 2.0—Enrollment Data—Data Capture, Transfer, and Entry

This standard assesses whether:

- The organization has procedures for submitting measure-relevant information for data entry, and whether electronic transmissions of membership data have necessary procedures to ensure accuracy.
- Data entry processes are timely and accurate and include sufficient edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 2.0, Enrollment Data—Data Capture, Transfer, and Entry.* Data fields required for HEDIS measure reporting were captured appropriately. Based on the auditors' review, 10 of the MHPs processed eligibility files in a timely manner, but Aetna Better Health of Michigan had timeliness issues related to the processing of newborn enrollments. These issues were corrected by the MHP and reviewed by the auditor, who determined no impact to reporting. Enrollment information housed in the MHPs' systems was reconciled against the enrollment files provided by the



State. Sufficient data validations were in place to ensure that only accurate data were used for HEDIS reporting.

## IS 3.0—Practitioner Data—Data Capture, Transfer, and Entry

This standard assesses whether:

- Provider specialties are fully documented and mapped to HEDIS provider specialties necessary for measure reporting.
- The organization has effective procedures for submitting measure-relevant information for data entry, and whether electronic transmissions of practitioner data are checked to ensure accuracy.
- Data entry processes are timely and accurate and include edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

Ten of the MHPs were fully compliant with *IS 3.0, Practitioner Data—Data Capture, Transfer, and Entry,* whereas one MHP was only partially compliant with this standard. The MHPs had sufficient processes in place to capture all data elements required for HEDIS reporting. Primary care practitioners and specialists were appropriately identified by all MHPs. Provider specialties were fully and accurately mapped to HEDIS-specified provider types. Adequate validation processes were in place to ensure that only accurate provider data were used for HEDIS reporting.

# *IS 4.0—Medical Record Review Processes—Training, Sampling, Abstraction, and Oversight*

This standard assesses whether:

- Forms capture all fields relevant to measure reporting and whether electronic transmission procedures conform to industry standards and have necessary checking procedures to ensure data accuracy (logs, counts, receipts, hand-off and sign-off).
- Retrieval and abstraction of data from medical records are reliably and accurately performed.
- Data entry processes are timely and accurate and include sufficient edit checks to ensure accurate entry of submitted data in the files for measure reporting.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 4.0, Medical Record Review Processes—Training, Sampling, Abstraction, and Oversight.* Medical record data were used by all MHPs to report HEDIS hybrid measures. Medical record abstraction tools were reviewed and approved by the MHPs' auditors for HEDIS reporting. Contracted vendor staff or internal staff used by the MHPs had sufficient qualification



and training in the current year's HEDIS technical specifications and the use of MHP-specific abstraction tools to accurately conduct medical record reviews. Sufficient validation processes and edit checks were in place to ensure data completeness and data accuracy. Aetna Better Health of Michigan struggled to provide the auditor with final counts following medical record review validation; however, the auditor received the required documentation to resolve the issues and determined there was no impact to reporting.

## IS 5.0—Supplemental Data—Capture, Transfer, and Entry

This standard assesses whether:

- Nonstandard coding schemes are fully documented and mapped to industry standard codes.
- The organization has effective procedures for submitting measure-relevant information for data entry and whether electronic transmissions of data have validation procedures to ensure accuracy.
- Data entry processes are timely and accurate and include edit checks to ensure accurate entry of submitted data in transaction files.
- The organization continually assesses data completeness and takes steps to improve performance.
- The organization regularly monitors vendor performance against expected performance standards.

All MHPs were fully compliant with *IS 5.0, Supplemental Data—Capture, Transfer, and Entry.* Supplemental data sources used by the MHPs were verified and approved by the auditors. The auditors performed primary source verification of a sample of records selected from each nonstandard supplemental database used by the MHPs. In addition, the auditors reviewed the supplemental data impact reports provided by the MHPs for reasonability. Validation processes such as reconciliation between original data sources and MHP-specific data systems, edit checks, and system validations ensured data completeness and data accuracy. There were no issues noted regarding how the MHPs managed the collection, validation, and integration of the various supplemental data sources. The auditors continued to encourage the MHPs to explore ways to maximize the use of supplemental data.

# *IS 7.0—Data Integration—Accurate HEDIS Reporting, Control Procedures That Support HEDIS Reporting Integrity*

This standard assesses whether:

- Nonstandard coding schemes are fully documented and mapped to industry standard codes.
- Data transfers to repository from transaction files are accurate.
- File consolidations, extracts, and derivations are accurate.
- Repository structure and formatting are suitable for measures and enable required programming efforts.
- Report production is managed effectively and operators perform appropriately.



- Measure reporting software is managed properly with regard to development, methodology, documentation, revision control, and testing.
- Physical control procedures ensure measure data integrity such as physical security, data access authorization, disaster recovery facilities, and fire protection.
- The organization regularly monitors vendor performance against expected performance standards.

Ten of the MHPs were fully compliant with *IS 7.0, Data Integration—Accurate HEDIS Reporting Control Procedures That Support HEDIS Reporting Integrity*, and one MHP was not fully compliant with this standard. All the MHPs but one contracted with a software vendor producing NCQA-certified measures to calculate HEDIS rates. For the MHP that did not use a software vendor, the auditor requested, reviewed, and approved source code for a selected core set of HEDIS measures. For all MHPs, the auditors determined that data mapping, data transfers, and file consolidations were sufficient. Adequate validation processes were in place for 10 of the MHPs to ensure that only accurate and complete data were used for HEDIS reporting. Aetna Better Health of Michigan did not have a mechanism in place to monitor or ensure that all data feeds were received for loading. However, the rates submitted were reportable and were not materially biased. The auditors did not document any issues with the MHPs' data integration and report production processes. Sufficient vendor oversight was in place for each MHP using a software vendor.



## Glossary

Table 12-1 below provides definitions of terms and acronyms used throughout this report.

| Term              | Description  |
|-------------------|--|
| ADHD              | Attention-deficit/hyperactivity disorder.  |
| Audit Result      | The HEDIS auditor's final determination, based on audit findings, of the appropriateness of the MHP to publicly report its HEDIS measure rates. Each measure indicator rate included in the HEDIS audit receives an audit result of <i>Reportable (R), Small Denominator (NA), Biased Rate (BR), No Benefit (NB), Not Required (NQ), Not Reported (NR),</i> and <i>Unaudited (UN).</i> |
| ADMIN%            | Percentage of the rate derived using administrative data (e.g., claims data and immunization registry).  |
| BMI               | Body mass index.   |
| BR                | Biased Rate; indicates that the MHP's reported rate was invalid, therefore, the rate was not presented.  |
| CVX               | Vaccine administered codes.  |
| Data Completeness | The degree to which occurring services/diagnoses appear in the MHP's administrative data systems.  |
| Denominator       | The number of members who meet all criteria specified in a measure for<br>inclusion in the eligible population. When using the administrative method,<br>the entire eligible population becomes the denominator. When using the<br>hybrid method, a sample of the eligible population becomes the denominator.   |
| DTaP              | Diphtheria, tetanus toxoids, and acellular pertussis vaccine.  |
| ED                | Emergency department.  |
| EDD               | Estimated date of delivery.  |
| EDI               | Electronic data interchange; the direct computer-to-computer transfer of data.   |
| Encounter Data    | Billing data received from a capitated provider. (Although the MHP does not reimburse the provider for each encounter, submission of encounter data allows the MHP to collect the data for future HEDIS reporting.)  |
| FAR               | Following the MHP's completion of any corrective actions, an auditor<br>completes the final audit report (FAR), documenting all final findings and<br>results of the HEDIS audit. The FAR includes a summary report, IS<br>capabilities assessment, medical record review validation findings, measure<br>results, and the auditor's audit opinion (the final audit statement).        |

## Table 12-1—Definition of Terms



| Term                         | Description   |
|------------------------------|---|
| HEDIS                        | The Healthcare Effectiveness Data and Information Set (HEDIS), developed<br>and maintained by NCQA, is a set of performance measures used to assess the<br>quality of care provided by managed health care organizations.   |
| HEDIS Repository             | The data warehouse where all data used for HEDIS reporting are stored.  |
| Hep A                        | Hepatitis A vaccine.  |
| Hep B                        | Hepatitis B vaccine.  |
| HiB Vaccine                  | Haemophilus influenza type B vaccine.   |
| НМО                          | Health maintenance organization.  |
| HPL                          | High performance level. (For most performance measures, MDHHS defined the HPL as the most recent national Medicaid 90th percentile. For measures such as <i>Comprehensive Diabetes Care—HbA1c Poor Control</i> [>9.0%], in which lower rates indicate better performance, the 10th percentile [rather than the 90th percentile] is considered the HPL.)               |
| HPV                          | Human papillomavirus vaccine.   |
| HSAG                         | Health Services Advisory Group, Inc., the State's external quality review organization.   |
| Hybrid Measures              | Measures that can be reported using the hybrid method.  |
| IDSS                         | The Interactive Data Submission System, a tool used to submit data to NCQA.   |
| IPV                          | Inactivated polio virus vaccine.  |
| IS                           | Information system: an automated system for collecting, processing, and transmitting data.  |
| IS Standards                 | Information System (IS) standards: an NCQA-defined set of standards that measure how an organization collects, stores, analyzes, and reports medical, customer service, member, practitioner, and vendor data. <sup>12-1</sup>  |
| LPL                          | Low performance level. (For most performance measures, MDHHS defined<br>the LPL as the most recent national Medicaid 25th percentile. For measures<br>such as <i>Comprehensive Diabetes Care—HbA1c Poor Control</i> [>9.0%], in<br>which lower rates in indicate better performance, the 75th percentile [rather<br>than the 25th percentile] is considered the LPL). |
| Material Bias                | For most measures reported as a rate, any error that causes $a \pm 5$ percent difference in the reported rate is considered materially biased. For non-rate measures, any error that causes $a \pm 10$ percent difference in the reported rate or calculation is considered materially biased.  |
| Medical Record<br>Validation | The process that the MHP's medical record abstraction staff uses to identify numerator positive cases.  |

<sup>&</sup>lt;sup>12-1</sup> National Committee for Quality Assurance. HEDIS Compliance Audit Standards, Policies and Procedures, Volume 5. Washington D.C.



| Term                    | Description  |
|-------------------------|--|
| Medicaid<br>Percentiles | The NCQA national percentiles for each HEDIS measure for the Medicaid product line used to compare the MHP's performance and assess the reliability of the MHP's HEDIS rates.  |
| MDHHS                   | Michigan Department of Health and Human Services.  |
| MHP                     | Medicaid health plan.  |
| MMR                     | Measles, mumps, and rubella vaccine.   |
| MRR                     | Medical record review.   |
| NA                      | Small Denominator: indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate, resulting in an NA designation.  |
| NB                      | No Benefit: indicates that the required benefit to calculate the measure was not offered.  |
| NCQA                    | The National Committee for Quality Assurance (NCQA) is a not-for-profit<br>organization that assesses, through accreditation reviews and standardized<br>measures, the quality of care provided by managed healthcare delivery<br>systems; reports results of those assessments to employers, consumers, public<br>purchasers, and regulators; and ultimately seeks to improve the health care<br>provided within the managed care industry. |
| NR                      | Not Reported: indicates that the MHP chose not to report the required HEDIS 2018 measure indicator rate. This designation was assigned to rates during previous reporting years to indicate one of the following designations: The MHP chose not to report the required measure indicator rate, or the MHP's reported rate was invalid.  |
| Numerator               | The number of members in the denominator who received all the services as specified in the measure.  |
| NQ                      | Not Required: indicates that the MHP was not required to report this measure.  |
| OB/GYN                  | Obstetrician/Gynecologist.   |
| PCP                     | Primary care practitioner.   |
| PCV                     | Pneumococcal conjugate vaccine.  |
| POP                     | Eligible population.   |
| Provider Data           | Electronic files containing information about physicians such as type of physician, specialty, reimbursement arrangement, and office location.   |
| RV                      | Rotavirus vaccine.   |
| Software Vendor         | A third party, with source code certified by NCQA, that contracts with the MHP to write source code for HEDIS measures. (For the measures to be certified, the vendor must submit programming codes associated with the measure to NCQA for automated testing of program logic, and a minimum percentage of the measures must receive a "Pass" or "Pass With Qualifications" designation.)   |



| Term            | Description   |
|-----------------|---|
| UN              | Unaudited: indicates that the organization chose to report a measure that is<br>not required to be audited. This result applies only to a limited set of<br>measures. |
| URI             | Upper respiratory infection.  |
| Quality Compass | NCQA Quality Compass benchmark.   |
| VZV             | Varicella zoster virus (chicken pox) vaccine.   |



## Appendix A. Tabular Results

Appendix A presents tabular results for each measure indicator. Where applicable, the results provided include the eligible population and rate as well as the Michigan Medicaid Weighted Average (MWA) for HEDIS 2016, HEDIS 2017, and HEDIS 2018. To align with calculations from prior years, HSAG calculated traditional averages for measure indicators in the Utilization measure domain; therefore, the Medicaid Average (MA) is presented for utilization-based measures. Yellow shading with one cross (<sup>+</sup>) indicates that the HEDIS 2018 rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

# **Child & Adolescent Care Performance Measure Results**

| Plan           | Eligible<br>Population | Combo 2<br>Rate | Combo 3<br>Rate | Combo 4<br>Rate | Combo 5<br>Rate | Combo 6<br>Rate | Combo 7<br>Rate | Combo 8<br>Rate | Combo 9<br>Rate     | Combo 10<br>Rate |
|----------------|------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------------|------------------|
| AET            | 799                    | 63.26%          | 57.18%          | 56.69%          | 48.91%          | 23.36%          | 48.42%          | 23.11%          | 20.68%              | 20.44%           |
| BCC            | 2,400                  | 74.45%          | 72.02%+         | 70.32%+         | 63.02%+         | 41.12%+         | 61.80%+         | 40.39%+         | 36.50% <sup>+</sup> | 36.01%+          |
| HAR            | 154                    | 59.48%          | 52.94%          | 51.63%          | 42.48%          | 20.92%          | 41.83%          | 20.92%          | 18.95%              | 18.95%           |
| MCL            | 3,448                  | 73.72%          | 70.80%          | 68.86%          | 63.02%+         | 36.50%          | 61.31%+         | 36.01%          | 33.09%              | 32.60%           |
| MER            | 10,043                 | 78.10%+         | 73.72%+         | 72.02%+         | 64.48%+         | 41.61%+         | 63.26%+         | 41.36%+         | 37.96%+             | 37.71%+          |
| MID            | 24                     | NA                  | NA               |
| MOL            | 6,708                  | 76.60%+         | 71.68%+         | 69.78%+         | 60.29%+         | 36.61%          | 59.06%+         | 36.21%          | 31.60%              | 31.31%           |
| PRI            | 2,490                  | 82.97%+         | 81.02%+         | 79.56%+         | 73.48%+         | 56.20%+         | 72.02%+         | 55.47%+         | 51.82%+             | 51.09%+          |
| ТНС            | 822                    | 71.29%          | 65.45%          | 64.48%          | 53.77%          | 32.12%          | 53.04%          | 31.63%          | 27.25%              | 27.01%           |
| UNI            | 4,547                  | 75.91%+         | 71.53%          | 71.29%+         | 61.56%+         | 37.71%          | 61.56%+         | 37.71%          | 34.31%+             | 34.31%+          |
| UPP            | 887                    | 73.97%          | 70.56%          | 67.40%          | 56.93%          | 48.18%+         | 55.23%          | 47.20%+         | 41.85%+             | 41.61%+          |
| HEDIS 2018 MWA |                        | 76.35%+         | 72.28%+         | 70.75%+         | 62.63%+         | <b>39.93%</b> + | 61.53%+         | <b>39.56%</b> + | 35.85%+             | 35.55%+          |
| HEDIS 2017 MWA |                        | 76.95%          | 72.84%          | 70.43%          | 61.73%          | 39.84%          | 60.05%          | 39.20%          | 34.47%              | 33.98%           |
| HEDIS 2016 MWA |                        | 76.15%          | 71.05%          | 67.50%          | 58.78%          | 40.45%          | 56.15%          | 39.27%          | 34.97%              | 33.92%           |

#### Table A-1—MHP and MWA Results for Childhood Immunization Status

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.





| Plan           | Eligible<br>Population | Combination 1<br>Rate |
|----------------|------------------------|-----------------------|
| AET            | 795                    | 81.75%+               |
| BCC            | 2,080                  | 88.08%+               |
| HAR            | 64                     | 75.00%                |
| MCL            | 3,268                  | 84.18%+               |
| MER            | 7,923                  | 83.45%+               |
| MID            | 17                     | NA                    |
| MOL            | 7,510                  | 86.87%+               |
| PRI            | 2,168                  | 87.59%+               |
| THC            | 1,081                  | 85.16%+               |
| UNI            | 5,230                  | 84.91%+               |
| UPP            | 760                    | 80.78%+               |
| HEDIS 2018 MWA |                        | 85.14%+               |
| HEDIS 2017 MWA |                        | 86.73%                |
| HEDIS 2016 MWA |                        | 86.99%                |

## Table A-2—MHP and MWA Results for Immunizations for Adolescents

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



| Plan           | Well-Child Visits<br>in the First 15<br>Months of Life—<br>Six or More<br>Visits—Eligible<br>Population | Well-Child Visits<br>in the First 15<br>Months of Life—<br>Six or More<br>Visits—Rate | Well-Child Visits<br>in the Third,<br>Fourth, Fifth, and<br>Sixth Years of<br>Life—<br>Eligible<br>Population | Well-Child Visits<br>in the Third,<br>Fourth, Fifth, and<br>Sixth Years of<br>Life—Rate | Adolescent Well-<br>Care Visits—<br>Eligible<br>Population | Adolescent<br>Well-Care<br>Visits—Rate |
|----------------|---|---|---|---|--|--|
| AET            | 547   | 49.39%  | 3,397   | 67.84%  | 7,622  | 51.82%+                                |
| BCC            | 2,002   | 66.67%+   | 10,852  | 68.86%  | 20,210   | 54.74%+                                |
| HAR            | 57  | 43.86%  | 589   | 61.31%  | 708  | 30.41%                                 |
| MCL            | 2,793   | 70.32%+   | 14,698  | 69.10%  | 26,736   | 45.50%                                 |
| MER            | 8,315   | 76.40%+   | 41,017  | 78.83%+   | 66,036   | 60.34%+                                |
| MID            | 9   | NA  | 126   | 57.14%  | 203  | 31.03%                                 |
| MOL            | 5,455   | 70.56%+   | 30,330  | 75.08%+   | 61,981   | 54.39%+                                |
| PRI            | 2,079   | 77.30%+   | 10,077  | 75.41%+   | 18,158   | 61.67%+                                |
| THC            | 642   | 70.32%+   | 3,935   | 74.45%+   | 9,213  | 55.96%+                                |
| UNI            | 3,720   | 68.61%+   | 21,920  | 77.37%+   | 44,073   | 63.26%+                                |
| UPP            | 918   | 72.75%+   | 3,550   | 75.18%+   | 6,478  | 47.93%                                 |
| HEDIS 2018 MWA |   | 71.89%+   |   | 75.19%+   |  | <b>56.75%</b> <sup>+</sup>             |
| HEDIS 2017 MWA |   | 69.79%  |   | 76.09%  |  | 55.69%                                 |
| HEDIS 2016 MWA |   | 66.22%  |   | 75.11%  |  | 54.74%                                 |

#### Table A-3—MHP and MWA Results for Well-Child Visits and Adolescent Well-Care Visits

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 799                    | 72.99%+ |
| BCC            | 2,400                  | 76.64%+ |
| HAR            | 153                    | 72.55%+ |
| MCL            | 3,457                  | 85.16%+ |
| MER            | 10,043                 | 81.02%+ |
| MID            | 24                     | NA      |
| MOL            | 6,723                  | 78.83%+ |
| PRI            | 2,490                  | 84.54%+ |
| THC            | 822                    | 70.80%  |
| UNI            | 4,547                  | 81.51%+ |
| UPP            | 887                    | 82.73%+ |
| HEDIS 2018 MWA |                        | 80.55%+ |
| HEDIS 2017 MWA |                        | 80.98%  |
| HEDIS 2016 MWA |                        | 79.55%  |

Table A-4—MHP and MWA Results for Lead Screening in Children

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 575                    | 91.65%+ |
| BCC            | 2,724                  | 88.36%  |
| HAR            | 113                    | 93.81%+ |
| MCL            | 3,558                  | 85.58%  |
| MER            | 11,566                 | 87.90%  |
| MID            | 37                     | 81.08%  |
| MOL            | 8,165                  | 87.40%  |
| PRI            | 2,824                  | 93.94%+ |
| THC            | 1,024                  | 92.09%+ |
| UNI            | 7,148                  | 90.42%+ |
| UPP            | 905                    | 93.59%+ |
| HEDIS 2018 MWA |                        | 88.83%  |
| HEDIS 2017 MWA |                        | 88.94%  |
| HEDIS 2016 MWA |                        | 89.09%  |

## Table A-5—MHP and MWA Results for Appropriate Treatment for Children With Upper Respiratory Infection

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



| Plan           | Eligible<br>Population | Rate    |  |  |  |  |
|----------------|------------------------|---------|--|--|--|--|
| AET            | 324                    | 70.68%  |  |  |  |  |
| BCC            | 1,704                  | 81.63%+ |  |  |  |  |
| HAR            | 36                     | 72.22%  |  |  |  |  |
| MCL            | 3,263                  | 83.27%+ |  |  |  |  |
| MER            | 8,854                  | 80.53%+ |  |  |  |  |
| MID            | 20                     | NA      |  |  |  |  |
| MOL            | 6,259                  | 75.12%  |  |  |  |  |
| PRI            | 2,198                  | 86.44%+ |  |  |  |  |
| THC            | 553                    | 69.62%  |  |  |  |  |
| UNI            | 4,689                  | 76.71%+ |  |  |  |  |
| UPP            | 625                    | 80.16%+ |  |  |  |  |
| HEDIS 2018 MWA |                        | 79.20%+ |  |  |  |  |
| HEDIS 2017 MWA |                        | 70.91%  |  |  |  |  |
| HEDIS 2016 MWA |                        | 68.41%  |  |  |  |  |

## Table A-6—MHP and MWA Results for Appropriate Testing for Children With Pharyngitis

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 



| Plan           | Initiation Phase—<br>Eligible<br>Population | Initiation Phase—<br>Rate <sup>1</sup> | Continuation and<br>Maintenance<br>Phase—Eligible<br>Population | Continuation and<br>Maintenance<br>Phase—Rate <sup>1</sup> |
|----------------|---|--|---|--|
| AET            | 229   | 23.14%                                 | 34  | 47.06%   |
| BCC            | 515   | 48.35%+                                | 115   | 62.61%+  |
| HAR            | 25  | NA                                     | 0   | NA   |
| MCL            | 972   | 45.37%+                                | 320   | 57.50%+  |
| MER            | 3,945                                       | 40.71%                                 | 1,409   | 47.91%   |
| MID            | 3   | NA                                     | 2   | NA   |
| MOL            | 2,118                                       | 48.91%+                                | 537   | 61.82%+  |
| PRI            | 155   | 36.13%                                 | 52  | 40.38%   |
| THC            | 277   | 53.79%+                                | 42  | 66.67%+  |
| UNI            | 1,634                                       | 44.49%                                 | 405   | 58.02%+  |
| UPP            | 255   | 48.24%+                                | 103   | 52.43%   |
| HEDIS 2018 MWA |   | 43.86%                                 |   | 53.56%   |
| HEDIS 2017 MWA |   | 42.54%                                 |   | 55.03%   |
| HEDIS 2016 MWA |   | 42.58%                                 |   | 53.96%   |

# Table A-7—MHP and MWA Results for Follow-Up Care for Children Prescribed ADHD Medication Phase Initiation Phase and Continuation and Maintenance Phase

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate. <sup>1</sup>Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when comparing rates between 2018 and prior years.



## Women—Adult Care Performance Measure Results

| Plan           | Breast Cancer<br>Screening—<br>Eligible<br>Population | Breast Cancer<br>Screening—Rate <sup>1</sup> | Cervical Cancer<br>Screening—<br>Eligible<br>Population | Cervical Cancer<br>Screening—Rate |
|----------------|---|--|---|-----------------------------------|
| AET            | 1,307   | 55.55%                                       | 7,912   | 60.26%+                           |
| BCC            | 3,101   | 60.24%                                       | 33,038  | 61.80%+                           |
| HAR            | 194   | 65.46%                                       | 1,189   | 47.20%                            |
| MCL            | 6,389   | 62.86%                                       | 34,888  | 61.80%+                           |
| MER            | 14,705  | 64.17%                                       | 97,876  | 65.21%+                           |
| MID            | 942   | 55.41%                                       | 1,395   | 52.93%                            |
| MOL            | 11,880  | 61.50%                                       | 70,476  | 72.34%+                           |
| PRI            | 4,268   | 63.99%                                       | 23,125  | 68.85%+                           |
| THC            | 2,013   | 50.82%                                       | 10,044  | 60.10%+                           |
| UNI            | 8,466   | 62.65%                                       | 46,844  | 67.88%+                           |
| UPP            | 1,765   | 64.08%                                       | 9,251   | 63.02%+                           |
| HEDIS 2018 MWA |   | 62.13%                                       |   | <b>66.19%</b> <sup>+</sup>        |
| HEDIS 2017 MWA |   | —  |   | 64.84%                            |
| HEDIS 2016 MWA |   | _  |   | 63.79%                            |

#### Table A-8—MHP and MWA Results for Breast and Cervical Cancer Screening in Women

Yellow shading with one cross (+) indicates the HEDIS 2017 MHP or MWA rate was at or above the Quality Compass HEDIS 2016 national Medicaid 50th percentile.

<sup>1</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.



| Plan           | Ages 16 to 20<br>Years—Eligible<br>Population | Ages 16 to 20<br>Years—Rate | Ages 21 to 24<br>Years—Eligible<br>Population | Ages 21 to 24<br>Years—Rate | Total—Eligible<br>Population | Total—Rate |
|----------------|---|-----------------------------|---|-----------------------------|------------------------------|------------|
| AET            | 1,175   | 70.30%+                     | 729   | 73.39%+                     | 1,904                        | 71.48%+    |
| BCC            | 2,684   | 63.52%+                     | 2,729   | 69.29%+                     | 5,413                        | 66.43%+    |
| HAR            | 98  | 73.47%+                     | 107   | 73.83%+                     | 205                          | 73.66%+    |
| MCL            | 3,798   | 53.79%+                     | 2,968   | 62.43%                      | 6,766                        | 57.58%+    |
| MER            | 9,145   | 62.30%+                     | 8,626   | 68.50%+                     | 17,771                       | 65.31%+    |
| MID            | 25  | NA                          | 48  | 52.08%                      | 73                           | 57.53%+    |
| MOL            | 8,289   | 65.16%+                     | 5,880   | 70.44%+                     | 14,169                       | 67.35%+    |
| PRI            | 2,585   | 65.53%+                     | 1,870   | 68.61%+                     | 4,455                        | 66.82%+    |
| THC            | 1,331   | $68.07\%^{+}$               | 800   | 70.00%+                     | 2,131                        | 68.79%+    |
| UNI            | 5,736   | 67.29%+                     | 3,841   | 70.87%+                     | 9,577                        | 68.73%+    |
| UPP            | 927   | 46.17%                      | 672   | 60.71%                      | 1,599                        | 52.28%     |
| HEDIS 2018 MWA |   | <b>63.28%</b> <sup>+</sup>  |   | <b>68.65%</b> <sup>+</sup>  |                              | 65.65%+    |
| HEDIS 2017 MWA |   | 62.27%                      |   | 68.89%                      |                              | 65.23%     |
| HEDIS 2016 MWA |   | 60.75%                      |   | 67.85%                      |                              | 63.86%     |

#### Table A-9—MHP and MWA Results for Chlamydia Screening in Women

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



## Access to Care Performance Measure Results

## Table A-10—MHP and MWA Results for Children and Adolescents' Access to Primary Care Practitioners

| Plan           | Ages 12 to 24<br>Months—<br>Eligible<br>Population | Ages 12 to 24<br>Months— Rate | Ages 25<br>Months to<br>6 Years—<br>Eligible<br>Population | Ages 25<br>Months to 6<br>Years— Rate | Ages 7 to 11<br>Years—Eligible<br>Population | Ages 7 to 11<br>Years—Rate | Ages 12 to 19<br>Years—Eligible<br>Population | Ages 12 to 19<br>Years—Rate |
|----------------|--|-------------------------------|--|---------------------------------------|--|----------------------------|---|-----------------------------|
| AET            | 916  | 89.30%                        | 4,215  | 80.69%                                | 3,439  | 84.97%                     | 5,400   | 82.70%                      |
| BCC            | 3,598  | 93.83%                        | 13,435   | 84.89%                                | 6,380  | 89.84%                     | 8,980   | 88.42%                      |
| HAR            | 228  | 82.46%                        | 773  | 69.86%                                | 240  | 77.50%                     | 230   | 69.13%                      |
| MCL            | 4,118  | 92.30%                        | 18,204   | 83.68%                                | 13,107                                       | 88.57%                     | 18,012  | 87.18%                      |
| MER            | 12,455   | 96.84%+                       | 51,218   | 90.53%+                               | 34,262                                       | 92.59%+                    | 41,615  | 92.06%+                     |
| MID            | 46   | 76.09%                        | 163  | 66.87%                                | 31   | 74.19%                     | 48  | 70.83%                      |
| MOL            | 7,714  | 95.41%                        | 37,038   | 88.71%+                               | 32,274                                       | 91.63%+                    | 44,581  | 90.83%+                     |
| PRI            | 3,321  | 96.18%+                       | 12,481   | 86.67%                                | 8,270  | 90.54%                     | 11,237  | 91.09%+                     |
| THC            | 953  | 92.76%                        | 4,779  | 83.03%                                | 3,894  | 87.90%                     | 6,499   | 86.71%                      |
| UNI            | 5,220  | 95.11%                        | 26,425   | 88.96%+                               | 23,490                                       | 91.73%+                    | 31,222  | 91.91%+                     |
| UPP            | 1,089  | 97.15%+                       | 4,381  | 89.84%+                               | 3,310  | 92.15%+                    | 4,428   | 92.03%+                     |
| HEDIS 2018 MWA |  | 95.16%                        |  | <b>87.89%</b> <sup>+</sup>            |  | <b>91.13%</b> <sup>+</sup> |   | <b>90.42%</b> <sup>+</sup>  |
| HEDIS 2017 MWA |  | 96.06%                        |  | 89.08%                                |  | 91.39%                     |   | 90.79%                      |
| HEDIS 2016 MWA |  | 96.20%                        |  | 88.79%                                |  | 90.85%                     |   | 89.86%                      |

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



| Plan           | Ages 20 to 44<br>Years—Eligible<br>Population | Ages 20 to 44<br>Years—Rate | Ages 45 to 64<br>Years—Eligible<br>Population | Ages 45 to 64<br>Years—Rate | Ages 65+<br>Years—Eligible<br>Population | Ages 65+<br>Years—Rate | Total—Eligible<br>Population | Total—Rate |
|----------------|---|-----------------------------|---|-----------------------------|--|------------------------|------------------------------|------------|
| AET            | 9,993   | 68.58%                      | 6,099   | 80.70%                      | 41                                       | 82.93%                 | 16,133                       | 73.20%     |
| BCC            | 42,277  | 75.08%                      | 26,548  | 84.08%                      | 285                                      | 83.16%                 | 69,110                       | 78.57%     |
| HAR            | 2,126   | 50.05%                      | 1,506   | 70.72%                      | 10                                       | NA                     | 3,642                        | 58.62%     |
| MCL            | 42,151  | 78.71%                      | 28,398  | 87.89%+                     | 51                                       | 84.31%                 | 70,600                       | 82.41%+    |
| MER            | 115,702                                       | 80.45%+                     | 66,207  | 88.81%+                     | 2,131                                    | 94.89%+                | 184,040                      | 83.63%+    |
| MID            | 1,338   | 70.18%                      | 1,584   | 89.20%+                     | 2,085                                    | 87.67%+                | 5,007                        | 83.48%+    |
| MOL            | 79,816  | 79.17%+                     | 52,945  | 88.11%+                     | 4,226                                    | 92.66%+                | 136,987                      | 83.04%+    |
| PRI            | 24,968  | $80.88\%^{+}$               | 15,622  | 89.42%+                     | 1,475                                    | 93.56%+                | 42,065                       | 84.49%+    |
| THC            | 11,798  | 74.92%                      | 8,524   | 84.31%                      | 167                                      | 79.64%                 | 20,489                       | 78.87%     |
| UNI            | 54,507  | 78.88%                      | 34,626  | 88.66%+                     | 399                                      | 95.99%+                | 89,532                       | 82.74%+    |
| UPP            | 10,455  | 82.87%+                     | 6,915   | 87.40%+                     | 13                                       | NA                     | 17,383                       | 84.66%+    |
| HEDIS 2018 MWA |   | 78.64%                      |   | <b>87.57%</b> <sup>+</sup>  |  | <b>91.79%</b> +        |                              | 82.25%+    |
| HEDIS 2017 MWA |   | 81.68%                      |   | 89.21%                      |  | 90.26%                 |                              | 84.73%     |
| HEDIS 2016 MWA |   | 82.76%                      |   | 89.81%                      |  | 91.15%                 |                              | 85.62%     |

## Table A-11—MHP and MWA Results for Adults' Access to Preventive/Ambulatory Health Services

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 316                    | 37.03%+ |
| BCC            | 1,401                  | 30.84%+ |
| HAR            | 50                     | 30.00%+ |
| MCL            | 1,839                  | 29.91%+ |
| MER            | 5,052                  | 30.32%+ |
| MID            | 57                     | 35.09%+ |
| MOL            | 3,713                  | 33.02%+ |
| PRI            | 1,251                  | 42.29%+ |
| THC            | 500                    | 30.80%+ |
| UNI            | 2,720                  | 33.20%+ |
| UPP            | 531                    | 25.24%  |
| HEDIS 2018 MWA |                        | 32.20%+ |
| HEDIS 2017 MWA |                        | 29.23%  |
| HEDIS 2016 MWA |                        | 26.94%  |

#### Table A-12—MHP and MWA Results for Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



# **Obesity Performance Measure Results**

| Plan           | Eligible<br>Population | BMI Percentile—<br>Total—Rate | Counseling for<br>Nutrition—<br>Total—Rate | Counseling for<br>Physical Activity—<br>Total—Rate |
|----------------|------------------------|-------------------------------|--|--|
| AET            | 9,003                  | 87.78%+                       | 75.06%+                                    | 65.34%+  |
| BCC            | 27,261                 | 82.24%+                       | $74.94\%^{+}$                              | 64.72%+  |
| HAR            | 839                    | 70.32%                        | 66.67%                                     | 46.96%   |
| MCL            | 37,076                 | 81.02%+                       | 63.99%                                     | 56.45%   |
| MER            | 110,914                | 82.24%+                       | 72.51%+                                    | 67.15%+  |
| MID            | 178                    | 73.86%+                       | 64.20%                                     | 56.25%   |
| MOL            | 89,964                 | 84.64%+                       | 76.82%+                                    | 68.75%+  |
| PRI            | 26,947                 | 95.32%+                       | 81.87%+                                    | 79.53%+  |
| THC            | 10,815                 | 78.59%+                       | 73.72%+                                    | 57.91%   |
| UNI            | 67,537                 | 85.89%+                       | 77.86%+                                    | 70.32%+  |
| UPP            | 10,281                 | 89.78%+                       | 72.26%+                                    | 70.80%+  |
| HEDIS 2018 MWA |                        | 84.40%+                       | <b>74.50%</b> <sup>+</sup>                 | <b>67.49%</b> <sup>+</sup>                         |
| HEDIS 2017 MWA |                        | 82.10%                        | 72.21%                                     | 61.24%   |
| HEDIS 2016 MWA |                        | 74.93%                        | 65.77%                                     | 57.88%   |

#### Table A-13—MHP and MWA Results for Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



| Plan           | Eligible<br>Population | Rate                       |
|----------------|------------------------|----------------------------|
| AET            | 9,198                  | 94.34%+                    |
| BCC            | 28,899                 | 91.73%+                    |
| HAR            | 1,365                  | 71.07%                     |
| MCL            | 41,780                 | 93.67%+                    |
| MER            | 105,811                | 94.89%+                    |
| MID            | 2,368                  | 91.28%+                    |
| MOL            | 89,173                 | 96.00%+                    |
| PRI            | 23,703                 | 97.00%+                    |
| THC            | 12,618                 | 84.67%                     |
| UNI            | 57,628                 | 94.65%+                    |
| UPP            | 11,127                 | 96.84%+                    |
| HEDIS 2018 MWA |                        | <b>94.47%</b> <sup>+</sup> |
| HEDIS 2017 MWA |                        | 92.86%                     |
| HEDIS 2016 MWA |                        | 89.92%                     |

### Table A-14—MHP and MWA Results for Adult BMI Assessment

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



# **Pregnancy Care Performance Measure Results**

| Plan           | Eligible<br>Population | Timeliness of<br>Prenatal<br>Care—Rate | Postpartum<br>Care—Rate    |
|----------------|------------------------|--|----------------------------|
| AET            | 807                    | 72.26%                                 | 53.28%                     |
| BCC            | 3,537                  | 76.40%                                 | 60.58%                     |
| HAR            | 116                    | 35.34%                                 | 46.55%                     |
| MCL            | 3,431                  | 77.86%                                 | 66.67%+                    |
| MER            | 10,719                 | 85.40%+                                | 67.15%+                    |
| MID            | 61                     | 55.74%                                 | 59.02%                     |
| MOL            | 6,485                  | 77.32%                                 | 73.80%+                    |
| PRI            | 2,532                  | 83.45%                                 | 71.53%+                    |
| THC            | 879                    | 63.99%                                 | 48.18%                     |
| UNI            | 4,506                  | 78.83%                                 | 67.15%+                    |
| UPP            | 833                    | 92.94%+                                | 73.72%+                    |
| HEDIS 2018 MWA |                        | 80.23%                                 | <b>67.27%</b> <sup>+</sup> |
| HEDIS 2017 MWA |                        | 81.57%                                 | 68.96%                     |
| HEDIS 2016 MWA |                        | 78.63%                                 | 61.73%                     |

### Table A-15—MHP and MWA Results for Prenatal and Postpartum Care

Yellow shading with one cross (+) indicates the HEDIS 2017 MHP or MWA rate was at or above the Quality Compass HEDIS 2016 national Medicaid 50th percentile.



## Living With Illness Performance Measure Results

| Plan           | Eligible<br>Population | Hemoglobin<br>A1c (HbA1c)<br>Testing—Rate | HbA1c Control<br>(<8.0%)—Rate | Eye Exam<br>(Retinal)<br>Performed—<br>Rate | Blood Pressure<br>Control (<140<br>90 mmHg)—<br>Rate | HbA1c Poor<br>Control<br>(>9.0%)—<br>Rate* | Medical<br>Attention for<br>Nephropathy<br>—Rate |
|----------------|------------------------|---|-------------------------------|---|--|--|--|
| AET            | 1,782                  | 78.59%                                    | 45.74%                        | 47.93%                                      | 47.69%   | 45.99%                                     | 91.24%+  |
| BCC            | 7,123                  | 86.31%                                    | 47.81%                        | 55.84%+                                     | 61.50%+  | 43.61%                                     | 90.33%+  |
| HAR            | 326                    | 77.61%                                    | 40.18%                        | 41.41%                                      | 39.26%   | 53.07%                                     | 88.04%   |
| MCL            | 7,609                  | 90.27%+                                   | 45.74%                        | 64.23%+                                     | 69.34%+  | 43.80%                                     | 90.02%   |
| MER            | 19,402                 | 88.04%+                                   | 51.47%+                       | 69.84%+                                     | 66.90%+  | 38.65%+                                    | 90.64%+  |
| MID            | 1,103                  | 85.16%                                    | 52.31%+                       | 59.37%+                                     | 60.58%   | 37.47%+                                    | 92.94%+  |
| MOL            | 17,473                 | 90.42%+                                   | 54.55%+                       | 62.16%+                                     | 51.11%   | 33.91%+                                    | 92.87%+  |
| PRI            | 4,933                  | 94.07%+                                   | 67.01%+                       | 73.71%+                                     | 76.80%+  | 22.68%+                                    | 94.85%+  |
| THC            | 2,546                  | 82.00%                                    | 38.93%                        | 50.61%                                      | 41.85%   | 52.07%                                     | 90.02%   |
| UNI            | 11,297                 | 89.29%+                                   | 57.29%+                       | 64.43%+                                     | 66.29%+  | 31.29%+                                    | 94.43%+  |
| UPP            | 1,572                  | 92.32%+                                   | 60.00%+                       | 71.25%+                                     | 77.50%+  | 30.00%+                                    | 91.07%+  |
| HEDIS 2018 MWA |                        | <b>88.81%</b> <sup>+</sup>                | <b>52.73%</b> <sup>+</sup>    | <b>64.18%</b> <sup>+</sup>                  | 62.23% <sup>+</sup>                                  | 36.88%+                                    | <b>91.94%</b> <sup>+</sup>                       |
| HEDIS 2017 MWA |                        | 87.79%                                    | 53.16%                        | 62.85%                                      | 61.73%   | 36.07%                                     | 91.14%   |
| HEDIS 2016 MWA |                        | 86.89%                                    | 50.91%                        | 59.61%                                      | 59.38%   | 39.30%                                     | 91.28%   |

Table A-16—MHP and MWA Results for Comprehensive Diabetes Care

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

\* For this indicator, a lower rate indicates better performance.



| Plan           | Eligible Population | Medication<br>Compliance 50%—<br>Total—Rate <sup>1</sup> | Medication<br>Compliance 75%—<br>Total—Rate |
|----------------|---------------------|--|---|
| AET            | 509                 | 57.17%   | 29.47%                                      |
| BCC            | 1,661               | 88.38%+  | 73.33%+                                     |
| HAR            | 33                  | 69.70%+  | 36.36%+                                     |
| MCL            | 2,445               | 66.01%+  | 43.52%+                                     |
| MER            | 4,781               | 72.29%+  | 51.22%+                                     |
| MID            | 36                  | 77.78%+  | 72.22%+                                     |
| MOL            | 4,349               | 62.41%+  | 38.56%+                                     |
| PRI            | 1,451               | 65.82%+  | 45.07%+                                     |
| THC            | 633                 | 87.36%+  | 72.51%+                                     |
| UNI            | 3,006               | 75.52%+  | 57.49%+                                     |
| UPP            | 552                 | 71.01%+  | 46.56%+                                     |
| HEDIS 2018 MWA |                     | <b>70.74%</b> <sup>+</sup>                               | <b>49.83%</b> <sup>+</sup>                  |
| HEDIS 2017 MWA |                     | 71.33%   | 49.96%                                      |
| HEDIS 2016 MWA |                     | 67.13%   | 43.79%                                      |

#### Table A-17—MHP and MWA Results for Medication Management for People With Asthma

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

<sup>1</sup>Please note, the Medication Compliance 50%-Total measure indicator was compared to the 2017 national Medicaid NCQA Audit Means and Percentiles as Quality Compass benchmarks are not available for this measure.



| Plan           | Eligible   | Rate    |
|----------------|------------|---------|
| Pidli          | Population | Rate    |
| AET            | 677        | 57.46%  |
| BCC            | 2,003      | 55.92%  |
| HAR            | 41         | 58.54%  |
| MCL            | 2,912      | 67.03%+ |
| MER            | 5,767      | 60.17%  |
| MID            | 58         | 25.86%  |
| MOL            | 5,403      | 63.06%+ |
| PRI            | 1,636      | 73.04%+ |
| THC            | 881        | 52.33%  |
| UNI            | 3,670      | 62.26%+ |
| UPP            | 721        | 59.92%  |
| HEDIS 2018 MWA |            | 62.06%  |
| HEDIS 2017 MWA |            | 62.63%  |
| HEDIS 2016 MWA |            | 62.18%  |

### Table A-18—MHP and MWA Results for Asthma Medication Ratio

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



|                | Eligible   |                            |
|----------------|------------|----------------------------|
| Plan           | Population | Rate                       |
| AET            | 3,437      | 49.76%                     |
| BCC            | 12,115     | 46.96%                     |
| HAR            | 637        | 28.71%                     |
| MCL            | 12,007     | 61.56%+                    |
| MER            | 31,374     | 67.15%+                    |
| MID            | 1,854      | 51.14%                     |
| MOL            | 29,416     | 51.82%                     |
| PRI            | 7,460      | 65.57%+                    |
| THC            | 4,659      | 29.68%                     |
| UNI            | 17,101     | 64.48%+                    |
| UPP            | 2,378      | 72.75%+                    |
| HEDIS 2018 MWA |            | <b>58.21%</b> <sup>+</sup> |
| HEDIS 2017 MWA |            | 56.75%                     |
| HEDIS 2016 MWA |            | 55.54%                     |

## Table A-19—MHP and MWA Results for Controlling High Blood Pressure

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



| Plan           | Eligible<br>Population | Advising Smokers<br>and Tobacco<br>Users to Quit—<br>Rate | Discussing<br>Cessation<br>Medications—<br>Rate | Discussing<br>Cessation<br>Strategies—<br>Rate |
|----------------|------------------------|---|---|--|
| AET            | 41,841                 | 81.10%+   | 61.81%+   | 57.71%+  |
| BCC            | 175,714                | 77.50%+   | 54.48%+   | 45.36%+  |
| HAR            | 5,584                  | 80.79%+   | 63.16%+   | 52.61%+  |
| MCL            | 170,771                | 76.54%  | 54.55%+   | 46.27%+  |
| MER            | 475,867                | 81.25%+   | 54.90%+   | 45.79%+  |
| MID            | 11,281                 | 83.27%+   | $60.65\%^+$                                     | 48.01%+  |
| MOL            | 332,032                | 81.08%+   | 58.57%+   | 46.01%+  |
| PRI            | 73,665                 | 83.65%+   | 60.90%+   | 48.08%+  |
| THC            | 44,480                 | 78.67%+   | 57.96%+   | 45.73%+  |
| UNI            | 228,021                | 83.54%+   | 61.27%+   | 52.87%+  |
| UPP            | 41,805                 | 77.95%+   | 56.82%+   | 46.65%+  |
| HEDIS 2018 MWA |                        | 80.59%+   | <b>57.14%</b> <sup>+</sup>                      | 47.32%+  |
| HEDIS 2017 MWA |                        | 80.15%  | 55.95%  | 45.89%   |
| HEDIS 2016 MWA |                        | 79.75%  | 55.04%  | 45.20%   |

## Table A-20—MHP and MWA Results for Medical Assistance With Smoking and Tobacco Use Cessation

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



|                | Eligible   | Effective Acute<br>Phase   | Effective<br>Continuation<br>Phase |
|----------------|------------|----------------------------|------------------------------------|
| Plan           | Population |                            | Treatment—Rate <sup>1</sup>        |
| AET            | 620        | 47.10%                     | 33.39%                             |
| BCC            | 2,903      | 77.13%+                    | 61.87%+                            |
| HAR            | 52         | 57.69%+                    | 42.31%+                            |
| MCL            | 4,012      | 58.05%+                    | 40.80%+                            |
| MER            | 12,343     | 54.45%+                    | 36.08%                             |
| MID            | 131        | 52.67%+                    | 33.59%                             |
| MOL            | 5,873      | 54.54%+                    | 37.54%+                            |
| PRI            | 94         | 71.28%+                    | 51.06%+                            |
| THC            | 739        | 68.20%+                    | 55.35%+                            |
| UNI            | 3,918      | 61.66%+                    | 46.89%+                            |
| UPP            | 640        | 59.84%+                    | 41.41%+                            |
| HEDIS 2018 MWA |            | <b>58.27%</b> <sup>+</sup> | 41.25%+                            |
| HEDIS 2017 MWA |            | 52.72%                     | 36.03%                             |
| HEDIS 2016 MWA |            | 60.36%                     | 42.21%                             |

#### Table A-21—MHP and MWA Results for Antidepressant Medication Management

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

<sup>1</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when comparing rates between 2018 and prior years.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 343                    | 87.76%+ |
| BCC            | 2,349                  | 81.57%+ |
| HAR            | 36                     | 83.33%+ |
| MCL            | 3,623                  | 82.06%+ |
| MER            | 4,850                  | 85.63%+ |
| MID            | 283                    | 72.79%  |
| MOL            | 4,409                  | 85.87%+ |
| PRI            | 693                    | 84.56%+ |
| THC            | 461                    | 83.73%+ |
| UNI            | 2,004                  | 85.33%+ |
| UPP            | 399                    | 87.97%+ |
| HEDIS 2018 MWA |                        | 84.31%+ |
| HEDIS 2017 MWA |                        | 83.09%  |
| HEDIS 2016 MWA |                        | 82.61%  |

### Table A-22—MHP and MWA Results for Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 70                     | 64.29%  |
| BCC            | 219                    | 63.01%  |
| HAR            | 8                      | NA      |
| MCL            | 281                    | 77.58%+ |
| MER            | 455                    | 71.65%+ |
| MID            | 56                     | 71.43%+ |
| MOL            | 686                    | 70.70%+ |
| PRI            | 93                     | 56.99%  |
| THC            | 97                     | 59.79%  |
| UNI            | 308                    | 71.10%+ |
| UPP            | 25                     | NA      |
| HEDIS 2018 MWA |                        | 69.97%  |
| HEDIS 2017 MWA |                        | 69.01%  |
| HEDIS 2016 MWA |                        | 69.98%  |

### Table A-23—MHP and MWA Results for Diabetes Monitoring for People With Diabetes and Schizophrenia

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 



| Plan           | Eligible<br>Population | Rate   |
|----------------|------------------------|--------|
| AET            | 16                     | NA     |
| BCC            | 37                     | 75.68% |
| HAR            | 2                      | NA     |
| MCL            | 26                     | NA     |
| MER            | 73                     | 76.71% |
| MID            | 7                      | NA     |
| MOL            | 119                    | 77.31% |
| PRI            | 12                     | NA     |
| THC            | 16                     | NA     |
| UNI            | 65                     | 75.38% |
| UPP            | 3                      | NA     |
| HEDIS 2018 MWA |                        | 76.86% |
| HEDIS 2017 MWA |                        | 69.64% |
| HEDIS 2016 MWA |                        | 74.46% |

# Table A-24—MHP and MWA Results for Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia

NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.



| Plan           | Eligible<br>Population | Rate    |
|----------------|------------------------|---------|
| AET            | 241                    | 53.53%  |
| BCC            | 1,093                  | 55.99%  |
| HAR            | 23                     | NA      |
| MCL            | 1,250                  | 70.56%+ |
| MER            | 1,488                  | 67.07%+ |
| MID            | 201                    | 71.14%+ |
| MOL            | 2,374                  | 64.74%+ |
| PRI            | 235                    | 64.26%+ |
| THC            | 286                    | 48.95%  |
| UNI            | 972                    | 55.04%  |
| UPP            | 107                    | 82.24%+ |
| HEDIS 2018 MWA |                        | 63.18%+ |
| HEDIS 2017 MWA |                        | 61.16%  |
| HEDIS 2016 MWA |                        | 58.76%  |

#### Table A-25—MHP and MWA Results for Adherence to Antipsychotic Medications for Individuals With Schizophrenia

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

*NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.* 



| Plan           | ACE Inhibitors or<br>ARBs—Eligible<br>Population | ACE Inhibitors or<br>ARBs—Rate | Diuretics—Eligible<br>Population | Diuretics—Rate | Total—Eligible<br>Population | Total—Rate <sup>1</sup> |
|----------------|--|--------------------------------|----------------------------------|----------------|------------------------------|-------------------------|
| AET            | 1,813  | 87.26%                         | 1,555                            | 86.24%         | 3,368                        | 86.79%                  |
| BCC            | 9,059  | 86.11%                         | 7,163                            | 85.52%         | 16,222                       | 85.85%                  |
| HAR            | 317  | 85.17%                         | 266                              | 83.83%         | 583                          | 84.56%                  |
| MCL            | 8,711  | 85.90%                         | 5,972                            | 86.89%         | 14,683                       | 86.30%                  |
| MER            | 18,252   | 83.26%                         | 12,527                           | 83.70%         | 30,779                       | 83.44%                  |
| MID            | 1,457  | 85.45%                         | 1,045                            | 85.65%         | 2,502                        | 85.53%                  |
| MOL            | 18,408   | 88.48%+                        | 13,678                           | 88.54%+        | 32,086                       | 88.51%                  |
| PRI            | 5,115  | 88.29%+                        | 3,478                            | 87.81%         | 8,593                        | 88.09%                  |
| ТНС            | 3,312  | 87.17%                         | 2,751                            | 86.04%         | 6,063                        | 86.66%                  |
| UNI            | 11,137   | 88.88%+                        | 7,690                            | 88.73%+        | 18,827                       | 88.82%                  |
| UPP            | 1,960  | 87.50%                         | 1,347                            | 87.53%         | 3,307                        | 87.51%                  |
| HEDIS 2018 MWA |  | 86.60%                         |                                  | 86.64%         |                              | 86.62%                  |
| HEDIS 2017 MWA |  | 87.00%                         |                                  | 87.08%         |                              |                         |
| HEDIS 2016 MWA |  | 87.20%                         |                                  | 86.88%         |                              |                         |

### Table A-26—MHP and MWA Results for Annual Monitoring for Patients on Persistent Medications

Yellow shading with one cross (+) indicates the HEDIS 2018 MHP or MWA rate was at or above the Quality Compass HEDIS 2017 national Medicaid 50th percentile.

<sup>1</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.



## Health Plan Diversity and Utilization Measure Results

The Health Plan Diversity and Utilization measures' MHP and MWA results are presented in tabular format in Section 9 and Section 10 of this report.



### **Appendix B.** Trend Tables

Appendix B includes trend tables for the MHPs. Where applicable, each measure's HEDIS 2016, HEDIS 2017, and HEDIS 2018 rates are presented. HEDIS 2017 and HEDIS 2018 rates were compared based on a Chi-square test of statistical significance with a *p* value <0.05. Values in the 2017–2018 Comparison column that are shaded green with one cross (<sup>+</sup>) indicate statistically significant improvement from the previous year. Values in the 2017–2018 Comparison column shaded red with two crosses (<sup>++</sup>) indicate a statistically significant decline in performance from the previous year.

Details regarding the trend analysis and performance ratings are found in Section 2.





| Table | B-1- | ΔFT | Trend  | Table |
|-------|------|-----|--------|-------|
| Iable | D-T- | ALI | ILCIIU | Iable |

|  |                | , <b>T</b> AFI 11 | cha rabic             |                                      |  |
|--|----------------|-------------------|-----------------------|--------------------------------------|--|
| Measure  | HEDIS 2016     | HEDIS 2017        | HEDIS 2018            | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Child & Adolescent Care  |                |                   |                       |                                      |  |
| Childhood Immunization S   | Status         |                   |                       |                                      |  |
| Combination 2  | 68.75%         | 69.68%            | 63.26%                | -6.42++                              | *                                      |
| Combination 3  | 60.88%         | 64.12%            | 57.18%                | -6.94++                              | *                                      |
| Combination 4  | 58.80%         | 63.43%            | 56.69%                | -6.74++                              | *                                      |
| Combination 5  | 49.77%         | 50.69%            | 48.91%                | -1.78                                | *                                      |
| Combination 6  | 29.40%         | 27.08%            | 23.36%                | -3.72                                | *                                      |
| Combination 7  | 48.61%         | 50.00%            | 48.42%                | -1.58                                | *                                      |
| Combination 8  | 29.17%         | 27.08%            | 23.11%                | -3.97                                | *                                      |
| Combination 9  | 24.31%         | 22.92%            | 20.68%                | -2.24                                | *                                      |
| Combination 10   | 24.31%         | 22.92%            | 20.44%                | -2.48                                | *                                      |
| Well-Child Visits in the Fir   | rst 15 Months  | s of Life         |                       | L                                    |  |
| Six or More Visits   | 44.68%         | 48.61%            | 49.39%                | +0.78                                | *                                      |
| Lead Screening in Children   | n              | L.                |                       |                                      |  |
| Lead Screening in<br>Children  | 73.61%         | 73.15%            | 72.99%                | -0.16                                | ***                                    |
| Well-Child Visits in the Th  | ird, Fourth, I | Fifth, and Six    | th Years of Lif       | e                                    |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 71.30%         | 71.67%            | 67.84%                | -3.83                                | **                                     |
| Adolescent Well-Care Visit   | 's             | L.                |                       |                                      |  |
| Adolescent Well-Care<br>Visits   | 51.39%         | 48.84%            | 51.82%                | +2.98                                | ***                                    |
| Immunizations for Adolesc  | ents           |                   |                       | <u> </u>                             | <u> </u>                               |
| Combination 1  | 89.68%         | 82.87%            | 81.75%                | -1.12                                | ***                                    |
| Appropriate Treatment for  | Children Wi    | th Upper Resp     | piratory Infecti      | on                                   |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 89.72%         | 90.49%            | 91.65%                | +1.16                                | ***                                    |
| Appropriate Testing for Ch   | uildren With I | Pharyngitis       |                       |                                      |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 55.44%         | 62.92%            | 70.68%                | +7.76+                               | **                                     |
| Follow-Up Care for Childr  | en Prescribed  | d ADHD Med        | lication <sup>3</sup> |                                      |  |
| Initiation Phase   | 23.73%         | 19.46%            | 23.14%                | +3.68                                | *                                      |
| Continuation and<br>Maintenance Phase  | 36.59%         | 32.26%            | 47.06%                | +14.80                               | *                                      |
|  | 1              | 1                 |                       | 1                                    | 1                                      |

| Measure   |              | HEDIS 2017    | HEDIS 2018       | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|---|--------------|---------------|------------------|--------------------------------------|--|--|--|--|
|   | HEDIS 2010   | HEDIS 2017    | HEDIS 2018       | Companson                            | Level-                                 |  |  |  |
| Women – Adult Care  |              |               |                  |                                      |  |  |  |  |
| Breast Cancer Screening <sup>4</sup>                                    |              |               |                  |                                      |  |  |  |  |
| Breast Cancer Screening   |              |               | 55.55%           | NC                                   | NC                                     |  |  |  |
| Cervical Cancer<br>Screening  |              | -             |                  |                                      |  |  |  |  |
| Cervical Cancer<br>Screening  | 64.47%       | 64.07%        | 60.26%           | -3.81                                | ***                                    |  |  |  |
| Chlamydia Screening in Women  |              |               |                  |                                      |  |  |  |  |
| Ages 16 to 20 Years   | 66.77%       | 69.86%        | 70.30%           | +0.44                                | *****                                  |  |  |  |
| Ages 21 to 24 Years   | 71.24%       | 76.35%        | 73.39%           | -2.96                                | *****                                  |  |  |  |
| Total   | 68.44%       | 72.25%        | 71.48%           | -0.77                                | *****                                  |  |  |  |
| Access to Care  | L            | L             |                  |                                      | . <u>.</u>                             |  |  |  |
| Children and Adolescents'   | Access to Pr | imarv Care Pi | ractitioners     |                                      | · · · · · · · · · · · · · · · · · · ·  |  |  |  |
| Ages 12 to 24 Months  | 90.84%       | 86.31%        | 89.30%           | +2.99                                | *                                      |  |  |  |
| Ages 25 Months to 6<br>Years  | 81.16%       | 83.09%        | 80.69%           | -2.40++                              | *                                      |  |  |  |
| Ages 7 to 11 Years  | 86.76%       | 85.88%        | 84.97%           | -0.91                                | *                                      |  |  |  |
| Ages 12 to 19 Years   | 83.70%       | 83.04%        | 82.70%           | -0.34                                | *                                      |  |  |  |
| Adults' Access to Preventiv   |              |               |                  |                                      |  |  |  |  |
| Ages 20 to 44 Years   | 76.58%       | 72.47%        | 68.58%           | -3.89++                              | *                                      |  |  |  |
| Ages 45 to 64 Years   | 85.73%       | 82.70%        | 80.70%           | -2.00++                              | *                                      |  |  |  |
| Ages 65+ Years  | NA           | NA            | 82.93%           | NC                                   | **                                     |  |  |  |
| Total   | 80.23%       | 76.42%        | 73.20%           | -3.22++                              | *                                      |  |  |  |
| Avoidance of Antibiotic Tre   |              |               |                  |                                      |  |  |  |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis | 35.83%       | 32.89%        | 37.03%           | +4.14                                | ****                                   |  |  |  |
| Obesity   | ·            | . <u></u>     |                  |                                      |  |  |  |  |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for | Nutrition and | l Physical Activ | vity for                             |  |  |  |  |
| BMI Percentile—Total  | 70.30%       | 78.01%        | 87.78%           | +9.77+                               | *****                                  |  |  |  |
| Counseling for<br>Nutrition—Total                                       | 64.60%       | 71.30%        | 75.06%           | +3.76                                | ***                                    |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 55.45%       | 58.80%        | 65.34%           | +6.54                                | ***                                    |  |  |  |
| Adult BMI Assessment  | 1            | 1             |                  |                                      | 1                                      |  |  |  |
| Adult BMI Assessment  | 90.21%       | 90.96%        | 94.34%           | +3.38                                | *****                                  |  |  |  |
|   | /01/0        | 20.2075       | 2.10.170         | 10.00                                | 1                                      |  |  |  |





| Table B-1—AET Trend Table | Table | B-1—AET | Trend | Table |
|---------------------------|-------|---------|-------|-------|
|---------------------------|-------|---------|-------|-------|

|   | Table c                                       | 0-1—AEI II      | enu rabie         |                                      |  |
|---|---|-----------------|-------------------|--------------------------------------|--|
| Measure                                       | HEDIS 2016                                    | HEDIS 2017      | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Pregnancy Care                                | <u>,                                     </u> |                 |                   |                                      |  |
| Prenatal and Postpartum (                     | Care  |                 |                   |                                      | ·                                      |
| Timeliness of Prenatal<br>Care                | 62.38%  | 65.89%          | 72.26%            | +6.37+                               | *                                      |
| Postpartum Care                               | 45.56%  | 51.74%          | 53.28%            | +1.54                                | *                                      |
| Living With Illness                           |   |                 |                   |                                      |  |
| Comprehensive Diabetes C                      | are   |                 |                   |                                      | -                                      |
| Hemoglobin A1c<br>(HbA1c) Testing             | 84.36%  | 86.31%          | 78.59%            | -7.72**                              | *                                      |
| HbA1c Poor Control<br>(>9.0%)*                | 46.41%  | 42.38%          | 45.99%            | +3.61                                | **                                     |
| HbA1c Control (<8.0%)                         | 45.38%  | 48.34%          | 45.74%            | -2.60                                | **                                     |
| Eye Exam (Retinal)<br>Performed               | 49.36%  | 47.90%          | 47.93%            | +0.03                                | **                                     |
| Medical Attention for<br>Nephropathy          | 91.03%  | 92.05%          | 91.24%            | -0.81                                | ***                                    |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 52.18%  | 55.41%          | 47.69%            | -7.72**                              | *                                      |
| Medication Management f                       | or People Wi                                  | th Asthma       |                   |                                      |  |
| Medication Compliance<br>50%—Total            | 66.55%  | 83.19%          | 57.17%            | -26.02++                             | **                                     |
| Medication Compliance<br>75%—Total            | 39.93%  | 63.26%          | 29.47%            | -33.79++                             | **                                     |
| Asthma Medication Ratio                       |   |                 |                   |                                      | <u></u>                                |
| Total   | 41.49%  | 61.03%          | 57.46%            | -3.57                                | **                                     |
| Controlling High Blood Pr                     | essure  |                 |                   |                                      |  |
| Controlling High Blood<br>Pressure            | 39.91%  | 52.93%          | 49.76%            | -3.17                                | **                                     |
| Medical Assistance With S                     | moking and I                                  | Tobacco Use     | Cessation         |                                      | ·                                      |
| Advising Smokers and<br>Tobacco Users to Quit | 79.92%  | 80.65%          | 81.10%            | +0.45                                | ****                                   |
| Discussing Cessation<br>Medications           | 55.74%  | 58.06%          | 61.81%            | +3.75                                | ****                                   |
| Discussing Cessation<br>Strategies            | 46.22%  | 51.63%          | 57.71%            | +6.08                                | ****                                   |
| Antidepressant Medication                     | Managemen                                     | at <sup>3</sup> |                   | •                                    |  |
| Effective Acute Phase<br>Treatment            | 37.84%  | 52.90%          | 47.10%            | -5.80                                | *                                      |
|   | *   |                 |                   |                                      |  |

| Measure  | HEDIS 2016                             | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|--|----------------|-----------------|--------------------------------------|--|--|--|--|
| Effective Continuation   | 24.59%                                 | 40.00%         | 33.39%          | -6.61 <sup>++</sup>                  | **                                     |  |  |  |
| Phase Treatment         21.57.8         10.0078         55.57.8         0.001         10.001           Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are         Using Antipsychotic Medications         10.0078         10.007 |  |                |                 |                                      |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications  | 83.87%                                 | 80.47%         | 87.76%          | +7.29+                               | ****                                   |  |  |  |
| Diabetes Monitoring for Pe   | cople With D                           | iabetes and So | chizophrenia    |                                      |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia   | 66.00%                                 | 57.81%         | 64.29%          | +6.48                                | *                                      |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia   | for People                             | With Cardiova  | ıscular Disease | and                                  |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia   | NA                                     | NA             | NA              | NC                                   | NC                                     |  |  |  |
| Adherence to Antipsychotic   | Medication                             | s for Individu | als With Schize | ophrenia                             | ·                                      |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia  | 51.37%                                 | 55.87%         | 53.53%          | -2.34                                | *                                      |  |  |  |
| Annual Monitoring for Pat  | tients on Pers                         | sistent Medica | tions           |                                      |  |  |  |  |
| ACE Inhibitors or ARBs   | 82.94%                                 | 84.25%         | 87.26%          | +3.01+                               | **                                     |  |  |  |
| Diuretics  | 83.69%                                 | 85.50%         | 86.24%          | +0.74                                | **                                     |  |  |  |
| $Total^4$  |  |                | 86.79%          | NC                                   | NC                                     |  |  |  |
| Health Plan Diversity <sup>5</sup>   |  |                |                 |                                      |  |  |  |  |
| Race/Ethnicity Diversity of  | Race/Ethnicity Diversity of Membership |                |                 |                                      |  |  |  |  |
| Total—White  | 18.01%                                 | 26.93%         | 26.57%          | -0.36                                | NC                                     |  |  |  |
| Total—Black or African<br>American   | 70.29%                                 | 60.30%         | 60.54%          | +0.24                                | NC                                     |  |  |  |
| Total—American-Indian<br>and Alaska Native   | 0.12%                                  | 0.15%          | 0.15%           | 0.00                                 | NC                                     |  |  |  |
| Total—Asian  | 0.60%                                  | 0.66%          | 0.65%           | -0.01                                | NC                                     |  |  |  |



| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|------------|------------|------------|--------------------------------------|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.03%      | 0.04%      | 0.06%      | +0.02                                | NC                                     |
| Total—Some Other Race                                       | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Unknown   | 9.89%      | 5.66%      | 4.43%      | -1.23                                | NC                                     |
| Total—Declined  | 1.07%      | 6.26%      | 7.61%      | +1.35                                | NC                                     |
| Total—Hispanic or<br>Latino                                 | 2.58%      | 2.92%      | 3.14%      | +0.22                                | NC                                     |
| Language Diversity of Men                                   | nbership   |            |            |                                      |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>English     | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>Unknown     | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>English                            | 99.34%     | 99.25%     | 99.13%     | -0.12                                | NC                                     |
| Other Language Needs—<br>Non-English                        | 0.15%      | 0.63%      | 0.76%      | +0.13                                | NC                                     |
| Other Language Needs—<br>Unknown                            | 0.50%      | 0.13%      | 0.11%      | -0.02                                | NC                                     |

#### Table B-1—AET Trend Table

| Measure  | HEDIS 2016  | HEDIS 2017   | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|---|--------------|------------|--------------------------------------|--|--|--|--|
| Other Language Needs—<br>Declined  | 0.00%   | 0.00%        | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Utilization <sup>5</sup>   |   |              |            |                                      |  |  |  |  |
| Ambulatory Care—Total (Per 1,000 Member Months)  |   |              |            |                                      |  |  |  |  |
| ED Visits—Total*   | 83.70   | 83.32        | 82.21      | -1.11                                | *                                      |  |  |  |
| Outpatient Visits—Total  | 267.80  | 299.52       | 301.45     | +1.93                                | NC                                     |  |  |  |
| Inpatient Utilization—Gen  | eral Hospital   | /Acute Care- | -Total     |                                      |  |  |  |  |
| -<br>Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                             | 7.76  | 8.43         | 8.17       | -0.26                                | NC                                     |  |  |  |
| Total Inpatient—Average<br>Length of Stay—Total  | 3.81  | 3.93         | 4.14       | +0.21                                | NC                                     |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total   | 2.20  | 2.05         | 2.62       | +0.57                                | NC                                     |  |  |  |
| Maternity—Average<br>Length of Stay—Total  | 2.83  | 2.58         | 2.62       | +0.04                                | NC                                     |  |  |  |
| Surgery—Discharges per<br>1,000 Member Months—<br>Total  | 1.34  | 2.05         | 1.75       | -0.30                                | NC                                     |  |  |  |
| Surgery—Average<br>Length of Stay—Total  | 6.03  | 6.35         | 6.47       | +0.12                                | NC                                     |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total  | 4.81  | 4.86         | 4.47       | -0.39                                | NC                                     |  |  |  |
| Medicine—Average<br>Length of Stay—Total   | 3.52  | 3.33         | 3.88       | +0.55                                | NC                                     |  |  |  |
| Use of Opioids From Mult   | Use of Opioids From Multiple Providers (Per 1,000 Members)* |              |            |                                      |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                               | _   | _            | 230.92     | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                                |   | _            | 107.31     | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple<br>Pharmacies | _   | _            | 60.36      | NC                                   | NC                                     |  |  |  |





| Measure  | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |
|--|------------|------------|------------|--------------------------------------|--|--|
| Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |            |                                      |  |  |
| Use of Opioids at High<br>Dosage                   | —          | —          | 18.37      | NC                                   | NC                                     |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





| Table | B_2_ | BCC | Trend | Tahla |
|-------|------|-----|-------|-------|
| rable | D-2- | DUU | rrenu | rable |

|  | I able b     |                | enu rabie       |                                      |  |  |  |  |
|--|--------------|----------------|-----------------|--------------------------------------|--|--|--|--|
| Measure  |              | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|  | HEDIS 2016   | HEDIS 2017     | HEDIS 2018      | Comparison-                          | Level                                  |  |  |  |
| Child & Adolescent Care  |              |                |                 |                                      |  |  |  |  |
| Childhood Immunization S   |              | 1              | [               | [                                    | · · ·                                  |  |  |  |
| Combination 2  | 76.16%       | 79.40%         | 74.45%          | -4.95                                | **                                     |  |  |  |
| Combination 3  | 70.07%       | 75.00%         | 72.02%          | -2.98                                | ***                                    |  |  |  |
| Combination 4  | 68.13%       | 72.45%         | 70.32%          | -2.13                                | ***                                    |  |  |  |
| Combination 5  | 59.85%       | 62.96%         | 63.02%          | +0.06                                | ***                                    |  |  |  |
| Combination 6  | 43.55%       | 41.20%         | 41.12%          | -0.08                                | ***                                    |  |  |  |
| Combination 7  | 58.39%       | 60.88%         | 61.80%          | +0.92                                | ***                                    |  |  |  |
| Combination 8  | 42.58%       | 40.51%         | 40.39%          | -0.12                                | ***                                    |  |  |  |
| Combination 9  | 37.96%       | 34.49%         | 36.50%          | +2.01                                | ***                                    |  |  |  |
| Combination 10   | 36.98%       | 33.80%         | 36.01%          | +2.21                                | ***                                    |  |  |  |
| Well-Child Visits in the Fi  | rst 15 Month | s of Life      |                 |                                      | ·                                      |  |  |  |
| Six or More Visits   | 67.40%       | 71.06%         | 66.67%          | -4.39                                | ***                                    |  |  |  |
| Lead Screening in Childre  | n            |                | I               | I                                    | J                                      |  |  |  |
| Lead Screening in<br>Children  | 75.18%       | 76.16%         | 76.64%          | +0.48                                | ***                                    |  |  |  |
| Well-Child Visits in the Th  | ird, Fourth, | Fifth, and Six | xth Years of Li | fe                                   |  |  |  |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 79.32%       | 72.92%         | 68.86%          | -4.06                                | **                                     |  |  |  |
| Adolescent Well-Care Visit   | ts           | I              |                 |                                      |  |  |  |  |
| Adolescent Well-Care<br>Visits   | 60.10%       | 50.69%         | 54.74%          | +4.05                                | ***                                    |  |  |  |
| Immunizations for Adolesc  | cents        | I              |                 |                                      |  |  |  |  |
| Combination 1  | 86.86%       | 85.65%         | 88.08%          | +2.43                                | *****                                  |  |  |  |
| Appropriate Treatment for  | Children Wi  | th Upper Res   | piratory Infect | ion                                  | ·                                      |  |  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 92.52%       | 90.15%         | 88.36%          | -1.79++                              | **                                     |  |  |  |
| Appropriate Testing for Ch   | uildren With | Pharyngitis    |                 |                                      |  |  |  |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 72.61%       | 75.43%         | 81.63%          | +6.20+                               | ***                                    |  |  |  |
| Follow-Up Care for Children Prescribed ADHD Medication <sup>3</sup>          |              |                |                 |                                      |  |  |  |  |
| Initiation Phase   | 39.92%       | 51.28%         | 48.35%          | -2.93                                | ***                                    |  |  |  |
| Continuation and<br>Maintenance Phase  | 50.98%       | 57.53%         | 62.61%          | +5.08                                | ***                                    |  |  |  |
|  | 1            |                | 1               | 1                                    | 1                                      |  |  |  |

#### Table B-2—BCC Trend Table

|   | Tuble D      | Z DCC II      |                 |                                      |  |
|---|--------------|---------------|-----------------|--------------------------------------|--|
| Measure   | HEDIS 2016   | HEDIS 2017    | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Women – Adult Care  |              |               |                 | companion                            | Level                                  |
| Breast Cancer Screening <sup>4</sup>                                    |              |               |                 |                                      |  |
| Breast Cancer Screening   |              |               | 60.24%          | NC                                   | NC                                     |
| Cervical Cancer   |              |               | 00.2470         | NC                                   | ne                                     |
| Screening   |              |               |                 |                                      |  |
| Cervical Cancer<br>Screening  | 63.99%       | 61.83%        | 61.80%          | -0.03                                | ***                                    |
| Chlamydia Screening in W  | omen         |               |                 |                                      |  |
| Ages 16 to 20 Years   | 68.96%       | 64.21%        | 63.52%          | -0.69                                | ****                                   |
| Ages 21 to 24 Years   | 70.30%       | 70.56%        | 69.29%          | -1.27                                | ***                                    |
| Total   | 69.65%       | 67.39%        | 66.43%          | -0.96                                | ****                                   |
| Access to Care  | ·            |               |                 | ·                                    |  |
| Children and Adolescents'   | Access to Pr | imary Care P  | ractitioners    |                                      |  |
| Ages 12 to 24 Months  | 94.89%       | 95.34%        | 93.83%          | -1.51++                              | **                                     |
| Ages 25 Months to 6<br>Years  | 85.57%       | 85.86%        | 84.89%          | -0.97**                              | *                                      |
| Ages 7 to 11 Years  | 90.84%       | 89.09%        | 89.84%          | +0.75                                | **                                     |
| Ages 12 to 19 Years   | 89.38%       | 89.30%        | 88.42%          | -0.88                                | **                                     |
| Adults' Access to Preventiv   | e/Ambulator  | v Health Serv | vices           | l                                    |  |
| Ages 20 to 44 Years   | 78.39%       | 78.83%        | 75.08%          | -3.75++                              | **                                     |
| Ages 45 to 64 Years   | 86.09%       | 86.92%        | 84.08%          | -2.84++                              | **                                     |
| Ages 65+ Years  | 78.06%       | 79.89%        | 83.16%          | +3.27                                | **                                     |
| Total   | 81.69%       | 82.13%        | 78.57%          | -3.56++                              | **                                     |
| Avoidance of Antibiotic Tr  | eatment in A | dults With Ac | ute Bronchitis  |                                      | <b></b>                                |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis |              | 27.49%        | 30.84%          | +3.35                                | ***                                    |
| Obesity   | <u>.</u>     |               |                 |                                      |  |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for | Nutrition and | d Physical Acti | vity for                             |  |
| BMI Percentile—Total  | 89.54%       | 86.57%        | 82.24%          | -4.33                                | ****                                   |
| Counseling for<br>Nutrition—Total                                       | 78.83%       | 73.61%        | 74.94%          | +1.33                                | ***                                    |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 69.10%       | 64.58%        | 64.72%          | +0.14                                | ***                                    |
| Adult BMI Assessment  | u            | L             |                 | 1                                    |  |
| Adult BMI Assessment  | 89.78%       | 89.10%        | 91.73%          | +2.63                                | ****                                   |
|   |              |               |                 |                                      | 1                                      |





#### Table B-2—BCC Trend Table

|   | Tuble D           | -z-bcc n        |                   |                                      |  |
|---|-------------------|-----------------|-------------------|--------------------------------------|--|
| Measure                                       | <b>HEDIS 2016</b> | HEDIS 2017      | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Pregnancy Care                                |                   |                 |                   |                                      |  |
| Prenatal and Postpartum (                     | Care              |                 |                   |                                      |  |
| Timeliness of Prenatal<br>Care                | 80.54%            | 77.26%          | 76.40%            | -0.86                                | *                                      |
| Postpartum Care                               | 57.66%            | 62.41%          | 60.58%            | -1.83                                | **                                     |
| Living With Illness                           |                   |                 |                   | L.                                   | l                                      |
| Comprehensive Diabetes C                      | Care              |                 |                   |                                      |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 86.86%            | 85.28%          | 86.31%            | +1.03                                | **                                     |
| HbA1c Poor Control<br>(>9.0%)*                | 37.59%            | 41.62%          | 43.61%            | +1.99                                | **                                     |
| HbA1c Control (<8.0%)                         | 53.65%            | 46.36%          | 47.81%            | +1.45                                | **                                     |
| Eye Exam (Retinal)<br>Performed               | 62.04%            | 57.53%          | 55.84%            | -1.69                                | ***                                    |
| Medical Attention for<br>Nephropathy          | 93.07%            | 90.02%          | 90.33%            | +0.31                                | ***                                    |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 58.39%            | 55.84%          | 61.50%            | +5.66                                | ***                                    |
| Medication Management f                       | or People Wi      | th Asthma       |                   | I.                                   |  |
| Medication Compliance<br>50%—Total            | 76.62%            | 88.36%          | 88.38%            | +0.02                                | ****                                   |
| Medication Compliance<br>75%—Total            | 58.26%            | 74.39%          | 73.33%            | -1.06                                | ****                                   |
| Asthma Medication Ratio                       |                   |                 |                   |                                      |  |
| Total   | 53.96%            | 54.59%          | 55.92%            | +1.33                                | **                                     |
| Controlling High Blood Pr                     | ressure           |                 |                   |                                      | · · · · ·                              |
| Controlling High Blood<br>Pressure            | 54.99%            | 46.03%          | 46.96%            | +0.93                                | *                                      |
| Medical Assistance With S                     | moking and        | Tobacco Use     | Cessation         | I                                    | /                                      |
| Advising Smokers and<br>Tobacco Users to Quit | 77.27%            | 75.28%          | 77.50%            | +2.22                                | ***                                    |
| Discussing Cessation<br>Medications           | 52.86%            | 50.14%          | 54.48%            | +4.34                                | ***                                    |
| Discussing Cessation<br>Strategies            | 46.70%            | 41.71%          | 45.36%            | +3.65                                | ***                                    |
| Antidepressant Medication                     | Managemer         | ut <sup>3</sup> | -                 |                                      |  |
| Effective Acute Phase<br>Treatment            | 75.97%            | 74.52%          | 77.13%            | +2.61                                | ****                                   |
|   |                   |                 |                   |                                      |  |

#### Table B-2—BCC Trend Table

| Measure   | HEDIS 2016                          | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|-------------------------------------|----------------|-----------------|--------------------------------------|--|
| Effective Continuation<br>Phase Treatment   | 59.74%                              | 60.78%         | 61.87%          | +1.09                                | ****                                   |
| Diabetes Screening for Peo<br>Using Antipsychotic Medic   | 1                                   | hizophrenia o  | r Bipolar Disor | rder Who Are                         |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or<br>Bipolar Disorder Who<br>Are Using Antipsychotic<br>Medications | 89.19%                              | 81.20%         | 81.57%          | +0.37                                | ***                                    |
| Diabetes Monitoring for P   | eople With D                        | iabetes and S  | chizophrenia    |                                      |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 60.34%                              | 63.74%         | 63.01%          | -0.73                                | *                                      |
| Cardiovascular Monitorinį<br>Schizophrenia  | g for People                        | With Cardiov   | ascular Diseas  | e and                                |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA                                  | NA             | 75.68%          | NC                                   | **                                     |
| Adherence to Antipsychoti   | c Medication                        | s for Individu | als With Schiz  | ophrenia                             |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 52.40%                              | 57.38%         | 55.99%          | -1.39                                | **                                     |
| Annual Monitoring for Pa  | tients on Per                       | sistent Medico | ations          |                                      |  |
| ACE Inhibitors or ARBs  | 86.52%                              | 86.46%         | 86.11%          | -0.35                                | **                                     |
| Diuretics   | 84.75%                              | 86.15%         | 85.52%          | -0.63                                | **                                     |
| $Total^4$   |                                     |                | 85.85%          | NC                                   | NC                                     |
| Health Plan Diversity <sup>5</sup>  |                                     |                |                 |                                      |  |
| Race/Ethnicity Diversity of   | <sup>F</sup> Membershi <sub>l</sub> | 0              |                 |                                      |  |
| Total—White   | 36.95%                              | 42.89%         | 45.03%          | +2.14                                | NC                                     |
| Total—Black or African<br>American  | 44.44%                              | 35.79%         | 34.27%          | -1.52                                | NC                                     |
| Total—American-Indian<br>and Alaska Native  | 0.38%                               | 0.42%          | 0.44%           | +0.02                                | NC                                     |
| Total—Asian   | 1.20%                               | 1.63%          | 1.64%           | +0.01                                | NC                                     |
|   |                                     |                |                 |                                      |  |





#### Table B-2—BCC Trend Table

| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|------------|------------|------------|--------------------------------------|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.08%      | 0.07%      | 0.08%      | +0.01                                | NC                                     |
| Total—Some Other Race                                       | 3.47%      | 6.59%      | 7.17%      | +0.58                                | NC                                     |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Unknown   | 13.48%     | 10.00%     | 8.24%      | -1.76                                | NC                                     |
| Total—Declined  | 0.00%      | 2.61%      | 3.14%      | +0.53                                | NC                                     |
| Total—Hispanic or<br>Latino                                 | 0.00%      | 1.58%      | 5.49%      | +3.91                                | NC                                     |
| Language Diversity of Men                                   | nbership   |            |            |                                      |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 99.17%     | 97.90%     | 97.48%     | -0.42                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.37%      | 1.52%      | 2.46%      | +0.94                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.46%      | 0.59%      | 0.06%      | -0.53                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>English     | 99.17%     | 97.90%     | 97.48%     | -0.42                                | NC                                     |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.37%      | 1.52%      | 2.46%      | +0.94                                | NC                                     |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.46%      | 0.59%      | 0.06%      | -0.53                                | NC                                     |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language<br>Needs—English                             | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language<br>Needs—Non-English                         | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language<br>Needs—Unknown                             | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |

#### Table B-2—BCC Trend Table

| Measure  | HEDIS 2016                                      | HEDIS 2017    | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |  |  |
|--|---|---------------|------------|--------------------------------------|--|--|--|--|--|--|--|
| Other Language<br>Needs—Declined   | 0.00%   | 0.00%         | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |  |  |
| Utilization <sup>5</sup>   |   |               |            |                                      |  |  |  |  |  |  |  |
| Ambulatory Care—Total (  | Ambulatory Care—Total (Per 1,000 Member Months) |               |            |                                      |  |  |  |  |  |  |  |
| ED Visits—Total*   | 70.18   | 68.98         | 64.19      | -4.79                                | **                                     |  |  |  |  |  |  |
| Outpatient Visits—Total  | 554.98  | 396.06        | 400.42     | +4.36                                | NC                                     |  |  |  |  |  |  |
| Inpatient Utilization—Gen  | eral Hospita                                    | l/Acute Care- | -Total     | I                                    |  |  |  |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                                  | 9.18  | 7.94          | 7.55       | -0.39                                | NC                                     |  |  |  |  |  |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total  | 4.31  | 3.92          | 3.98       | +0.06                                | NC                                     |  |  |  |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total   | 2.80  | 2.80          | 2.75       | -0.05                                | NC                                     |  |  |  |  |  |  |
| Maternity—Average<br>Length of Stay—Total  | 2.94  | 2.65          | 2.61       | -0.04                                | NC                                     |  |  |  |  |  |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total   | 2.44  | 1.90          | 1.73       | -0.17                                | NC                                     |  |  |  |  |  |  |
| Surgery—Average<br>Length of Stay—Total  | 6.75  | 6.37          | 6.22       | -0.15                                | NC                                     |  |  |  |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total  | 4.54  | 3.87          | 3.68       | -0.19                                | NC                                     |  |  |  |  |  |  |
| Medicine—Average<br>Length of Stay—Total   | 3.65  | 3.43          | 3.72       | +0.29                                | NC                                     |  |  |  |  |  |  |
| Use of Opioids From Mult   | tiple Provide                                   | rs (Per 1,000 | Members)*  |                                      |  |  |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                               |   |               | 203.46     | NC                                   | NC                                     |  |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                                | _   | _             | 162.05     | NC                                   | NC                                     |  |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple<br>Pharmacies | _   | _             | 84.60      | NC                                   | NC                                     |  |  |  |  |  |  |

#### APPENDIX B. TREND TABLES



#### Table B-2—BCC Trend Table

| Measure  | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|------------|------------|------------|--------------------------------------|--|--|--|--|
| Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |            |                                      |  |  |  |  |
| Use of Opioids at High<br>Dosage                   | —          | —          | 72.08      | NC                                   | NC                                     |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





|  |   |                   |                 | 2017–2018                      | 2018 Performance   |  |  |  |  |
|--|---|-------------------|-----------------|--------------------------------|--------------------|--|--|--|--|
| Measure  | HEDIS 2016  | <b>HEDIS 2017</b> | HEDIS 2018      | <b>Comparison</b> <sup>1</sup> | Level <sup>2</sup> |  |  |  |  |
| Child & Adolescent Care  |   |                   |                 |                                |                    |  |  |  |  |
| Childhood Immunization S   | tatus   |                   |                 | 1                              | 1                  |  |  |  |  |
| Combination 2  | 79.86%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 3  | 73.84%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 4  | 71.30%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 5  | 63.43%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 6  | 38.43%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 7  | 61.34%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 8  | 37.27%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 9  | 33.10%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Combination 10   | 31.94%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Well-Child Visits in the Fir   | st 15 Months  | s of Life         |                 |                                |                    |  |  |  |  |
| Six or More Visits   | 56.02%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Lead Screening in Children   | ı   |                   |                 |                                |                    |  |  |  |  |
| Lead Screening in<br>Children  | 74.07%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Well-Child Visits in the Th  | ird, Fourth,  | Fifth, and Six    | th Years of Lij | fe                             |                    |  |  |  |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 76.85%  | 56.36%            | 57.14%          | +0.78                          | *                  |  |  |  |  |
| Adolescent Well-Care Visit   | s   |                   |                 |                                |                    |  |  |  |  |
| Adolescent Well-Care<br>Visits   | 54.99%  | 24.07%            | 31.03%          | +6.96                          | *                  |  |  |  |  |
| Immunizations for Adolesc  | ents  |                   |                 | <u> </u>                       | <u></u>            |  |  |  |  |
| Combination 1  | 87.73%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Appropriate Treatment for  | Children Wi   | th Upper Res      | piratory Infect | ion                            | I                  |  |  |  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 88.19%  | NA                | 81.08%          | NC                             | *                  |  |  |  |  |
| Appropriate Testing for Ch   | ildren With I   | Pharyngitis       |                 |                                |                    |  |  |  |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 67.98%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Follow-Up Care for Childre   | Follow-Up Care for Children Prescribed ADHD Medication <sup>3</sup> |                   |                 |                                |                    |  |  |  |  |
| Initiation Phase   | 31.86%  | NA                | NA              | NC                             | NC                 |  |  |  |  |
| Continuation and<br>Maintenance Phase  | 33.33%  | NA                | NA              | NC                             | NC                 |  |  |  |  |

#### Table B-3—MID Trend Table

|   | TUDIC        |               |                 |                                      |  |
|---|--------------|---------------|-----------------|--------------------------------------|--|
| Measure   | HEDIS 2016   | HEDIS 2017    | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Women – Adult Care  |              |               |                 |                                      |  |
| Breast Cancer Screening <sup>4</sup>                                    |              |               |                 |                                      |  |
| Breast Cancer Screening   |              | _             | 55.41%          | NC                                   | NC                                     |
| Cervical Cancer   |              | L             |                 |                                      | <u> </u>                               |
| Screening   |              |               |                 |                                      |  |
| Cervical Cancer   | 59.35%       | 52.26%        | 52.93%          | +0.67                                | **                                     |
| Screening   |              |               |                 |                                      |  |
| Chlamydia Screening in W  |              | NT A          | NT A            | NG                                   | NG                                     |
| Ages 16 to 20 Years   | 58.75%       | NA            | NA              | NC                                   | NC                                     |
| Ages 21 to 24 Years   | 64.76%       | 47.62%        | 52.08%          | +4.46                                | *                                      |
| Total   | 61.37%       | 44.83%        | 57.53%          | +12.70                               | ***                                    |
| Access to Care  |              |               |                 |                                      |  |
| Children and Adolescents'   |              | 1             |                 |                                      |  |
| Ages 12 to 24 Months  | 95.21%       | NA            | 76.09%          | NC                                   | *                                      |
| Ages 25 Months to 6<br>Years  | 86.58%       | 65.71%        | 66.87%          | +1.16                                | *                                      |
| Ages 7 to 11 Years  | 89.22%       | 75.76%        | 74.19%          | -1.57                                | *                                      |
| Ages 12 to 19 Years   | 87.47%       | 68.00%        | 70.83%          | +2.83                                | *                                      |
| Adults' Access to Preventiv   | e/Ambulator  | y Health Serv | vices           | 1                                    | 1                                      |
| Ages 20 to 44 Years   | 77.66%       | 73.02%        | 70.18%          | -2.84                                | *                                      |
| Ages 45 to 64 Years   | 88.04%       | 90.16%        | 89.20%          | -0.96                                | ****                                   |
| Ages 65+ Years  | 89.06%       | 85.05%        | 87.67%          | +2.62+                               | ***                                    |
| Total   | 82.14%       | 83.86%        | 83.48%          | -0.38                                | ***                                    |
| Avoidance of Antibiotic Tre   | eatment in A | dults With Ac | ute Bronchitis  |                                      | J                                      |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis | 33.23%       | NA            | 35.09%          | NC                                   | ****                                   |
| Obesity   |              |               |                 | ·                                    | ,                                      |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for | Nutrition and | l Physical Acti | vity for                             |  |
| BMI Percentile—Total  | 74.17%       | 87.64%        | 73.86%          | -13.78++                             | ***                                    |
| Counseling for<br>Nutrition—Total                                       | 62.80%       | 70.79%        | 64.20%          | -6.59                                | **                                     |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 54.98%       | 64.04%        | 56.25%          | -7.79                                | **                                     |
| Adult BMI Assessment  |              | 1             |                 | 1                                    | 1                                      |
| Adult BMI Assessment  | 85.42%       | 89.95%        | 91.28%          | +1.33                                | ****                                   |





| Measure                                       | HEDIS 2016   | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|--------------|-----------------|------------|--------------------------------------|--|
| Pregnancy Care                                |              |                 |            |                                      |  |
| Prenatal and Postpartum (                     | Care         |                 |            |                                      |  |
| Timeliness of Prenatal<br>Care                | 71.93%       | 50.00%          | 55.74%     | +5.74                                | *                                      |
| Postpartum Care                               | 51.04%       | 40.38%          | 59.02%     | +18.64+                              | *                                      |
| Living With Illness                           |              |                 |            |                                      |  |
| Comprehensive Diabetes C                      | Care         |                 |            |                                      |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 85.93%       | 86.37%          | 85.16%     | -1.21                                | **                                     |
| HbA1c Poor Control (>9.0%)*                   | 48.44%       | 39.90%          | 37.47%     | -2.43                                | ***                                    |
| HbA1c Control (<8.0%)                         | 45.04%       | 52.31%          | 52.31%     | 0.00                                 | ***                                    |
| Eye Exam (Retinal)<br>Performed               | 57.19%       | 54.74%          | 59.37%     | +4.63                                | ***                                    |
| Medical Attention for<br>Nephropathy          | 88.74%       | 94.89%          | 92.94%     | -1.95                                | ****                                   |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 44.74%       | 57.91%          | 60.58%     | +2.67                                | **                                     |
| Medication Management f                       | or People Wi | th Asthma       |            |                                      | <u></u>                                |
| Medication Compliance<br>50%—Total            | 62.98%       | NA              | 77.78%     | NC                                   | ****                                   |
| Medication Compliance<br>75%—Total            | 34.90%       | NA              | 72.22%     | NC                                   | ****                                   |
| Asthma Medication Ratio                       |              |                 |            |                                      | <u>.</u>                               |
| Total   | 60.26%       | NA              | 25.86%     | NC                                   | *                                      |
| Controlling High Blood Pr                     | essure       |                 |            |                                      | ·····                                  |
| Controlling High Blood<br>Pressure            | 53.86%       | 60.58%          | 51.14%     | -9.44**                              | **                                     |
| Medical Assistance With S                     | moking and   | Tobacco Use     | Cessation  |                                      | <b>-</b>                               |
| Advising Smokers and<br>Tobacco Users to Quit | 81.74%       | 82.11%          | 83.27%     | +1.16                                | ****                                   |
| Discussing Cessation<br>Medications           | 52.57%       | 58.30%          | 60.65%     | +2.35                                | *****                                  |
| Discussing Cessation<br>Strategies            | 44.21%       | 44.44%          | 48.01%     | +3.57                                | ***                                    |
| Antidepressant Medication                     | Managemen    | ut <sup>3</sup> |            |                                      |  |
| Effective Acute Phase<br>Treatment            | 37.50%       | 47.12%          | 52.67%     | +5.55                                | ***                                    |
|   | 1            |                 |            | I                                    | 1                                      |

#### Table B-3—MID Trend Table

| Measure   | HEDIS 2016   | HEDIS 2017     | HEDIS 2018     | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |  |
|---|--|----------------|----------------|--------------------------------------|--|--|--|--|--|--|
| Effective Continuation<br>Phase Treatment   | 23.44%   | 31.73%         | 33.59%         | +1.86                                | **                                     |  |  |  |  |  |
| Diabetes Screening for Peo<br>Using Antipsychotic Medic   | Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are |                |                |                                      |  |  |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or<br>Bipolar Disorder Who<br>Are Using Antipsychotic<br>Medications | 81.58%   | 68.00%         | 72.79%         | +4.79                                | *                                      |  |  |  |  |  |
| Diabetes Monitoring for Pe  | eople With D   | iabetes and S  | chizophrenia   |                                      |  |  |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 65.69%   | 64.10%         | 71.43%         | +7.33                                | ***                                    |  |  |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia  | g for People   | With Cardiov   | ascular Diseas | e and                                |  |  |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA   | NA             | NA             | NC                                   | NC                                     |  |  |  |  |  |
| Adherence to Antipsychotic  | c Medication   | s for Individu | als With Schiz | ophrenia                             |  |  |  |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 5.04%  | 69.41%         | 71.14%         | +1.73                                | ****                                   |  |  |  |  |  |
| Annual Monitoring for Pa  | tients on Per  | sistent Medice | ations         |                                      |  |  |  |  |  |  |
| ACE Inhibitors or ARBs  | 86.17%   | 83.40%         | 85.45%         | +2.05                                | *                                      |  |  |  |  |  |
| Diuretics   | 84.95%   | 84.75%         | 85.65%         | +0.90                                | **                                     |  |  |  |  |  |
| $Total^4$   | _  | —              | 85.53%         | NC                                   | NC                                     |  |  |  |  |  |
| Health Plan Diversity <sup>5</sup>  |  |                |                |                                      |  |  |  |  |  |  |
| Race/Ethnicity Diversity of   | <sup>r</sup> Membershi <sub>l</sub>  | 9              |                |                                      |  |  |  |  |  |  |
| Total—White   | 43.61%   | 46.63%         | 47.76%         | +1.13                                | NC                                     |  |  |  |  |  |
| Total—Black or African<br>American  | 37.40%   | 35.69%         | 35.71%         | +0.02                                | NC                                     |  |  |  |  |  |
| Total—American-Indian<br>and Alaska Native  | 0.18%  | 0.00%          | 0.00%          | 0.00                                 | NC                                     |  |  |  |  |  |
| Total—Asian   | 2.02%  | 2.36%          | 2.04%          | -0.32                                | NC                                     |  |  |  |  |  |



| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |
|---|------------|------------|------------|--------------------------------------|--|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.18%      | 0.29%      | 0.21%      | -0.08                                | NC                                     |  |
| Total—Some Other Race                                       | 4.58%      | 2.64%      | 2.72%      | +0.08                                | NC                                     |  |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Total—Unknown   | 12.03%     | 12.39%     | 11.57%     | -0.82                                | NC                                     |  |
| Total—Declined  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Total—Hispanic or<br>Latino                                 | 4.58%      | 2.64%      | 2.72%      | +0.08                                | NC                                     |  |
| Language Diversity of Men                                   | nbership   |            |            |                                      |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>English     | 0.00%      | 0.00%      | 100.00%    | +100.00                              | NC                                     |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 100.00%    | 100.00%    | 0.00%      | -100.00                              | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Other Language<br>Needs—English                             | 0.00%      | 0.00%      | 100.00%    | +100.00                              | NC                                     |  |
| Other Language<br>Needs—Non-English                         | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |
| Other Language<br>Needs—Unknown                             | 100.00%    | 100.00%    | 0.00%      | -100.00                              | NC                                     |  |

#### APPENDIX B. TREND TABLES

#### Table B-3—MID Trend Table

| Measure  | HEDIS 2016     | HEDIS 2017    | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|--|----------------|---------------|------------|--------------------------------------|--|
| Other Language<br>Needs—Declined   | 0.00%          | 0.00%         | 0.00%      | 0.00                                 | NC                                     |
| Utilization <sup>5</sup>   |                |               |            |                                      |  |
| Ambulatory Care—Total (  | Per 1,000 Me   | mber Months   | 5)         |                                      |  |
| ED Visits—Total*   | 66.64          | 75.28         | 71.25      | -4.03                                | **                                     |
| Outpatient Visits—Total  | 405.99         | 539.45        | 506.48     | -32.97                               | NC                                     |
| Inpatient Utilization—Gen  | eral Hospita   | l/Acute Care- | -Total     | L                                    |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                                  | 9.24           | 16.85         | 12.18      | -4.67                                | NC                                     |
| Total Inpatient—<br>Average Length of<br>Stay—Total  | 3.87           | BR            | 5.80       | NC                                   | NC                                     |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total   | 2.77           | 1.30          | 1.19       | -0.11                                | NC                                     |
| Maternity—Average<br>Length of Stay—Total  | 2.52           | BR            | 3.03       | NC                                   | NC                                     |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total   | 2.16           | 3.59          | 2.94       | -0.65                                | NC                                     |
| Surgery—Average<br>Length of Stay—Total  | 6.26           | BR            | 8.07       | NC                                   | NC                                     |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total  | 5.06           | 12.46         | 8.52       | -3.94                                | NC                                     |
| Medicine—Average<br>Length of Stay—Total   | 3.38           | BR            | 5.25       | NC                                   | NC                                     |
| Use of Opioids From Mult   | tiple Provider | rs (Per 1,000 | Members)*  |                                      |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                               | _              | _             | 169.54     | NC                                   | NC                                     |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                                | _              |               | 48.67      | NC                                   | NC                                     |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple<br>Pharmacies |                | _             | 28.26      | NC                                   | NC                                     |





| Measure                          | HEDIS 2016   | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|----------------------------------|--|------------|------------|--------------------------------------|--|--|--|--|
| Use of Opioids at High Do        | Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |                                      |  |  |  |  |
| Use of Opioids at High<br>Dosage | _  | —          | 0.00       | NC                                   | NC                                     |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate, or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





| Tabla | D /  |      | Trand | Table |
|-------|------|------|-------|-------|
| rable | B-4- | •нак | irena | rable |

|  |                   | 5-4—пак і      | Tena Table            |                         |                    |
|--|-------------------|----------------|-----------------------|-------------------------|--------------------|
|  |                   |                |                       | 2017–2018               | 2018 Performance   |
| Measure  | <b>HEDIS 2016</b> | HEDIS 2017     | HEDIS 2018            | Comparison <sup>1</sup> | Level <sup>2</sup> |
| Child & Adolescent Care  |                   |                |                       |                         |                    |
| <b>Childhood Immunization S</b>  | Status            |                |                       |                         |                    |
| Combination 2  | 48.57%            | 60.71%         | 59.48%                | -1.23                   | *                  |
| Combination 3  | 44.29%            | 50.00%         | 52.94%                | +2.94                   | *                  |
| Combination 4  | 42.86%            | 46.43%         | 51.63%                | +5.20                   | *                  |
| Combination 5  | 32.86%            | 37.50%         | 42.48%                | +4.98                   | *                  |
| Combination 6  | 21.43%            | 19.64%         | 20.92%                | +1.28                   | *                  |
| Combination 7  | 31.43%            | 35.71%         | 41.83%                | +6.12                   | *                  |
| Combination 8  | 20.00%            | 19.64%         | 20.92%                | +1.28                   | *                  |
| Combination 9  | 18.57%            | 16.07%         | 18.95%                | +2.88                   | *                  |
| Combination 10   | 17.14%            | 16.07%         | 18.95%                | +2.88                   | *                  |
| Well-Child Visits in the Fir   | rst 15 Months     | s of Life      |                       |                         |                    |
| Six or More Visits   | NA                | NA             | 43.86%                | NC                      | *                  |
| Lead Screening in Children   | n                 |                |                       |                         |                    |
| Lead Screening in<br>Children  | 71.43%            | 67.86%         | 72.55%                | +4.69                   | ***                |
| Well-Child Visits in the Th  | ird, Fourth,      | Fifth, and Six | th Years of Lif       | e                       |                    |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 62.89%            | 69.68%         | 61.31%                | -8.37**                 | *                  |
| Adolescent Well-Care Visit   | 's                |                |                       |                         |                    |
| Adolescent Well-Care<br>Visits   | 35.51%            | 42.82%         | 30.41%                | -12.41**                | *                  |
| Immunizations for Adolesc  | ents              |                |                       | · · · ·                 | <b>-</b>           |
| Combination 1  | 58.33%            | 68.42%         | 75.00%                | +6.58                   | **                 |
| Appropriate Treatment for  | Children Wi       | th Upper Res   | viratory Infecti      | on                      |                    |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 96.61%            | 90.34%         | 93.81%                | +3.47                   | ****               |
| Appropriate Testing for Ch   | uildren With I    | Pharyngitis    |                       |                         |                    |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | NA                | 59.09%         | 72.22%                | +13.13                  | **                 |
| Follow-Up Care for Childr  | en Prescribe      | d ADHD Med     | lication <sup>3</sup> |                         |                    |
| Initiation Phase   | NA                | NA             | NA                    | NC                      | NC                 |
| Continuation and<br>Maintenance Phase  | NA                | NA             | NA                    | NC                      | NC                 |

#### Table B-4—HAR Trend Table

|   | Table         |               | Tellu Table      |                                      |  |
|---|---------------|---------------|------------------|--------------------------------------|--|
| Measure   | HEDIS 2016    | HEDIS 2017    | HEDIS 2018       | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Women – Adult Care  |               |               |                  |                                      |  |
| Breast Cancer Screening <sup>4</sup>                                    |               |               |                  |                                      |  |
| Breast Cancer Screening   |               |               | 65.46%           | NC                                   | NC                                     |
| Cervical Cancer   | <u> </u>      |               | 03.1070          | 110                                  | 1.0                                    |
| Screening   |               |               |                  |                                      |  |
| Cervical Cancer   | 42.58%        | 56.20%        | 47.20%           | <b>-9.00</b> <sup>++</sup>           | *                                      |
| Screening   |               | 2012070       |                  |                                      |  |
| Chlamydia Screening in W  | 1             |               |                  |                                      |  |
| Ages 16 to 20 Years   | 71.88%        | 70.49%        | 73.47%           | +2.98                                | ****                                   |
| Ages 21 to 24 Years   | 73.47%        | 70.67%        | 73.83%           | +3.16                                | ****                                   |
| Total   | 72.84%        | 70.59%        | 73.66%           | +3.07                                | ****                                   |
| Access to Care  |               |               |                  |                                      |  |
| Children and Adolescents'   | Access to Pri | imary Care Pi | ractitioners     |                                      |  |
| Ages 12 to 24 Months  | 82.35%        | 86.05%        | 82.46%           | -3.59                                | *                                      |
| Ages 25 Months to 6<br>Years  | 73.16%        | 76.97%        | 69.86%           | -7.11++                              | *                                      |
| Ages 7 to 11 Years  | 71.65%        | 79.14%        | 77.50%           | -1.64                                | *                                      |
| Ages 12 to 19 Years   | 67.02%        | 65.25%        | 69.13%           | +3.88                                | *                                      |
| Adults' Access to Preventiv   | e/Ambulator   | y Health Serv | ices             |                                      |  |
| Ages 20 to 44 Years   | 56.44%        | 59.28%        | 50.05%           | -9.23++                              | *                                      |
| Ages 45 to 64 Years   | 76.43%        | 77.85%        | 70.72%           | -7.13++                              | *                                      |
| Ages 65+ Years  | NA            | NA            | NA               | NC                                   | NC                                     |
| Total   | 66.87%        | 68.12%        | 58.62%           | -9.50++                              | *                                      |
| Avoidance of Antibiotic Tr  | eatment in A  | dults With Ac | ute Bronchitis   |                                      |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis | 40.00%        | 20.51%        | 30.00%           | +9.49                                | ***                                    |
| Obesity   |               |               |                  |                                      |  |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for  | Nutrition and | l Physical Activ | vity for                             |  |
| BMI Percentile—Total  | 73.97%        | 79.08%        | 70.32%           | -8.76++                              | **                                     |
| Counseling for<br>Nutrition—Total                                       | 69.83%        | 79.81%        | 66.67%           | -13.14++                             | **                                     |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 57.66%        | 57.91%        | 46.96%           | -10.95**                             | *                                      |
| Adult BMI Assessment  |               |               |                  |                                      |  |
| Adult BMI Assessment  | 74.19%        | 90.27%        | 71.07%           | <b>-19.20</b> <sup>++</sup>          | *                                      |
|   |               |               |                  |                                      |  |



#### Table B-4—HAR Trend Table

| Measure                                       | HEDIS 2016   | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|--------------|-----------------|------------|--------------------------------------|--|
| Pregnancy Care                                |              |                 |            |                                      |  |
| Prenatal and Postpartum C                     | Care         |                 |            |                                      |  |
| Timeliness of Prenatal<br>Care                | 34.41%       | 47.13%          | 35.34%     | -11.79                               | *                                      |
| Postpartum Care                               | 33.33%       | 42.53%          | 46.55%     | +4.02                                | *                                      |
| Living With Illness                           |              |                 |            |                                      |  |
| Comprehensive Diabetes C                      | are          |                 |            |                                      |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 75.64%       | 88.00%          | 77.61%     | -10.39++                             | *                                      |
| HbA1c Poor Control<br>(>9.0%)*                | 73.08%       | 41.33%          | 53.07%     | +11.74**                             | *                                      |
| HbA1c Control (<8.0%)                         | 22.22%       | 52.67%          | 40.18%     | -12.49++                             | *                                      |
| Eye Exam (Retinal)<br>Performed               | 46.15%       | 45.67%          | 41.41%     | -4.26                                | *                                      |
| Medical Attention for<br>Nephropathy          | 91.03%       | 90.00%          | 88.04%     | -1.96                                | *                                      |
| Blood Pressure Control (<140/90 mm Hg)        | 31.20%       | 46.33%          | 39.26%     | -7.07                                | *                                      |
| Medication Management for                     | or People Wi | th Asthma       |            |                                      |  |
| Medication Compliance<br>50%—Total            | NA           | NA              | 69.70%     | NC                                   | ****                                   |
| Medication Compliance<br>75%—Total            | NA           | NA              | 36.36%     | NC                                   | ***                                    |
| Asthma Medication Ratio                       |              |                 |            |                                      |  |
| Total   | NA           | 43.90%          | 58.54%     | +14.64                               | **                                     |
| Controlling High Blood Pr                     | essure       |                 |            |                                      |  |
| Controlling High Blood<br>Pressure            | 31.39%       | 34.06%          | 28.71%     | -5.35                                | *                                      |
| Medical Assistance With Se                    | moking and   | Tobacco Use     | Cessation  |                                      |  |
| Advising Smokers and<br>Tobacco Users to Quit | 78.41%       | 79.06%          | 80.79%     | +1.73                                | ****                                   |
| Discussing Cessation<br>Medications           | 54.51%       | 58.99%          | 63.16%     | +4.17                                | ****                                   |
| Discussing Cessation<br>Strategies            | 45.28%       | 50.00%          | 52.61%     | +2.61                                | ****                                   |
| Antidepressant Medication                     | Managemen    | ut <sup>3</sup> |            |                                      |  |
| Effective Acute Phase<br>Treatment            | NA           | NA              | 57.69%     | NC                                   | ****                                   |

#### APPENDIX B. TREND TABLES

#### Table B-4—HAR Trend Table

|   | Table L       |                | Tellu Table     |                                      |  |
|---|---------------|----------------|-----------------|--------------------------------------|--|
| Measure   | HEDIS 2016    | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Effective Continuation<br>Phase Treatment   | NA            | NA             | 42.31%          | NC                                   | ****                                   |
| Diabetes Screening for Peo<br>Using Antipsychotic Medic   |               | uizophrenia ol | r Bipolar Disor | der Who Are                          |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | NA            | 72.73%         | 83.33%          | +10.60                               | ***                                    |
| Diabetes Monitoring for Pe  | ople With D   | iabetes and S  | chizophrenia    |                                      |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | NA            | NA             | NA              | NC                                   | NC                                     |
| Cardiovascular Monitoring<br>Schizophrenia  | for People    | With Cardiove  | iscular Disease | e and                                | <u> </u>                               |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA            | NA             | NA              | NC                                   | NC                                     |
| Adherence to Antipsychotic  | Medication    | s for Individu | als With Schize | ophrenia                             |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | NA            | NA             | NA              | NC                                   | NC                                     |
| Annual Monitoring for Pat   | ients on Pers | sistent Medica | tions           |                                      |  |
| ACE Inhibitors or ARBs  | 87.30%        | 87.79%         | 85.17%          | -2.62                                | *                                      |
| Diuretics   | 85.20%        | 85.19%         | 83.83%          | -1.36                                | *                                      |
| $Total^4$   |               |                | 84.56%          | NC                                   | NC                                     |
| Health Plan Diversity <sup>5</sup>  |               |                |                 |                                      |  |
| Race/Ethnicity Diversity of   | Membership    | )              |                 |                                      |  |
| Total—White   | 2.39%         | 28.46%         | 27.17%          | -1.29                                | NC                                     |
| Total—Black or African<br>American  | 44.08%        | 51.78%         | 51.38%          | -0.40                                | NC                                     |
| Total—American-Indian<br>and Alaska Native  | 10.69%        | 1.13%          | 0.12%           | -1.01                                | NC                                     |
| Total—Asian   | 15.88%        | 2.09%          | 0.00%           | -2.09                                | NC                                     |



#### Table B-4—HAR Trend Table

|   | Table      |            |                   |                                      |  |  |
|---|------------|------------|-------------------|--------------------------------------|--|--|
| Measure   | HEDIS 2016 | HEDIS 2017 | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.00%      | 0.00%      | 0.99%             | +0.99                                | NC                                     |  |
| Total—Some Other Race                                       | 0.00%      | 0.00%      | 3.96%             | +3.96                                | NC                                     |  |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Total-Unknown   | 26.96%     | 16.54%     | 16.38%            | -0.16                                | NC                                     |  |
| Total—Declined  | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Total—Hispanic or<br>Latino                                 | 0.00%      | 3.59%      | 3.96%             | +0.37                                | NC                                     |  |
| Language Diversity of Men                                   | nbership   |            |                   |                                      | ·                                      |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 72.57%     | 99.04%     | 98.98%            | -0.06                                | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.51%      | 0.92%      | 0.99%             | +0.07                                | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 26.93%     | 0.05%      | 0.03%             | -0.02                                | NC                                     |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>English     | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 100.00%    | 100.00%    | 100.00%           | 0.00                                 | NC                                     |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Other Language Needs—<br>English                            | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Other Language Needs—<br>Non-English                        | 0.00%      | 0.00%      | 0.00%             | 0.00                                 | NC                                     |  |
| Other Language Needs—<br>Unknown                            | 100.00%    | 100.00%    | 100.00%           | 0.00                                 | NC                                     |  |

#### Table B-4—HAR Trend Table

| Measure   | HEDIS 2016     | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |
|---|----------------|-----------------|------------|--------------------------------------|--|--|
| Other Language Needs—<br>Declined   | 0.00%          | 0.00%           | 0.00%      | 0.00                                 | NC                                     |  |
| Utilization <sup>5</sup>  |                |                 |            |                                      |  |  |
| Ambulatory Care—Total (   | Per 1,000 Me   | mber Months     | ;)         |                                      | •                                      |  |
| ED Visits—Total*  | 79.99          | 82.34           | 71.57      | -10.77                               | **                                     |  |
| Outpatient Visits—Total   | 241.28         | 251.03          | 225.08     | -25.95                               | NC                                     |  |
| Inpatient Utilization—Gen   | eral Hospita   | /Acute Care–    | -Total     |                                      |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                               | 9.83           | 9.03            | 7.43       | -1.60                                | NC                                     |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total   | 3.89           | 4.15            | 4.89       | +0.74                                | NC                                     |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total                                      | 1.76           | 0.26            | 0.88       | +0.62                                | NC                                     |  |
| Maternity—Average<br>Length of Stay—Total   | 2.47           | 2.47            | 2.40       | -0.07                                | NC                                     |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total  | 2.09           | 2.73            | 1.88       | -0.85                                | NC                                     |  |
| Surgery—Average<br>Length of Stay—Total   | 5.67           | 4.80            | 6.14       | +1.34                                | NC                                     |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                                       | 6.06           | 4.85            | 4.30       | -0.55                                | NC                                     |  |
| Medicine—Average<br>Length of Stay—Total  | 3.56           | 3.53            | 4.82       | +1.29                                | NC                                     |  |
| Use of Opioids From Mult  | tiple Provider | rs (Per 1,000 ) | Members)*  |                                      |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                            |                |                 | 255.03     | NC                                   | NC                                     |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                             | _              | _               | 337.81     | NC                                   | NC                                     |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple Pharmacies |                | _               | 241.61     | NC                                   | NC                                     |  |

#### APPENDIX B. TREND TABLES



#### Table B-4—HAR Trend Table

| Measure                          | HEDIS 2016   | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|----------------------------------|--|------------|------------|--------------------------------------|--|--|--|--|
| Use of Opioids at High Do        | Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |                                      |  |  |  |  |
| Use of Opioids at High<br>Dosage | _  | _          | 5.17       | NC                                   | NC                                     |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the *MHP* followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





| Tablo | B-5-MCL   | Trend | Tahlo |
|-------|-----------|-------|-------|
| rapie | D-3-IVICL | rrenu | lable |

|  | I able D       |                | enu rabie       |                                      |  |  |  |  |
|--|----------------|----------------|-----------------|--------------------------------------|--|--|--|--|
| Measure  | HEDIS 2016     | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
| Child & Adolescent Care  |                |                |                 |                                      |  |  |  |  |
| Childhood Immunization S   | Status         |                |                 |                                      |  |  |  |  |
| Combination 2  | 74.70%         | 79.81%         | 73.72%          | -6.09++                              | **                                     |  |  |  |
| Combination 3  | 68.61%         | 75.67%         | 70.80%          | -4.87                                | **                                     |  |  |  |
| Combination 4  | 64.72%         | 73.97%         | 68.86%          | -5.11                                | **                                     |  |  |  |
| Combination 5  | 54.99%         | 68.13%         | 63.02%          | -5.11                                | ***                                    |  |  |  |
| Combination 6  | 38.93%         | 40.88%         | 36.50%          | -4.38                                | **                                     |  |  |  |
| Combination 7  | 53.04%         | 66.42%         | 61.31%          | -5.11                                | ***                                    |  |  |  |
| Combination 8  | 38.44%         | 40.88%         | 36.01%          | -4.87                                | **                                     |  |  |  |
| Combination 9  | 32.85%         | 37.71%         | 33.09%          | -4.62                                | **                                     |  |  |  |
| Combination 10   | 32.85%         | 37.71%         | 32.60%          | -5.11                                | **                                     |  |  |  |
| Well-Child Visits in the Fi  | rst 15 Months  |                |                 |                                      |  |  |  |  |
| Six or More Visits   | 66.42%         | 64.48%         | 70.32%          | +5.84                                | ****                                   |  |  |  |
| Lead Screening in Childre  |                |                |                 |                                      |  |  |  |  |
| Lead Screening in<br>Children  | 92.21%         | 94.40%         | 85.16%          | -9.24**                              | ****                                   |  |  |  |
| Well-Child Visits in the Th  | ird, Fourth,   | Fifth, and Six | th Years of Lif | fe                                   | •                                      |  |  |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 71.29%         | 70.07%         | 69.10%          | -0.97                                | **                                     |  |  |  |
| Adolescent Well-Care Visit   | ts             | 1              |                 | I                                    |  |  |  |  |
| Adolescent Well-Care<br>Visits   | 46.23%         | 47.20%         | 45.50%          | -1.70                                | **                                     |  |  |  |
| Immunizations for Adolesc  | ents           | L.             |                 | <u> </u>                             | ±                                      |  |  |  |
| Combination 1  | 82.73%         | 84.43%         | 84.18%          | -0.25                                | ****                                   |  |  |  |
| Appropriate Treatment for  | Children Wi    | th Upper Res   | piratory Infect | ion                                  |  |  |  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 86.74%         | 86.33%         | 85.58%          | -0.75                                | *                                      |  |  |  |
| Appropriate Testing for Ch   | uildren With I | Pharyngitis    |                 |                                      |  |  |  |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 70.37%         | 70.40%         | 83.27%          | +12.87+                              | ****                                   |  |  |  |
| Follow-Up Care for Children Prescribed ADHD Medication <sup>3</sup>          |                |                |                 |                                      |  |  |  |  |
| Initiation Phase   | 42.27%         | 39.67%         | 45.37%          | +5.70+                               | ***                                    |  |  |  |
| Continuation and<br>Maintenance Phase  | 54.07%         | 43.98%         | 57.50%          | +13.52+                              | ***                                    |  |  |  |
|  | 1              |                | G               |                                      |  |  |  |  |

| Measure   |              | HEDIS 2017    | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|---|--------------|---------------|-----------------|--------------------------------------|--|--|--|--|--|
|   | HEDIS 2010   | HEDIS 2017    | HEDIS 2018      | Companson                            | Level                                  |  |  |  |  |
| Women – Adult Care  |              |               |                 |                                      | ·                                      |  |  |  |  |
| Breast Cancer Screening <sup>4</sup>                                    |              |               |                 |                                      |  |  |  |  |  |
| Breast Cancer Screening   |              |               | 62.86%          | NC                                   | NC                                     |  |  |  |  |
| Cervical Cancer<br>Screening  |              |               |                 |                                      |  |  |  |  |  |
| Cervical Cancer<br>Screening  | 63.02%       | 56.93%        | 61.80%          | +4.87                                | ***                                    |  |  |  |  |
| Chlamydia Screening in W  | omen         | <b>I</b>      |                 |                                      |  |  |  |  |  |
| Ages 16 to 20 Years   | 50.36%       | 52.81%        | 53.79%          | +0.98                                | ***                                    |  |  |  |  |
| Ages 21 to 24 Years   | 60.12%       | 59.87%        | 62.43%          | +2.56+                               | **                                     |  |  |  |  |
| Total   | 54.81%       | 56.01%        | 57.58%          | +1.57                                | ***                                    |  |  |  |  |
| Access to Care  |              | JJ            |                 |                                      |  |  |  |  |  |
| Children and Adolescents'   | Access to Pr | imarv Care Pi | ractitioners    |                                      |  |  |  |  |  |
| Ages 12 to 24 Months  | 95.44%       | 94.66%        | 92.30%          | -2.36++                              | *                                      |  |  |  |  |
| Ages 25 Months to 6<br>Years  | 86.68%       | 87.10%        | 83.68%          | -3.42++                              | *                                      |  |  |  |  |
| Ages 7 to 11 Years  | 87.98%       | 89.00%        | 88.57%          | -0.43                                | **                                     |  |  |  |  |
| Ages 12 to 19 Years   | 86.62%       | 88.30%        | 87.18%          | -1.12++                              | **                                     |  |  |  |  |
| Adults' Access to Preventiv   |              |               |                 |                                      |  |  |  |  |  |
| Ages 20 to 44 Years   | 83.34%       | 82.10%        | 78.71%          | -3.39++                              | **                                     |  |  |  |  |
| Ages 45 to 64 Years   | 89.87%       | 89.58%        | 87.89%          | -1.69++                              | ***                                    |  |  |  |  |
| Ages 65+ Years  | 90.48%       | NA            | 84.31%          | NC                                   | **                                     |  |  |  |  |
| Total   | 86.05%       | 85.18%        | 82.41%          | -2.77**                              | ***                                    |  |  |  |  |
| Avoidance of Antibiotic Tr  | eatment in A | dults With Ac | ute Bronchitis  |                                      | <b>.</b>                               |  |  |  |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis |              | 26.35%        | 29.91%          | +3.56+                               | ***                                    |  |  |  |  |
| Obesity   |              |               |                 |                                      |  |  |  |  |  |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for | Nutrition and | l Physical Acti | vity for                             |  |  |  |  |  |
| BMI Percentile—Total  | 66.67%       | 83.45%        | 81.02%          | -2.43                                | ****                                   |  |  |  |  |
| Counseling for<br>Nutrition—Total                                       | 50.85%       | 60.34%        | 63.99%          | +3.65                                | **                                     |  |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 44.53%       | 50.85%        | 56.45%          | +5.60                                | **                                     |  |  |  |  |
| Adult BMI Assessment  | 1            |               |                 |                                      | 1                                      |  |  |  |  |
| Adult BMI Assessment  | 87.83%       | 91.48%        | 93.67%          | +2.19                                | ****                                   |  |  |  |  |
|   | 0            |               |                 |                                      | 1                                      |  |  |  |  |





|   | Table B      |                 |                   |                                      |  |
|---|--------------|-----------------|-------------------|--------------------------------------|--|
| Measure                                       | HEDIS 2016   | HEDIS 2017      | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Pregnancy Care                                |              |                 |                   |                                      |  |
| Prenatal and Postpartum (                     | Care         |                 |                   |                                      | ·                                      |
| Timeliness of Prenatal<br>Care                | 76.40%       | 86.13%          | 77.86%            | -8.27**                              | **                                     |
| Postpartum Care                               | 63.99%       | 64.23%          | 66.67%            | +2.44                                | ***                                    |
| Living With Illness                           |              |                 |                   |                                      |  |
| Comprehensive Diabetes C                      | are          |                 |                   |                                      |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 89.42%       | 87.59%          | 90.27%            | +2.68                                | ****                                   |
| HbA1c Poor Control (>9.0%)*                   | 36.50%       | 48.54%          | 43.80%            | -4.74                                | **                                     |
| HbA1c Control (<8.0%)                         | 51.09%       | 41.61%          | 45.74%            | +4.13                                | **                                     |
| Eye Exam (Retinal)<br>Performed               | 56.20%       | 58.03%          | 64.23%            | +6.20                                | ****                                   |
| Medical Attention for<br>Nephropathy          | 92.15%       | 88.87%          | 90.02%            | +1.15                                | **                                     |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 61.50%       | 66.24%          | 69.34%            | +3.10                                | ****                                   |
| Medication Management f                       | or People Wi | th Asthma       |                   |                                      |  |
| Medication Compliance<br>50%—Total            | 59.94%       | 84.33%          | 66.01%            | -18.32++                             | ****                                   |
| Medication Compliance<br>75%—Total            | 38.39%       | 67.87%          | 43.52%            | -24.35++                             | ****                                   |
| Asthma Medication Ratio                       |              |                 |                   |                                      |  |
| Total   | 65.18%       | 66.09%          | 67.03%            | +0.94                                | ***                                    |
| Controlling High Blood Pr                     | essure       |                 |                   | ·                                    | ·                                      |
| Controlling High Blood<br>Pressure            | 54.74%       | 58.64%          | 61.56%            | +2.92                                | ***                                    |
| Medical Assistance With S                     | moking and [ | Tobacco Use     | Cessation         | L                                    |  |
| Advising Smokers and<br>Tobacco Users to Quit | 77.60%       | 76.79%          | 76.54%            | -0.25                                | **                                     |
| Discussing Cessation<br>Medications           | 50.54%       | 54.94%          | 54.55%            | -0.39                                | ***                                    |
| Discussing Cessation<br>Strategies            | 42.25%       | 47.70%          | 46.27%            | -1.43                                | ***                                    |
| Antidepressant Medication                     | Managemen    | ut <sup>3</sup> | -                 | ·                                    |  |
| Effective Acute Phase<br>Treatment            | 58.33%       | 45.65%          | 58.05%            | +12.40+                              | ****                                   |
|   |              |                 |                   | •                                    |  |

#### Table B-5—MCL Trend Table

| Measure   | HEDIS 2016    | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|---|---------------|----------------|-----------------|--------------------------------------|--|--|--|--|--|
| Effective Continuation<br>Phase Treatment   | 39.15%        | 29.70%         | 40.80%          | +11.10+                              | ***                                    |  |  |  |  |
| Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are  |               |                |                 |                                      |  |  |  |  |  |
| Using Antipsychotic Medice  | ations        |                |                 |                                      |  |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | 81.62%        | 82.62%         | 82.06%          | -0.56                                | ***                                    |  |  |  |  |
| Diabetes Monitoring for Pe  | cople With D  | iabetes and S  | chizophrenia    |                                      |  |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 63.59%        | 72.17%         | 77.58%          | +5.41                                | ****                                   |  |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia  | for People    | With Cardiovo  | iscular Disease | e and                                |  |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA            | NA             | NA              | NC                                   | NC                                     |  |  |  |  |
| Adherence to Antipsychotic  | Medication    | s for Individu | als With Schize | ophrenia                             | ·                                      |  |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 66.45%        | 63.27%         | 70.56%          | +7.29+                               | ****                                   |  |  |  |  |
| Annual Monitoring for Pat   | ients on Pers | sistent Medica | tions           |                                      |  |  |  |  |  |
| ACE Inhibitors or ARBs  | 86.14%        | 84.68%         | 85.90%          | +1.22+                               | *                                      |  |  |  |  |
| Diuretics   | 86.37%        | 85.62%         | 86.89%          | +1.27+                               | **                                     |  |  |  |  |
| $Total^4$   |               | _              | 86.30%          | NC                                   | NC                                     |  |  |  |  |
| Health Plan Diversity <sup>5</sup>  | L             |                |                 |                                      |  |  |  |  |  |
| Race/Ethnicity Diversity of   | Membership    | )              |                 |                                      |  |  |  |  |  |
| Total—White   | 68.72%        | 66.67%         | 66.14%          | -0.53                                | NC                                     |  |  |  |  |
| Total—Black or African<br>American  | 15.26%        | 17.27%         | 18.23%          | +0.96                                | NC                                     |  |  |  |  |
| Total—American-Indian<br>and Alaska Native  | 0.55%         | 0.54%          | 0.51%           | -0.03                                | NC                                     |  |  |  |  |
|   |               |                |                 |                                      |  |  |  |  |  |



| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|---|------------|------------|------------|--------------------------------------|--|--|--|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.07%      | 0.79%      | 0.07%      | -0.72                                | NC                                     |  |  |  |
| Total—Some Other Race                                       | 5.05%      | 5.51%      | 5.45%      | -0.06                                | NC                                     |  |  |  |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Unknown   | 9.64%      | 9.22%      | 8.96%      | -0.26                                | NC                                     |  |  |  |
| Total—Declined  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Hispanic or<br>Latino                                 | 5.05%      | 5.51%      | 5.45%      | -0.06                                | NC                                     |  |  |  |
| Language Diversity of Men                                   | nbership   |            |            | L                                    | ·                                      |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 96.40%     | 96.45%     | 95.62%     | -0.83                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.20%      | 0.77%      | 0.77%      | 0.00                                 | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 3.40%      | 2.78%      | 3.61%      | +0.83                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>English     | NR         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—Non-<br>English | NR         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Declined    | NR         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>English                            | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>Non-English                        | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>Unknown                            | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |  |  |

### APPENDIX B. TREND TABLES

#### Table B-5—MCL Trend Table

| Measure   | HEDIS 2016    | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|---|---------------|-----------------|------------|--------------------------------------|--|--|--|--|--|
| Other Language Needs—<br>Declined   | 0.00%         | 0.00%           | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Utilization <sup>5</sup>  |               |                 |            |                                      |  |  |  |  |  |
| Ambulatory Care—Total (Per 1,000 Member Months)   |               |                 |            |                                      |  |  |  |  |  |
| ED Visits—Total*  | 70.80         | 70.81           | 74.32      | +3.51                                | *                                      |  |  |  |  |
| Outpatient Visits—Total   | 430.13        | 552.80          | 558.58     | +5.78                                | NC                                     |  |  |  |  |
| Inpatient Utilization—Gen   | eral Hospital | l/Acute Care-   | -Total     | L                                    |  |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                               | 7.42          | 8.38            | 8.84       | +0.46                                | NC                                     |  |  |  |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total   | 3.45          | 3.87            | 4.44       | +0.57                                | NC                                     |  |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total                                      | 2.65          | 2.72            | 2.66       | -0.06                                | NC                                     |  |  |  |  |
| Maternity—Average<br>Length of Stay—Total   | 2.33          | 2.46            | 2.24       | -0.22                                | NC                                     |  |  |  |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total  | 2.01          | 4.09            | 2.16       | -1.93                                | NC                                     |  |  |  |  |
| Surgery—Average<br>Length of Stay—Total   | 4.85          | 4.70            | 5.96       | +1.26                                | NC                                     |  |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                                       | 3.47          | 1.47            | 4.71       | +3.24                                | NC                                     |  |  |  |  |
| Medicine—Average<br>Length of Stay—Total  | 3.27          | 3.61            | 4.69       | +1.08                                | NC                                     |  |  |  |  |
| Use of Opioids From Mult  | iple Provider | rs (Per 1,000 I | Members)*  |                                      |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                            | _             | _               | 151.71     | NC                                   | NC                                     |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                             |               |                 | 87.45      | NC                                   | NC                                     |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple Pharmacies |               |                 | 33.88      | NC                                   | NC                                     |  |  |  |  |

#### APPENDIX B. TREND TABLES



#### Table B-5—MCL Trend Table

| Measure                          | HEDIS 2016   | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|----------------------------------|--|------------|------------|--------------------------------------|--|--|--|--|--|
| Use of Opioids at High Do        | Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |                                      |  |  |  |  |  |
| Use of Opioids at High<br>Dosage | —  | _          | 23.70      | NC                                   | NC                                     |  |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

*NR* indicates that the auditor determined that the HEDIS 2016 rate was materially biased or that the MHP chose not report a rate for this measure indicator.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





#### Table B-6—MER Trend Table

| Measure  | HEDIS 2016   | HEDIS 2017     | HEDIS 2018            | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup>       |
|--|--------------|----------------|-----------------------|--------------------------------------|--|
| Child & Adolescent Care  |              |                |                       |                                      |  |
| Childhood Immunization S   | Status       |                |                       |                                      |  |
| Combination 2  | 77.91%       | 78.60%         | 78.10%                | -0.50                                | ***  |
| Combination 3  | 72.79%       | 74.88%         | 73.72%                | -1.16                                | ***  |
| Combination 4  | 68.84%       | 71.63%         | 72.02%                | +0.39                                | ***  |
| Combination 5  | 59.07%       | 64.42%         | 64.48%                | +0.06                                | ***  |
| Combination 6  | 42.79%       | 40.70%         | 41.61%                | +0.91                                | ***  |
| Combination 7  | 55.81%       | 62.33%         | 63.26%                | +0.93                                | ****   |
| Combination 8  | 41.86%       | 40.00%         | 41.36%                | +1.36                                | ***  |
| Combination 9  | 36.28%       | 35.81%         | 37.96%                | +2.15                                | ***  |
| Combination 10   | 35.35%       | 35.35%         | 37.71%                | +2.36                                | ***  |
| Well-Child Visits in the Fir   | st 15 Month  | s of Life      | L                     | !                                    | ·  |
| Six or More Visits   | 75.21%       | 74.88%         | 76.40%                | +1.52                                | *****  |
| Lead Screening in Children   | n            | L.             |                       |                                      | <u></u>                                      |
| Lead Screening in<br>Children  | 80.32%       | 81.14%         | 81.02%                | -0.12                                | ****   |
| Well-Child Visits in the Th  | ird, Fourth, | Fifth, and Six | th Years of Lif       | fe                                   |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 77.27%       | 78.42%         | 78.83%                | +0.41                                | ****   |
| Adolescent Well-Care Visit   | s            |                | I                     | J                                    | J  |
| Adolescent Well-Care<br>Visits   | 59.72%       | 64.42%         | 60.34%                | -4.08                                | ****   |
| Immunizations for Adolesc  | ents         |                | ·                     | <u> </u>                             | <u>.                                    </u> |
| Combination 1  | 86.11%       | 86.60%         | 83.45%                | -3.15                                | ***  |
| Appropriate Treatment for  | Children Wi  | th Upper Res   | piratory Infecti      | ion                                  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 89.77%       | 89.44%         | 87.90%                | -1.54++                              | **   |
| Appropriate Testing for Ch   | ildren With  | Pharyngitis    |                       |                                      |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 72.84%       | 73.43%         | 80.53%                | +7.10+                               | ***  |
| Follow-Up Care for Childr  | en Prescribe | d ADHD Mea     | lication <sup>3</sup> |                                      |  |
| Initiation Phase   | 45.88%       | 41.74%         | 40.71%                | -1.03                                | **   |
| Continuation and<br>Maintenance Phase  | 57.59%       | 55.97%         | 47.91%                | -8.06++                              | *  |
|  | 1            | I              | 1                     |                                      |  |

#### Table B-6—MER Trend Table

| Measure  |              | HEDIS 2017       | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|--|--------------|------------------|-----------------|--------------------------------------|--|--|--|--|--|
|  | HEDI3 2010   | HEDI3 2017       | HEDI3 2018      | companson                            | Level                                  |  |  |  |  |
| Women – Adult Care                                     |              |                  |                 |                                      |  |  |  |  |  |
| Breast Cancer Screening <sup>4</sup>                   |              |                  | 64.170/         | NG                                   | NG                                     |  |  |  |  |
| Breast Cancer Screening                                |              |                  | 64.17%          | NC                                   | NC                                     |  |  |  |  |
| Cervical Cancer<br>Screening                           |              |                  |                 |                                      |  |  |  |  |  |
| Cervical Cancer  |              |                  |                 |                                      |  |  |  |  |  |
| Screening  | 63.91%       | 65.50%           | 65.21%          | -0.29                                | ***                                    |  |  |  |  |
| Chlamydia Screening in W                               | omen         |                  |                 |                                      |  |  |  |  |  |
| Ages 16 to 20 Years                                    | 60.65%       | 60.49%           | 62.30%          | $+1.81^{+}$                          | ****                                   |  |  |  |  |
| Ages 21 to 24 Years                                    | 68.47%       | 69.23%           | 68.50%          | -0.73                                | ***                                    |  |  |  |  |
| Total  | 64.41%       | 64.88%           | 65.31%          | +0.43                                | ****                                   |  |  |  |  |
| Access to Care   | 01.1170      | 01.0070          | 00.0170         | 10.15                                |  |  |  |  |  |
| Children and Adolescents'                              | Access to Pr | imary Care P     | ractitioners    |                                      |  |  |  |  |  |
| Ages 12 to 24 Months                                   | 97.69%       | 97.37%           | 96.84%          | -0.53++                              | ***                                    |  |  |  |  |
| Ages 25 Months to 6                                    | 97.0970      | 91.3770          | 90.8470         | -0.55                                |  |  |  |  |  |
| Years  | 91.25%       | 90.69%           | 90.53%          | -0.16                                | ***                                    |  |  |  |  |
| Ages 7 to 11 Years                                     | 92.57%       | 92.53%           | 92.59%          | +0.06                                | ***                                    |  |  |  |  |
| Ages 12 to 19 Years                                    | 92.74%       | 92.90%           | 92.06%          | -0.84++                              | ***                                    |  |  |  |  |
| Adults' Access to Preventiv                            |              |                  |                 |                                      |  |  |  |  |  |
| Ages 20 to 44 Years                                    | 85.37%       | 83.55%           | 80.45%          | -3.10++                              | ***                                    |  |  |  |  |
| Ages 45 to 64 Years                                    | 91.57%       | 90.46%           | 88.81%          | -1.65++                              | ***                                    |  |  |  |  |
| Ages 65+ Years   | 91.50%       | 92.62%           | 94.89%          | +2.27+                               | ****                                   |  |  |  |  |
| Total  | 87.70%       | 92.02%<br>86.17% | 83.63%          | -2.54++                              | ***                                    |  |  |  |  |
| Avoidance of Antibiotic Tre                            |              |                  |                 | -2.54                                | ~~~                                    |  |  |  |  |
| Avoidance of Antibiotic Tre                            | euimeni in A | uuus wun Ac      | ule Bronchuls   |                                      |  |  |  |  |  |
| Treatment in Adults With                               | 23.57%       | 26.18%           | 30.32%          | +4.14+                               | ***                                    |  |  |  |  |
| Acute Bronchitis                                       | 2010770      | 2011070          | 2012270         |                                      |  |  |  |  |  |
| Obesity  |              |                  | L               |                                      | J                                      |  |  |  |  |
| Weight Assessment and Co<br>Children/Adolescents       | unseling for | Nutrition and    | l Physical Acti | vity for                             |  |  |  |  |  |
| BMI Percentile—Total                                   | 74.53%       | 81.48%           | 82.24%          | +0.76                                | ****                                   |  |  |  |  |
| Counseling for   | (0.000)      | 70.150           | 70.510          | 0.51                                 |  |  |  |  |  |
| Nutrition—Total  | 68.22%       | 73.15%           | 72.51%          | -0.64                                | ***                                    |  |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup> | 55.14%       | 59.49%           | 67.15%          | +7.66+                               | ***                                    |  |  |  |  |
| Adult BMI Assessment                                   |              |                  | •               |                                      | -                                      |  |  |  |  |
| Adult BMI Assessment                                   | 94.08%       | 96.28%           | 94.89%          | -1.39                                | *****                                  |  |  |  |  |
|  | I            |                  | 1               | 1                                    | 1                                      |  |  |  |  |





#### Table B-6—MER Trend Table

| Measure                                       | HEDIS 2016   | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |  |
|---|--------------|-----------------|------------|--------------------------------------|--|--|--|--|--|--|
| Pregnancy Care                                |              |                 |            |                                      |  |  |  |  |  |  |
| Prenatal and Postpartum C                     | Care         |                 |            |                                      |  |  |  |  |  |  |
| Timeliness of Prenatal<br>Care                | 88.11%       | 82.87%          | 85.40%     | +2.53                                | ***                                    |  |  |  |  |  |
| Postpartum Care                               | 68.53%       | 71.30%          | 67.15%     | -4.15                                | ***                                    |  |  |  |  |  |
| Living With Illness                           |              |                 |            |                                      |  |  |  |  |  |  |
| Comprehensive Diabetes C                      | are          |                 |            |                                      |  |  |  |  |  |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 85.60%       | 87.79%          | 88.04%     | +0.25                                | ***                                    |  |  |  |  |  |
| HbA1c Poor Control (>9.0%)*                   | 39.97%       | 35.42%          | 38.65%     | +3.23                                | ***                                    |  |  |  |  |  |
| HbA1c Control (<8.0%)                         | 50.23%       | 52.67%          | 51.47%     | -1.20                                | ***                                    |  |  |  |  |  |
| Eye Exam (Retinal)<br>Performed               | 61.87%       | 67.63%          | 69.84%     | +2.21                                | ****                                   |  |  |  |  |  |
| Medical Attention for<br>Nephropathy          | 88.67%       | 91.45%          | 90.64%     | -0.81                                | ***                                    |  |  |  |  |  |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 68.15%       | 65.65%          | 66.90%     | +1.25                                | ***                                    |  |  |  |  |  |
| Medication Management for                     | or People Wi | th Asthma       |            | L                                    |  |  |  |  |  |  |
| Medication Compliance<br>50%—Total            | 71.23%       | 72.33%          | 72.29%     | -0.04                                | ****                                   |  |  |  |  |  |
| Medication Compliance<br>75%—Total            | 48.68%       | 51.35%          | 51.22%     | -0.13                                | ****                                   |  |  |  |  |  |
| Asthma Medication Ratio                       | ,            |                 |            | ,                                    |  |  |  |  |  |  |
| Total   | 69.48%       | 61.92%          | 60.17%     | -1.75                                | **                                     |  |  |  |  |  |
| Controlling High Blood Pr                     | essure       |                 |            |                                      | ·                                      |  |  |  |  |  |
| Controlling High Blood<br>Pressure            | 67.79%       | 67.15%          | 67.15%     | 0.00                                 | ****                                   |  |  |  |  |  |
| Medical Assistance With Si                    | moking and   | Tobacco Use     | Cessation  |                                      |  |  |  |  |  |  |
| Advising Smokers and<br>Tobacco Users to Quit | 80.16%       | 81.16%          | 81.25%     | +0.09                                | ****                                   |  |  |  |  |  |
| Discussing Cessation<br>Medications           | 55.69%       | 54.30%          | 54.90%     | +0.60                                | ***                                    |  |  |  |  |  |
| Discussing Cessation<br>Strategies            | 44.88%       | 44.68%          | 45.79%     | +1.11                                | ***                                    |  |  |  |  |  |
| Antidepressant Medication                     | Managemen    | nt <sup>3</sup> |            |                                      |  |  |  |  |  |  |
| Effective Acute Phase<br>Treatment            | 70.45%       | 50.92%          | 54.45%     | +3.53+                               | ***                                    |  |  |  |  |  |

#### Table B-6—MER Trend Table

|   |   |                |                   | 2017-2018               | 2018 Performance   |  |  |  |  |  |
|---|---|----------------|-------------------|-------------------------|--------------------|--|--|--|--|--|
| Measure   | HEDIS 2016  | HEDIS 2017     | <b>HEDIS 2018</b> | Comparison <sup>1</sup> | Level <sup>2</sup> |  |  |  |  |  |
| Effective Continuation<br>Phase Treatment   | 50.24%  | 31.77%         | 36.08%            | +4.31+                  | **                 |  |  |  |  |  |
|   | Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are<br>Using Antipsychotic Medications |                |                   |                         |                    |  |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or<br>Bipolar Disorder Who<br>Are Using Antipsychotic<br>Medications | 80.27%  | 83.11%         | 85.63%            | +2.52+                  | ****               |  |  |  |  |  |
| Diabetes Monitoring for Po  | eople With D  | iabetes and S  | chizophrenia      | I                       |                    |  |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 73.63%  | 66.04%         | 71.65%            | +5.61                   | ***                |  |  |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia  | g for People  | With Cardiove  | ascular Diseaso   | e and                   |                    |  |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | 80.00%  | 55.88%         | 76.71%            | +20.83+                 | **                 |  |  |  |  |  |
| Adherence to Antipsychotic  | c Medication  | s for Individu | als With Schiz    | ophrenia                |                    |  |  |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 61.59%  | 63.52%         | 67.07%            | +3.55+                  | ****               |  |  |  |  |  |
| Annual Monitoring for Pa  | tients on Per   | sistent Medica | ations            |                         |                    |  |  |  |  |  |
| ACE Inhibitors or ARBs  | 87.38%  | 86.53%         | 83.26%            | -3.27**                 | *                  |  |  |  |  |  |
| Diuretics   | 87.53%  | 86.88%         | 83.70%            | -3.18++                 | *                  |  |  |  |  |  |
| $Total^4$   |   |                | 83.44%            | NC                      | NC                 |  |  |  |  |  |
| Health Plan Diversity <sup>5</sup>  |   |                |                   |                         |                    |  |  |  |  |  |
| Race/Ethnicity Diversity of   | <sup>e</sup> Membershi <sub>l</sub>   | D              |                   |                         |                    |  |  |  |  |  |
| Total—White   | 62.24%  | 61.97%         | 61.91%            | -0.06                   | NC                 |  |  |  |  |  |
| Total—Black or African<br>American  | 21.29%  | 21.51%         | 21.40%            | -0.11                   | NC                 |  |  |  |  |  |
| Total—American-Indian<br>and Alaska Native  | 0.45%   | 0.49%          | 0.46%             | -0.03                   | NC                 |  |  |  |  |  |
| Total—Asian   | 0.77%   | 0.73%          | 0.70%             | -0.03                   | NC                 |  |  |  |  |  |



#### Table B-6—MER Trend Table

| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|---|------------|------------|------------|--------------------------------------|--|--|--|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.06%      | 0.06%      | 0.05%      | -0.01                                | NC                                     |  |  |  |
| Total—Some Other Race                                       | 0.00%      | 0.00%      | 0.02%      | +0.02                                | NC                                     |  |  |  |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Unknown   | 5.66%      | 5.76%      | 6.08%      | +0.32                                | NC                                     |  |  |  |
| Total—Declined  | 9.53%      | 9.48%      | 9.38%      | -0.10                                | NC                                     |  |  |  |
| Total—Hispanic or<br>Latino                                 | 5.66%      | 5.75%      | 5.75%      | 0.00                                 | NC                                     |  |  |  |
| Language Diversity of Men                                   | nbership   |            |            |                                      |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 98.87%     | 98.69%     | 98.62%     | -0.07                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 1.13%      | 1.29%      | 1.35%      | +0.06                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.00%      | 0.02%      | 0.03%      | +0.01                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>English     | 98.87%     | 98.69%     | 98.62%     | -0.07                                | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 1.13%      | 1.29%      | 1.35%      | +0.06                                | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.00%      | 0.02%      | 0.03%      | +0.01                                | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language<br>Needs—English                             | 98.87%     | 98.69%     | 98.62%     | -0.07                                | NC                                     |  |  |  |
| Other Language<br>Needs—Non-English                         | 1.13%      | 1.29%      | 1.35%      | +0.06                                | NC                                     |  |  |  |
| Other Language<br>Needs—Unknown                             | 0.00%      | 0.02%      | 0.03%      | +0.01                                | NC                                     |  |  |  |

#### Table B-6—MER Trend Table

| Measure  | HEDIS 2016     | HEDIS 2017              | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|--|----------------|-------------------------|------------|--------------------------------------|--|--|--|--|--|
| Other Language<br>Needs—Declined   | 0.00%          | 0.00%                   | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Utilization <sup>5</sup>   |                |                         |            |                                      |  |  |  |  |  |
| Ambulatory Care—Total (  | Per 1,000 Me   | ember Months            | ;)         |                                      |  |  |  |  |  |
| ED Visits—Total*   | 80.18          | 77.48                   | 73.23      | -4.25                                | *                                      |  |  |  |  |
| Outpatient Visits—Total  | 392.51         | 398.30                  | 396.18     | -2.12                                | NC                                     |  |  |  |  |
| Inpatient Utilization—Gen  | eral Hospita   | l/Acute Care-           | -Total     |                                      |  |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                                  | 8.23           | 8.10                    | 7.55       | -0.55                                | NC                                     |  |  |  |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total  | 3.86           | 3.99                    | 3.99       | 0.00                                 | NC                                     |  |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total   | 2.65           | 3.42                    | 3.16       | -0.26                                | NC                                     |  |  |  |  |
| Maternity—Average<br>Length of Stay—Total  | 2.50           | 2.55                    | 2.58       | +0.03                                | NC                                     |  |  |  |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total   | 1.02           | 1.90                    | 1.71       | -0.19                                | NC                                     |  |  |  |  |
| Surgery—Average<br>Length of Stay—Total  | 5.73           | 6.29                    | 6.38       | +0.09                                | NC                                     |  |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total  | 5.33           | 3.74                    | 3.57       | -0.17                                | NC                                     |  |  |  |  |
| Medicine—Average<br>Length of Stay—Total   | 3.98           | 3.77                    | 3.74       | -0.03                                | NC                                     |  |  |  |  |
| Use of Opioids From Mult   | tiple Provider | rs ( <b>Per 1,000</b> I | Members)*  |                                      |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                               | _              | _                       | 214.34     | NC                                   | NC                                     |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                                | _              |                         | 71.53      | NC                                   | NC                                     |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple<br>Pharmacies | _              | _                       | 44.12      | NC                                   | NC                                     |  |  |  |  |

#### APPENDIX B. TREND TABLES



#### Table B-6—MER Trend Table

| Measure                          | HEDIS 2016    | HEDIS 2017   | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|----------------------------------|---------------|--------------|------------|--------------------------------------|--|
| Use of Opioids at High Do        | sage (Per 1,0 | 000 Members) | *          |                                      |  |
| Use of Opioids at High<br>Dosage | —             | _            | 26.48      | NC                                   | NC                                     |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





|  | Table B      |                |                       |                                      |  |
|--|--------------|----------------|-----------------------|--------------------------------------|--|
| Measure  | HEDIS 2016   | HEDIS 2017     | HEDIS 2018            | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Child & Adolescent Care  |              |                |                       |                                      |  |
| Childhood Immunization S   | Status       |                |                       |                                      |  |
| Combination 2  | 73.73%       | 71.74%         | 76.60%                | +4.86+                               | ***                                    |
| Combination 3  | 68.43%       | 68.65%         | 71.68%                | +3.03                                | ***                                    |
| Combination 4  | 65.56%       | 67.11%         | 69.78%                | +2.67                                | ***                                    |
| Combination 5  | 60.26%       | 58.28%         | 60.29%                | +2.01                                | ***                                    |
| Combination 6  | 36.42%       | 35.98%         | 36.61%                | +0.63                                | **                                     |
| Combination 7  | 57.84%       | 57.17%         | 59.06%                | +1.89                                | ***                                    |
| Combination 8  | 35.32%       | 35.32%         | 36.21%                | +0.89                                | **                                     |
| Combination 9  | 33.33%       | 30.68%         | 31.60%                | +0.92                                | **                                     |
| Combination 10   | 32.23%       | 30.24%         | 31.31%                | +1.07                                | **                                     |
| Well-Child Visits in the Fir   | rst 15 Month | s of Life      |                       |                                      |  |
| Six or More Visits   | 63.84%       | 68.79%         | 70.56%                | +1.77                                | ****                                   |
| Lead Screening in Children   | n            |                |                       |                                      |  |
| Lead Screening in<br>Children  | 72.19%       | 78.15%         | 78.83%                | +0.68                                | ***                                    |
| Well-Child Visits in the Th  | ird, Fourth, | Fifth, and Six | th Years of Lij       | fe                                   |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 76.15%       | 75.89%         | 75.08%                | -0.81                                | ***                                    |
| Adolescent Well-Care Visit   | s            | L.             |                       | I                                    |  |
| Adolescent Well-Care<br>Visits   | 57.21%       | 52.48%         | 54.39%                | +1.91                                | ***                                    |
| Immunizations for Adolesc  | ents         |                | <u> </u>              | <u> </u>                             | <u> </u>                               |
| Combination 1  | 90.54%       | 90.07%         | 86.87%                | -3.20++                              | ****                                   |
| Appropriate Treatment for  | Children Wi  | th Upper Res   | piratory Infect       | ion                                  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 88.44%       | 86.82%         | 87.40%                | +0.58                                | **                                     |
| Appropriate Testing for Ch   | ildren With  | Pharyngitis    |                       |                                      |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 62.82%       | 67.17%         | 75.12%                | +7.95+                               | **                                     |
| Follow-Up Care for Childr  | en Prescribe | d ADHD Mea     | lication <sup>3</sup> |                                      |  |
| Initiation Phase   | 37.42%       | 48.40%         | 48.91%                | +0.51                                | ***                                    |
| Continuation and<br>Maintenance Phase  | 45.83%       | 65.97%         | 61.82%                | -4.15                                | ***                                    |
|  | 1            | I              | 1                     | 1                                    | 1                                      |

#### Table B-7—MOL Trend Table

| Measure   |              | HEDIS 2017    | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|--------------|---------------|-----------------|--------------------------------------|--|
|   | HEDIS 2010   | HEDIS 2017    | HEDIS 2018      | Companson                            | Level                                  |
| Women – Adult Care  |              |               |                 |                                      | •                                      |
| Breast Cancer Screening <sup>4</sup>                                    |              |               |                 | :                                    |  |
| Breast Cancer Screening   |              |               | 61.50%          | NC                                   | NC                                     |
| Cervical Cancer<br>Screening  |              |               |                 |                                      |  |
| Cervical Cancer<br>Screening  | 65.63%       | 65.69%        | 72.34%          | +6.65+                               | ****                                   |
| Chlamydia Screening in W  | omen         |               |                 |                                      |  |
| Ages 16 to 20 Years   | 63.25%       | 63.27%        | 65.16%          | +1.89+                               | ****                                   |
| Ages 21 to 24 Years   | 70.83%       | 70.37%        | 70.44%          | +0.07                                | ****                                   |
| Total   | 66.33%       | 66.23%        | 67.35%          | +1.12+                               | ****                                   |
| Access to Care  |              | ·l            |                 | ,                                    |  |
| Children and Adolescents'   | Access to Pr | imary Care Pi | ractitioners    |                                      |  |
| Ages 12 to 24 Months  | 96.39%       | 96.02%        | 95.41%          | -0.61                                | **                                     |
| Ages 25 Months to 6<br>Years  | 88.57%       | 89.57%        | 88.71%          | -0.86++                              | ***                                    |
| Ages 7 to 11 Years  | 91.64%       | 92.52%        | 91.63%          | -0.89**                              | ***                                    |
| Ages 12 to 19 Years   | 90.53%       | 90.88%        | 90.83%          | -0.05                                | ***                                    |
| Adults' Access to Preventiv   |              |               |                 |                                      |  |
| Ages 20 to 44 Years   | 82.66%       | 81.58%        | 79.17%          | -2.41++                              | ***                                    |
| Ages 45 to 64 Years   | 89.94%       | 89.24%        | 88.11%          | -1.13**                              | ***                                    |
| Ages 65+ Years  | 96.13%       | 91.02%        | 92.66%          | +1.64+                               | ****                                   |
| Total   | 85.79%       | 84.82%        | 83.04%          | -1.78++                              | ***                                    |
| Avoidance of Antibiotic Tr  | eatment in A |               | ute Bronchitis  |                                      | <b></b>                                |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis | 27.70%       | 30.18%        | 33.02%          | +2.84+                               | ***                                    |
| Obesity   |              |               |                 |                                      |  |
| Weight Assessment and Co<br>Children/Adolescents                        | unseling for | Nutrition and | l Physical Acti | vity for                             |  |
| BMI Percentile—Total  | 80.46%       | 80.61%        | 84.64%          | +4.03                                | ****                                   |
| Counseling for<br>Nutrition—Total                                       | 67.82%       | 71.39%        | 76.82%          | +5.43                                | ****                                   |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 63.68%       | 63.59%        | 68.75%          | +5.16                                | ****                                   |
| Adult BMI Assessment  |              |               |                 |                                      |  |
| Adult BMI Assessment  | 90.15%       | 97.14%        | 96.00%          | -1.14                                | ****                                   |





|   | Tuble D      | / 100211        |            |                                      |  |
|---|--------------|-----------------|------------|--------------------------------------|--|
| Measure                                       | HEDIS 2016   | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Pregnancy Care                                |              |                 |            |                                      |  |
| Prenatal and Postpartum (                     | Care         |                 |            |                                      |  |
| Timeliness of Prenatal<br>Care                | 78.20%       | 83.33%          | 77.32%     | -6.01**                              | *                                      |
| Postpartum Care                               | 67.87%       | 75.80%          | 73.80%     | -2.00                                | ****                                   |
| Living With Illness                           |              |                 |            |                                      |  |
| Comprehensive Diabetes C                      | are          |                 |            |                                      |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 86.04%       | 87.64%          | 90.42%     | +2.78                                | ****                                   |
| HbA1c Poor Control<br>(>9.0%)*                | 41.44%       | 32.45%          | 33.91%     | +1.46                                | ****                                   |
| HbA1c Control (<8.0%)                         | 50.90%       | 56.73%          | 54.55%     | -2.18                                | ****                                   |
| Eye Exam (Retinal)<br>Performed               | 57.43%       | 62.03%          | 62.16%     | +0.13                                | ***                                    |
| Medical Attention for<br>Nephropathy          | 92.12%       | 90.73%          | 92.87%     | +2.14                                | ****                                   |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 55.41%       | 55.19%          | 51.11%     | -4.08                                | *                                      |
| Medication Management f                       | or People Wi | th Asthma       |            | I.                                   |  |
| Medication Compliance<br>50%—Total            | 55.61%       | 57.76%          | 62.41%     | +4.65+                               | ***                                    |
| Medication Compliance<br>75%—Total            | 30.92%       | 34.13%          | 38.56%     | +4.43+                               | ***                                    |
| Asthma Medication Ratio                       |              |                 |            |                                      |  |
| Total   | 61.35%       | 60.91%          | 63.06%     | +2.15                                | ***                                    |
| Controlling High Blood Pr                     | essure       |                 |            | <u> </u>                             | ·                                      |
| Controlling High Blood<br>Pressure            | 53.60%       | 49.04%          | 51.82%     | +2.78                                | **                                     |
| Medical Assistance With S                     | moking and   | Tobacco Use     | Cessation  |                                      |  |
| Advising Smokers and<br>Tobacco Users to Quit | 83.54%       | 80.93%          | 81.08%     | +0.15                                | ****                                   |
| Discussing Cessation<br>Medications           | 56.32%       | 57.56%          | 58.57%     | +1.01                                | ****                                   |
| Discussing Cessation<br>Strategies            | 45.94%       | 43.62%          | 46.01%     | +2.39                                | ***                                    |
| Antidepressant Medication                     | Managemen    | ut <sup>3</sup> |            |                                      |  |
| Effective Acute Phase<br>Treatment            | 51.46%       | 48.20%          | 54.54%     | +6.34+                               | ***                                    |
|   |              |                 |            |                                      |  |

#### Table B-7—MOL Trend Table

|   |                                     | _              |                 |                                      |  |
|---|-------------------------------------|----------------|-----------------|--------------------------------------|--|
| Measure   | HEDIS 2016                          | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup>       |
| Effective Continuation<br>Phase Treatment   | 34.29%                              | 32.61%         | 37.54%          | +4.93+                               | ***  |
| Diabetes Screening for Peo<br>Using Antipsychotic Medic   | 1                                   | nizophrenia o  | r Bipolar Disor | der Who Are                          |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or<br>Bipolar Disorder Who<br>Are Using Antipsychotic<br>Medications | 84.61%                              | 83.10%         | 85.87%          | +2.77+                               | ****   |
| Diabetes Monitoring for P   | eople With D                        | iabetes and S  | chizophrenia    | T.                                   |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 71.16%                              | 72.50%         | 70.70%          | -1.80                                | ***  |
| Cardiovascular Monitoring<br>Schizophrenia  | g for People                        | With Cardiovo  | ascular Disease | e and                                |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | 63.33%                              | 76.32%         | 77.31%          | +0.99                                | **   |
| Adherence to Antipsychotic  | c Medication                        | s for Individu | als With Schiz  | ophrenia                             | <u>,                                    </u> |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 66.61%                              | 61.20%         | 64.74%          | +3.54+                               | ***  |
| Annual Monitoring for Pa  | tients on Pers                      | sistent Medica | itions          |                                      |  |
| ACE Inhibitors or ARBs  | 88.15%                              | 87.44%         | 88.48%          | +1.04+                               | ***  |
| Diuretics   | 87.55%                              | 87.29%         | 88.54%          | +1.25+                               | ***  |
| $Total^4$   | —                                   |                | 88.51%          | NC                                   | NC   |
| Health Plan Diversity <sup>5</sup>  |                                     |                |                 |                                      |  |
| Race/Ethnicity Diversity of   | <sup>r</sup> Membershi <sub>l</sub> | )              |                 |                                      |  |
| Total—White   | 47.85%                              | 46.28%         | 45.47%          | -0.81                                | NC   |
| Total—Black or African<br>American  | 32.33%                              | 32.97%         | 33.92%          | +0.95                                | NC   |
| Total—American-Indian<br>and Alaska Native  | 0.26%                               | 0.28%          | 0.26%           | -0.02                                | NC   |
| Total—Asian   | 0.36%                               | 0.32%          | 0.32%           | 0.00                                 | NC   |



| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|---|------------|------------|------------|--------------------------------------|--|--|--|--|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Total—Some Other Race                                       | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Total—Unknown   | 19.20%     | 20.15%     | 20.02%     | -0.13                                | NC                                     |  |  |  |  |
| Total—Declined  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Total—Hispanic or<br>Latino                                 | 6.63%      | 6.40%      | 6.70%      | +0.30                                | NC                                     |  |  |  |  |
| Language Diversity of Men                                   | nbership   |            |            |                                      |  |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 98.99%     | 98.76%     | 98.66%     | -0.10                                | NC                                     |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.91%      | 1.12%      | 1.27%      | +0.15                                | NC                                     |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.10%      | 0.12%      | 0.07%      | -0.05                                | NC                                     |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Preferred Language for<br>Written Materials—<br>English     | 98.99%     | 98.76%     | 98.66%     | -0.10                                | NC                                     |  |  |  |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.91%      | 1.12%      | 1.27%      | +0.15                                | NC                                     |  |  |  |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.10%      | 0.12%      | 0.07%      | -0.05                                | NC                                     |  |  |  |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |
| Other Language<br>Needs—English                             | 98.99%     | 98.76%     | 98.66%     | -0.10                                | NC                                     |  |  |  |  |
| Other Language<br>Needs—Non-English                         | 0.91%      | 1.12%      | 1.27%      | +0.15                                | NC                                     |  |  |  |  |
| Other Language<br>Needs—Unknown                             | 0.10%      | 0.12%      | 0.07%      | -0.05                                | NC                                     |  |  |  |  |

#### Table B-7—MOL Trend Table

|  | Table B-7—MOL Trend Table |                 |            |                                      |  |  |  |  |  |  |
|--|---------------------------|-----------------|------------|--------------------------------------|--|--|--|--|--|--|
| Measure  | HEDIS 2016                | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |  |
| Other Language   | 0.000/                    | 0.000/          | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |  |
| Needs—Declined   | 0.00%                     | 0.00%           | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |  |
| Utilization <sup>5</sup>   |                           |                 |            |                                      |  |  |  |  |  |  |
| Ambulatory Care—Total (  | Per 1,000 Me              | ember Months    | r)         |                                      |  |  |  |  |  |  |
| ED Visits—Total*   | 75.32                     | 71.94           | 70.06      | -1.88                                | **                                     |  |  |  |  |  |
| Outpatient Visits—Total  | 410.12                    | 424.09          | 422.90     | -1.19                                | NC                                     |  |  |  |  |  |
| Inpatient Utilization—Gen  | eral Hospita              | l/Acute Care-   | -Total     |                                      |  |  |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                                  | 8.97                      | 7.42            | 7.63       | +0.21                                | NC                                     |  |  |  |  |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total  | 4.45                      | 4.62            | 4.58       | -0.04                                | NC                                     |  |  |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total   | 2.97                      | 2.65            | 2.56       | -0.09                                | NC                                     |  |  |  |  |  |
| Maternity—Average<br>Length of Stay—Total  | 2.73                      | 2.78            | 2.72       | -0.06                                | NC                                     |  |  |  |  |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total   | 1.90                      | 1.82            | 1.85       | +0.03                                | NC                                     |  |  |  |  |  |
| Surgery—Average<br>Length of Stay—Total  | 7.44                      | 7.75            | 7.69       | -0.06                                | NC                                     |  |  |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total  | 4.98                      | 3.71            | 3.93       | +0.22                                | NC                                     |  |  |  |  |  |
| Medicine—Average<br>Length of Stay—Total   | 4.03                      | 4.04            | 3.98       | -0.06                                | NC                                     |  |  |  |  |  |
| Use of Opioids From Mult   | tiple Provider            | rs (Per 1,000 l | Members)*  |                                      |  |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                               | _                         | _               | 224.19     | NC                                   | NC                                     |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                                | _                         |                 | 86.93      | NC                                   | NC                                     |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple<br>Pharmacies |                           |                 | 59.06      | NC                                   | NC                                     |  |  |  |  |  |





| Measure                          | HEDIS 2016   | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|----------------------------------|--|------------|------------|--------------------------------------|--|--|--|--|--|
| Use of Opioids at High Do        | Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |                                      |  |  |  |  |  |
| Use of Opioids at High<br>Dosage | —  | —          | 21.38      | NC                                   | NC                                     |  |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star$  = 25th to 49th percentile

 $\star$  = Below 25th percentile





|  | Table B       | -8—PRI Tre    | end Table             |                                      |  |
|--|---------------|---------------|-----------------------|--------------------------------------|--|
| Measure  | HEDIS<br>2016 | HEDIS 2017    | HEDIS 2018            | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Child & Adolescent Care  |               |               |                       |                                      |  |
| Childhood Immunization S   | tatus         |               |                       |                                      |  |
| Combination 2  | 82.88%        | 80.29%        | 82.97%                | +2.68                                | *****                                  |
| Combination 3  | 80.89%        | 77.13%        | 81.02%                | +3.89                                | *****                                  |
| Combination 4  | 78.16%        | 76.16%        | 79.56%                | +3.40                                | ****                                   |
| Combination 5  | 70.72%        | 69.34%        | 73.48%                | +4.14                                | *****                                  |
| Combination 6  | 57.07%        | 55.23%        | 56.20%                | +0.97                                | ****                                   |
| Combination 7  | 68.49%        | 68.37%        | 72.02%                | +3.65                                | *****                                  |
| Combination 8  | 56.08%        | 54.74%        | 55.47%                | +0.73                                | *****                                  |
| Combination 9  | 51.61%        | 50.36%        | 51.82%                | +1.46                                | *****                                  |
| Combination 10   | 50.62%        | 49.88%        | 51.09%                | +1.21                                | *****                                  |
| Well-Child Visits in the Fir   | st 15 Montl   | hs of Life    |                       | L                                    |  |
| Six or More Visits   | 69.16%        | 70.06%        | 77.30%                | +7.24+                               | *****                                  |
| Lead Screening in Children   | ı             |               | L                     |                                      |  |
| Lead Screening in<br>Children  | 83.39%        | 85.83%        | 84.54%                | -1.29                                | ****                                   |
| Well-Child Visits in the Thi   | rd, Fourth,   | Fifth, and Si | xth Years of L        | ife                                  |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 79.17%        | 76.34%        | 75.41%                | -0.93                                | ***                                    |
| Adolescent Well-Care Visits  | 5             | L             | 1                     | I                                    | JI.                                    |
| Adolescent Well-Care<br>Visits   | 52.58%        | 54.63%        | 61.67%                | +7.04+                               | ****                                   |
| Immunizations for Adolesc  | ents          |               | L                     |                                      |  |
| Combination 1  | 89.69%        | 91.24%        | 87.59%                | -3.65                                | ****                                   |
| Appropriate Treatment for  | Children W    | ith Upper Res | piratory Infec        | tion                                 |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 93.71%        | 93.63%        | 93.94%                | +0.31                                | ****                                   |
| Appropriate Testing for Ch   | ildren With   | Pharyngitis   |                       |                                      |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 79.07%        | 78.49%        | 86.44%                | +7.95+                               | ****                                   |
| Follow-Up Care for Childre   | en Prescrib   | ed ADHD Me    | dication <sup>3</sup> |                                      |  |
| Initiation Phase   | 39.06%        | 35.03%        | 36.13%                | +1.10                                | *                                      |
| Continuation and<br>Maintenance Phase  | 42.13%        | 33.33%        | 40.38%                | +7.05                                | *                                      |

#### Table B-8—PRI Trend Table

#### Table B-8—PRI Trend Table

|   |               | -              |                |                                      |  |
|---|---------------|----------------|----------------|--------------------------------------|--|
| Measure   | HEDIS<br>2016 | HEDIS 2017     | HEDIS 2018     | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Women – Adult Care  | 2010          | 112013 2017    | 112013 2010    | companison                           | Level                                  |
| Breast Cancer Screening <sup>4</sup>                                    |               |                |                |                                      |  |
| Breast Cancer Screening   |               |                | 63.99%         | NC                                   | NC                                     |
| Cervical Cancer Screening   |               |                | 03.9970        | ne                                   | Ne                                     |
| Cervical Cancer<br>Screening  | 63.06%        | 67.45%         | 68.85%         | +1.40                                | ****                                   |
| Chlamydia Screening in Wo   | omen          |                |                | I                                    | ŀ                                      |
| Ages 16 to 20 Years   | 63.93%        | 65.53%         | 65.53%         | 0.00                                 | ****                                   |
| Ages 21 to 24 Years   | 72.21%        | 70.08%         | 68.61%         | -1.47                                | ***                                    |
| Total   | 67.36%        | 67.45%         | 66.82%         | -0.63                                | ****                                   |
| Access to Care  |               | J              |                | L                                    | J                                      |
| Children and Adolescents'   | Access to P   | rimary Care H  | Practitioners  |                                      |  |
| Ages 12 to 24 Months  | 97.75%        | 96.96%         | 96.18%         | -0.78                                | ***                                    |
| Ages 25 Months to 6<br>Years  | 89.34%        | 89.67%         | 86.67%         | -3.00**                              | **                                     |
| Ages 7 to 11 Years  | 92.05%        | 91.78%         | 90.54%         | -1.24++                              | **                                     |
| Ages 12 to 19 Years   | 90.36%        | 90.92%         | 91.09%         | +0.17                                | ***                                    |
| Adults' Access to Preventive  | e/Ambulato    | ry Health Ser  | vices          |                                      |  |
| Ages 20 to 44 Years   | 85.15%        | 83.72%         | 80.88%         | -2.84++                              | ***                                    |
| Ages 45 to 64 Years   | 91.31%        | 90.79%         | 89.42%         | -1.37**                              | ****                                   |
| Ages 65+ Years  | 88.57%        | 94.38%         | 93.56%         | -0.82                                | *****                                  |
| Total   | 87.58%        | 86.74%         | 84.49%         | -2.25++                              | ***                                    |
| Avoidance of Antibiotic Tre   | atment in A   | Adults With A  | cute Bronchiti | s                                    |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis | 30.96%        | 37.91%         | 42.29%         | +4.38+                               | ****                                   |
| Obesity   |               |                |                |                                      |  |
| Weight Assessment and Con<br>Children/Adolescents                       | unseling fo   | r Nutrition an | d Physical Act | tivity for                           |  |
| BMI Percentile—Total  | 75.41%        | 88.08%         | 95.32%         | +7.24+                               | ****                                   |
| Counseling for<br>Nutrition—Total                                       | 60.66%        | 78.10%         | 81.87%         | +3.77                                | ****                                   |
| Counseling for Physical<br>Activity—Total <sup>4</sup>                  | 57.92%        | 73.72%         | 79.53%         | +5.81                                | ****                                   |
| Adult BMI Assessment  |               |                |                |                                      |  |
| Adult BMI Assessment  | 80.10%        | 95.56%         | 97.00%         | +1.44                                | *****                                  |



| Table B-8—PRI Trend Table                     |               |                 |            |                                      |  |  |  |  |  |
|---|---------------|-----------------|------------|--------------------------------------|--|--|--|--|--|
| Measure                                       | HEDIS<br>2016 | HEDIS 2017      | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
| Pregnancy Care                                |               |                 |            |                                      |  |  |  |  |  |
| Prenatal and Postpartum C                     | are           |                 |            |                                      |  |  |  |  |  |
| Timeliness of Prenatal<br>Care                | 63.56%        | 78.59%          | 83.45%     | +4.86                                | **                                     |  |  |  |  |
| Postpartum Care                               | 61.44%        | 69.34%          | 71.53%     | +2.19                                | ****                                   |  |  |  |  |
| Living With Illness                           |               |                 |            |                                      |  |  |  |  |  |
| Comprehensive Diabetes Co                     | are           |                 |            |                                      |  |  |  |  |  |
| Hemoglobin A1c<br>(HbA1c) Testing             | 94.89%        | 92.15%          | 94.07%     | +1.92                                | ****                                   |  |  |  |  |
| HbA1c Poor Control<br>(>9.0%)*                | 27.92%        | 31.93%          | 22.68%     | -9.25+                               | ****                                   |  |  |  |  |
| HbA1c Control (<8.0%)                         | 60.40%        | 62.41%          | 67.01%     | +4.60                                | ****                                   |  |  |  |  |
| Eye Exam (Retinal)<br>Performed               | 68.80%        | 71.72%          | 73.71%     | +1.99                                | ****                                   |  |  |  |  |
| Medical Attention for<br>Nephropathy          | 94.34%        | 91.61%          | 94.85%     | +3.24                                | ****                                   |  |  |  |  |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 49.27%        | 75.91%          | 76.80%     | +0.89                                | ****                                   |  |  |  |  |
| Medication Management for                     | or People W   | ith Asthma      |            |                                      | /                                      |  |  |  |  |
| Medication Compliance<br>50%—Total            | 75.03%        | 60.00%          | 65.82%     | +5.82+                               | ****                                   |  |  |  |  |
| Medication Compliance<br>75%—Total            | 54.29%        | 37.01%          | 45.07%     | +8.06+                               | ****                                   |  |  |  |  |
| Asthma Medication Ratio                       |               |                 |            |                                      |  |  |  |  |  |
| Total   | 84.31%        | 74.90%          | 73.04%     | -1.86                                | ****                                   |  |  |  |  |
| Controlling High Blood Pro                    | essure        |                 |            |                                      | -                                      |  |  |  |  |
| Controlling High Blood<br>Pressure            | 44.13%        | 67.15%          | 65.57%     | -1.58                                | ****                                   |  |  |  |  |
| Medical Assistance With Sn                    | noking and    | Tobacco Use     | Cessation  |                                      |  |  |  |  |  |
| Advising Smokers and<br>Tobacco Users to Quit | 79.10%        | 81.48%          | 83.65%     | +2.17                                | ****                                   |  |  |  |  |
| Discussing Cessation<br>Medications           | 51.75%        | 55.97%          | 60.90%     | +4.93                                | ****                                   |  |  |  |  |
| Discussing Cessation<br>Strategies            | 43.60%        | 46.62%          | 48.08%     | +1.46                                | ***                                    |  |  |  |  |
| Antidepressant Medication                     | Manageme      | nt <sup>3</sup> |            |                                      |  |  |  |  |  |
| Effective Acute Phase<br>Treatment            | 61.09%        | 64.29%          | 71.28%     | +6.99                                | ****                                   |  |  |  |  |

#### Table B-8—PRI Trend Table

#### APPENDIX B. TREND TABLES

#### Table B-8—PRI Trend Table

|   |               | • • • • • •     |                |                                      |  |  |  |  |
|---|---------------|-----------------|----------------|--------------------------------------|--|--|--|--|
| Measure   | HEDIS<br>2016 | HEDIS 2017      | HEDIS 2018     | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
| Effective Continuation<br>Phase Treatment   | 45.87%        | 53.06%          | 51.06%         | -2.00                                | ****                                   |  |  |  |
| Diabetes Screening for Peo  | ple With Sc   | hizophrenia o   | r Bipolar Diso | order Who Are                        |  |  |  |  |
| Using Antipsychotic Medications   |               |                 |                |                                      |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | 84.21%        | 84.70%          | 84.56%         | -0.14                                | ****                                   |  |  |  |
| Diabetes Monitoring for Pe  | ople With I   | Diabetes and S  | chizophrenia   |                                      |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 65.52%        | 60.98%          | 56.99%         | -3.99                                | *                                      |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia  | for People    | With Cardiov    | ascular Diseas | se and                               |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA            | NA              | NA             | NC                                   | NC                                     |  |  |  |
| Adherence to Antipsychotic  | Medication    | ns for Individi | uals With Schi | zophrenia                            |  |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 58.06%        | 62.34%          | 64.26%         | +1.92                                | ***                                    |  |  |  |
| Annual Monitoring for Pat   | ients on Pe   | rsistent Medic  | ations         |                                      |  |  |  |  |
| ACE Inhibitors or ARBs  | 87.19%        | 88.01%          | 88.29%         | +0.28                                | ***                                    |  |  |  |
| Diuretics   | 85.64%        | 88.08%          | 87.81%         | -0.27                                | **                                     |  |  |  |
| $Total^4$   | _             | _               | 88.09%         | NC                                   | NC                                     |  |  |  |
| Health Plan Diversity <sup>5</sup>  |               |                 |                |                                      | L                                      |  |  |  |
| Race/Ethnicity Diversity of   | Membershi     | ip              |                |                                      |  |  |  |  |
| Total—White   | 61.56%        | 61.71%          | 62.18%         | +0.47                                | NC                                     |  |  |  |
| Total—Black or African<br>American  | 13.23%        | 13.87%          | 14.10%         | +0.23                                | NC                                     |  |  |  |
| Total—American-Indian<br>and Alaska Native  | 0.56%         | 0.55%           | 0.55%          | 0.00                                 | NC                                     |  |  |  |
| Total—Asian   | 0.91%         | 0.91%           | 0.83%          | -0.08                                | NC                                     |  |  |  |



| Table B-8—PRI Trend Table                                   |               |            |            |                                      |  |  |  |  |
|---|---------------|------------|------------|--------------------------------------|--|--|--|--|
| Measure   | HEDIS<br>2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.06%         | 0.06%      | 0.07%      | +0.01                                | NC                                     |  |  |  |
| Total—Some Other Race                                       | 0.00%         | 0.00%      | 0.01%      | +0.01                                | NC                                     |  |  |  |
| Total—Two or More<br>Races                                  | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Unknown   | 23.67%        | 22.89%     | 22.27%     | -0.62                                | NC                                     |  |  |  |
| Total—Declined  | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Hispanic or<br>Latino                                 | 10.06%        | 10.73%     | 10.59%     | -0.14                                | NC                                     |  |  |  |
| Language Diversity of Men                                   | ıbership      |            |            | L                                    |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 100.00%       | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>English     | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 100.00%       | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>English                            | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>Non-English                        | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>Unknown                            | 100.00%       | 100.00%    | 100.00%    | 0.00                                 | NC                                     |  |  |  |

#### Table B-8—PRI Trend Table

APPENDIX B. TREND TABLES

#### Table B-8—PRI Trend Table

| Measure  | HEDIS<br>2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|---------------|------------|------------|--------------------------------------|--|--|--|--|
| Other Language Needs—<br>Declined                                      | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Utilization <sup>5</sup>   |               |            |            |                                      |  |  |  |  |
| Ambulatory Care—Total (Per 1,000 Member Months)                        |               |            |            |                                      |  |  |  |  |
| ED Visits—Total*   | 76.40         | 75.21      | 71.90      | -3.31                                | **                                     |  |  |  |
| Outpatient Visits—Total  | 382.40        | 378.48     | 381.02     | +2.54                                | NC                                     |  |  |  |
| Inpatient Utilization—General Hospital/Acute Care—Total                |               |            |            |                                      |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total        | 6.99          | 7.00       | 6.80       | -0.20                                | NC                                     |  |  |  |
| Total Inpatient—Average<br>Length of Stay—Total                        | NR            | 3.54       | 3.62       | +0.08                                | NC                                     |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total               | 3.18          | 3.25       | 2.95       | -0.30                                | NC                                     |  |  |  |
| Maternity—Average<br>Length of Stay—Total                              | NR            | 2.60       | 2.65       | +0.05                                | NC                                     |  |  |  |
| Surgery—Discharges per<br>1,000 Member Months—<br>Total                | 1.62          | 1.63       | 1.57       | -0.06                                | NC                                     |  |  |  |
| Surgery—Average<br>Length of Stay—Total                                | NR            | 4.35       | 4.48       | +0.13                                | NC                                     |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                | 3.11          | 3.10       | 3.17       | +0.07                                | NC                                     |  |  |  |
| Medicine—Average<br>Length of Stay—Total                               | NR            | 3.80       | 3.85       | +0.05                                | NC                                     |  |  |  |
| Use of Opioids From Multiple Providers(Per 1,000 Members)*             |               |            |            |                                      |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers     | _             |            | 294.43     | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies      | _             |            | 91.29      | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Prescribers<br>and Multiple Pharmacies | _             | _          | 55.72      | NC                                   | NC                                     |  |  |  |





#### Table B-8—PRI Trend Table

| Measure  | HEDIS<br>2016 | HEDIS 2017 | HEDIS 2018 |    | 2018 Performance<br>Level <sup>2</sup> |  |  |
|--|---------------|------------|------------|----|--|--|--|
| Use of Opioids at High Dosage (Per 1,000 Members)* |               |            |            |    |  |  |  |
| Use of Opioids at High<br>Dosage                   | _             | —          | 39.28      | NC | NC                                     |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

NC indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. NA indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

*NR* indicates that the auditor determined that the HEDIS 2016 rate was materially biased or that the MHP chose not report a rate for this measure indicator.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

- $\star \star = 25$ th to 49th percentile
- $\star$  = Below 25th percentile





|  |             | -9-IHC II         |                       |                                |                    |
|--|-------------|-------------------|-----------------------|--------------------------------|--------------------|
|  | HEDIS       |                   |                       | 2017–2018                      | 2018 Performance   |
| Measure  | 2016        | <b>HEDIS 2017</b> | HEDIS 2018            | <b>Comparison</b> <sup>1</sup> | Level <sup>2</sup> |
| Child & Adolescent Care  |             |                   |                       |                                |                    |
| Childhood Immunization St  | tatus       |                   |                       |                                |                    |
| Combination 2  | 64.58%      | 71.53%            | 71.29%                | -0.24                          | **                 |
| Combination 3  | 58.56%      | 65.28%            | 65.45%                | +0.17                          | **                 |
| Combination 4  | 57.41%      | 63.66%            | 64.48%                | +0.82                          | **                 |
| Combination 5  | 45.60%      | 53.70%            | 53.77%                | +0.07                          | *                  |
| Combination 6  | 27.31%      | 27.55%            | 32.12%                | +4.57                          | **                 |
| Combination 7  | 44.91%      | 52.78%            | 53.04%                | +0.26                          | **                 |
| Combination 8  | 27.08%      | 27.31%            | 31.63%                | +4.32                          | **                 |
| Combination 9  | 23.61%      | 22.45%            | 27.25%                | +4.80                          | **                 |
| Combination 10   | 23.38%      | 22.22%            | 27.01%                | +4.79                          | **                 |
| Well-Child Visits in the First   | st 15 Monti | hs of Life        |                       |                                |                    |
| Six or More Visits   | 54.86%      | 64.71%            | 70.32%                | +5.61                          | ****               |
| Lead Screening in Children   |             |                   |                       |                                |                    |
| Lead Screening in<br>Children  | 72.69%      | 70.74%            | 70.80%                | +0.06                          | **                 |
| Well-Child Visits in the Thi   | rd, Fourth, | Fifth, and Si     | xth Years of L        | ife                            |                    |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 69.44%      | 70.49%            | 74.45%                | +3.96                          | ***                |
| Adolescent Well-Care Visits  |             |                   |                       | I                              |                    |
| Adolescent Well-Care<br>Visits   | 48.61%      | 52.08%            | 55.96%                | +3.88                          | ***                |
| Immunizations for Adolesce   | ents        |                   |                       |                                | <u>.</u>           |
| Combination 1  | 81.74%      | 83.80%            | 85.16%                | +1.36                          | ****               |
| Appropriate Treatment for  | Children W  | vith Upper Res    | spiratory Infec       | tion                           |                    |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 87.55%      | 89.66%            | 92.09%                | +2.43+                         | ***                |
| Appropriate Testing for Chi  | dren With   | Pharyngitis       |                       |                                |                    |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 57.57%      | 63.11%            | 69.62%                | +6.51+                         | **                 |
| Follow-Up Care for Childre   | n Prescrib  | ed ADHD Me        | dication <sup>3</sup> |                                |                    |
| Initiation Phase   | 53.61%      | 50.00%            | 53.79%                | +3.79                          | ****               |
| Continuation and<br>Maintenance Phase  | 70.67%      | 62.79%            | 66.67%                | +3.88                          | ****               |

### Table B-9—THC Trend Table

| Measure  | HEDIS<br>2016 | HEDIS 2017     | HEDIS 2018     | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|---------------|----------------|----------------|--------------------------------------|--|--|--|--|
| Women – Adult Care   | 2010          | 112013 2017    | 112013 2010    | companison                           | Level                                  |  |  |  |
| Breast Cancer Screening <sup>4</sup>   |               |                |                |                                      |  |  |  |  |
| 8  |               |                | 50.82%         | NC                                   | NC                                     |  |  |  |
| Breast Cancer Screening  |               | —              | 50.82%         | NC                                   | NC                                     |  |  |  |
| Cervical Cancer Screening  |               |                |                |                                      |  |  |  |  |
| Cervical Cancer<br>Screening   | 60.19%        | 60.88%         | 60.10%         | -0.78                                | ***                                    |  |  |  |
| Chlamydia Screening in Wo  | men           |                |                |                                      |  |  |  |  |
| Ages 16 to 20 Years  | 63.48%        | 71.37%         | 68.07%         | -3.30                                | ****                                   |  |  |  |
| Ages 21 to 24 Years  | 67.51%        | 70.63%         | 70.00%         | -0.63                                | ****                                   |  |  |  |
| Total  | 65.09%        | 71.09%         | 68.79%         | -2.30                                | ****                                   |  |  |  |
| Access to Care   | 05.0770       | /1.09/0        | 00.7770        | 2.50                                 |  |  |  |  |
| Children and Adolescents' A  | Access to P   | rimary Care 1  | Practitioners  |                                      |  |  |  |  |
| Ages 12 to 24 Months   | 87.60%        | 93.83%         | 92.76%         | -1.07                                | *                                      |  |  |  |
| Ages 25 Months to 6  |               |                |                |                                      |  |  |  |  |
| Years  | 83.98%        | 85.89%         | 83.03%         | -2.86++                              | *                                      |  |  |  |
| Ages 7 to 11 Years   | 86.73%        | 87.88%         | 87.90%         | +0.02                                | **                                     |  |  |  |
| Ages 12 to 19 Years  | 85.17%        | 87.39%         | 86.71%         | -0.68                                | **                                     |  |  |  |
| Adults' Access to Preventive   | Ambulato      | ory Health Ser | vices          |                                      |  |  |  |  |
| Ages 20 to 44 Years  | 77.44%        | 76.89%         | 74.92%         | -1.97**                              | **                                     |  |  |  |
| Ages 45 to 64 Years  | 86.31%        | 86.07%         | 84.31%         | -1.76++                              | **                                     |  |  |  |
| Ages 65+ Years   | 72.60%        | 80.24%         | 79.64%         | -0.60                                | *                                      |  |  |  |
| Total  | 81.12%        | 80.81%         | 78.87%         | -1.94++                              | **                                     |  |  |  |
| Avoidance of Antibiotic Tre  | atment in 4   | Adults With A  | cute Bronchiti | s                                    |  |  |  |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis                          | 33.06%        | 27.33%         | 30.80%         | +3.47                                | ***                                    |  |  |  |
| Obesity  |               |                |                |                                      |  |  |  |  |
| Weight Assessment and Counseling for Nutrition and Physical Activity for<br>Children/Adolescents |               |                |                |                                      |  |  |  |  |
| BMI Percentile—Total   | 72.92%        | 78.87%         | 78.59%         | -0.28                                | ***                                    |  |  |  |
| Counseling for<br>Nutrition—Total  | 65.28%        | 71.13%         | 73.72%         | +2.59                                | ***                                    |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup>   | 56.25%        | 49.06%         | 57.91%         | +8.85+                               | **                                     |  |  |  |
| Adult BMI Assessment   |               |                |                |                                      |  |  |  |  |
| Adult BMI Assessment   | 89.29%        | 89.50%         | 84.67%         | -4.83                                | **                                     |  |  |  |



|   | Table D    | 5-9—THC Tr       |            |                                |                    |  |  |  |
|---|------------|------------------|------------|--------------------------------|--------------------|--|--|--|
|   | HEDIS      |                  |            | 2017–2018                      | 2018 Performance   |  |  |  |
| Measure                                       | 2016       | HEDIS 2017       | HEDIS 2018 | <b>Comparison</b> <sup>1</sup> | Level <sup>2</sup> |  |  |  |
| Pregnancy Care                                |            |                  |            |                                |                    |  |  |  |
| Prenatal and Postpartum Co                    | ıre        |                  |            |                                |                    |  |  |  |
| Timeliness of Prenatal<br>Care                | 68.91%     | 71.13%           | 63.99%     | -7.14++                        | *                  |  |  |  |
| Postpartum Care                               | 47.33%     | 48.83%           | 48.18%     | -0.65                          | *                  |  |  |  |
| Living With Illness                           |            |                  |            |                                |                    |  |  |  |
| Comprehensive Diabetes Ca                     | re         |                  |            |                                |                    |  |  |  |
| Hemoglobin A1c (HbA1c)<br>Testing             | 82.98%     | 82.95%           | 82.00%     | -0.95                          | *                  |  |  |  |
| HbA1c Poor Control<br>(>9.0%)*                | 53.19%     | 42.92%           | 52.07%     | +9.15++                        | *                  |  |  |  |
| HbA1c Control (<8.0%)                         | 37.39%     | 49.01%           | 38.93%     | -10.08++                       | *                  |  |  |  |
| Eye Exam (Retinal)<br>Performed               | 40.27%     | 46.27%           | 50.61%     | +4.34                          | **                 |  |  |  |
| Medical Attention for<br>Nephropathy          | 91.03%     | 91.32%           | 90.02%     | -1.30                          | **                 |  |  |  |
| Blood Pressure Control<br>(<140/90 mm Hg)     | 47.57%     | 50.68%           | 41.85%     | -8.83**                        | *                  |  |  |  |
| Medication Management fo                      | r People W | Vith Asthma      |            |                                |                    |  |  |  |
| Medication Compliance<br>50%—Total            | 84.59%     | 85.96%           | 87.36%     | +1.40                          | ****               |  |  |  |
| Medication Compliance<br>75%—Total            | 66.27%     | 69.98%           | 72.51%     | +2.53                          | ****               |  |  |  |
| Asthma Medication Ratio                       |            | ·                |            | ,                              |                    |  |  |  |
| Total   | 34.24%     | 47.11%           | 52.33%     | +5.22+                         | *                  |  |  |  |
| Controlling High Blood Pre                    | ssure      |                  |            |                                | ·                  |  |  |  |
| Controlling High Blood<br>Pressure            | 43.05%     | 38.53%           | 29.68%     | -8.85**                        | *                  |  |  |  |
| Medical Assistance With Sm                    | oking and  | Tobacco Use      | Cessation  |                                |                    |  |  |  |
| Advising Smokers and<br>Tobacco Users to Quit | 78.16%     | 79.95%           | 78.67%     | -1.28                          | ***                |  |  |  |
| Discussing Cessation<br>Medications           | 50.69%     | 55.16%           | 57.96%     | +2.80                          | ****               |  |  |  |
| Discussing Cessation<br>Strategies            | 42.29%     | 47.12%           | 45.73%     | -1.39                          | ***                |  |  |  |
| Antidepressant Medication                     | Manageme   | ent <sup>3</sup> |            | •                              |                    |  |  |  |
| Effective Acute Phase<br>Treatment            | 89.55%     | 55.59%           | 68.20%     | +12.61+                        | ****               |  |  |  |

### Table B-9—THC Trend Table

## APPENDIX B. TREND TABLES

### Table B-9—THC Trend Table

|   |               | ••             |                 |                                      |  |
|---|---------------|----------------|-----------------|--------------------------------------|--|
| Measure   | HEDIS<br>2016 | HEDIS 2017     | HEDIS 2018      | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Effective Continuation<br>Phase Treatment   | 73.34%        | 39.92%         | 55.35%          | +15.43+                              | ****                                   |
| Diabetes Screening for Peop   | ole With Sc   | hizophrenia d  | or Bipolar Diso | order Who Are                        |  |
| Using Antipsychotic Medica  |               | - 1            | 1               |                                      |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | 77.60%        | 82.33%         | 83.73%          | +1.40                                | ***                                    |
| Diabetes Monitoring for Peo   | ople With I   | Diabetes and S | Schizophrenia   |                                      |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 57.45%        | 59.26%         | 59.79%          | +0.53                                | *                                      |
| Cardiovascular Monitoring<br>Schizophrenia  | for People    | With Cardiov   | ascular Diseas  | se and                               |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA            | NA             | NA              | NC                                   | NC                                     |
| Adherence to Antipsychotic  | Medication    | ns for Individ | uals With Schi  | zophrenia                            |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 56.16%        | 48.47%         | 48.95%          | +0.48                                | *                                      |
| Annual Monitoring for Pati  | ents on Pe    | rsistent Medic | cations         |                                      |  |
| ACE Inhibitors or ARBs  | 85.62%        | 87.84%         | 87.17%          | -0.67                                | **                                     |
| Diuretics   | 85.07%        | 87.27%         | 86.04%          | -1.23                                | **                                     |
| $Total^4$   |               | _              | 86.66%          | NC                                   | NC                                     |
| Health Plan Diversity <sup>5</sup>  |               | 1              |                 | 1                                    |  |
| Race/Ethnicity Diversity of   | Membersh      | ip             |                 |                                      |  |
| Total—White   | 31.09%        | 30.70%         | 30.89%          | +0.19                                | NC                                     |
| Total—Black or African<br>American  | 54.16%        | 53.90%         | 54.27%          | +0.37                                | NC                                     |
| Total—American-Indian<br>and Alaska Native  | 0.23%         | 0.27%          | 0.28%           | +0.01                                | NC                                     |
| Total—Asian   | 1.15%         | 1.21%          | 1.15%           | -0.06                                | NC                                     |



|   | Table B-9—THC Trend Table |            |            |                                      |  |  |  |  |
|---|---------------------------|------------|------------|--------------------------------------|--|--|--|--|
| Measure   | HEDIS<br>2016             | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.07%                     | 0.06%      | 0.06%      | 0.00                                 | NC                                     |  |  |  |
| Total—Some Other Race                                       | 2.45%                     | 2.55%      | 2.63%      | +0.08                                | NC                                     |  |  |  |
| Total—Two or More<br>Races                                  | 0.00%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Unknown   | 10.84%                    | 11.31%     | 10.72%     | -0.59                                | NC                                     |  |  |  |
| Total—Declined  | 0.00%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Total—Hispanic or<br>Latino                                 | 2.45%                     | 2.55%      | 2.63%      | +0.08                                | NC                                     |  |  |  |
| Language Diversity of Mem                                   | bership                   |            |            |                                      |  |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 99.38%                    | 99.21%     | 99.13%     | -0.08                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.44%                     | 0.79%      | 0.87%      | +0.08                                | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.18%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>English     | 99.38%                    | 99.21%     | 99.13%     | -0.08                                | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.44%                     | 0.79%      | 0.87%      | +0.08                                | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.18%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |
| Other Language Needs—<br>English                            | 99.38%                    | 99.21%     | 99.13%     | -0.08                                | NC                                     |  |  |  |
| Other Language Needs—<br>Non-English                        | 0.44%                     | 0.79%      | 0.87%      | +0.08                                | NC                                     |  |  |  |
| Other Language Needs—<br>Unknown                            | 0.18%                     | 0.00%      | 0.00%      | 0.00                                 | NC                                     |  |  |  |

# 2018 HEDIS Aggregate Report for Michigan Medicaid State of Michigan

### APPENDIX B. TREND TABLES

## Table B-9—THC Trend Table

| Measure   | HEDIS<br>2016                                   | HEDIS 2017     | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |  |
|---|---|----------------|------------|--------------------------------------|--|--|--|--|--|--|
| Other Language Needs—<br>Declined   | 0.00%   | 0.00%          | 0.00%      | 0.00                                 | NC                                     |  |  |  |  |  |
| Utilization <sup>5</sup>  |   |                |            |                                      |  |  |  |  |  |  |
| Ambulatory Care—Total (P  | Ambulatory Care—Total (Per 1,000 Member Months) |                |            |                                      |  |  |  |  |  |  |
| ED Visits—Total*  | 72.75   | 73.95          | 70.05      | -3.90                                | **                                     |  |  |  |  |  |
| Outpatient Visits—Total   | 320.89  | 333.36         | 336.34     | +2.98                                | NC                                     |  |  |  |  |  |
| Inpatient Utilization—Gene  | ral Hospite                                     | al/Acute Care  | —Total     | I                                    |  |  |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                               | 10.45   | 10.15          | 10.34      | +0.19                                | NC                                     |  |  |  |  |  |
| Total Inpatient—Average<br>Length of Stay—Total   | 4.34  | 4.01           | 4.58       | +0.57                                | NC                                     |  |  |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total                                      | 2.70  | 2.37           | 2.40       | +0.03                                | NC                                     |  |  |  |  |  |
| Maternity—Average<br>Length of Stay—Total   | 2.66  | 2.63           | 2.69       | +0.06                                | NC                                     |  |  |  |  |  |
| Surgery—Discharges per<br>1,000 Member Months—<br>Total                                       | 2.35  | 2.30           | 2.08       | -0.22                                | NC                                     |  |  |  |  |  |
| Surgery—Average Length<br>of Stay—Total   | 7.63  | 6.54           | 7.05       | +0.51                                | NC                                     |  |  |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                                       | 6.10  | 6.07           | 6.44       | +0.37                                | NC                                     |  |  |  |  |  |
| Medicine—Average<br>Length of Stay—Total  | 3.64  | 3.45           | 4.32       | +0.87                                | NC                                     |  |  |  |  |  |
| Use of Opioids From Multi   | ple Provide                                     | ers (Per 1,000 | Members)*  |                                      |  |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                            |   | _              | 199.52     | NC                                   | NC                                     |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                             |   | _              | 84.30      | NC                                   | NC                                     |  |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple Pharmacies |   | _              | 52.59      | NC                                   | NC                                     |  |  |  |  |  |





#### Table B-9—THC Trend Table

| Measure  | HEDIS<br>2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |
|--|---------------|------------|------------|--------------------------------------|--|--|--|
| Use of Opioids at High Dosage (Per 1,000 Members)* |               |            |            |                                      |  |  |  |
| Use of Opioids at High<br>Dosage                   | _             | —          | 80.72      | NC                                   | NC                                     |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





#### Table B-10—UNI Trend Table

| Measure  |              | HEDIS 2017      | HEDIS 2018         | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|--|--------------|-----------------|--------------------|--------------------------------------|--|--|--|--|
|  | HEDI3 2010   | HEDI3 2017      | HEDI3 2018         | comparison                           | Level                                  |  |  |  |
| Child & Adolescent Care  |              |                 |                    |                                      |  |  |  |  |
| Childhood Immunization S   |              | <b>20.05</b> 0/ |                    |                                      |  |  |  |  |
| Combination 2  | 76.16%       | 78.35%          | 75.91%             | -2.44                                | ***                                    |  |  |  |
| Combination 3  | 71.78%       | 72.51%          | 71.53%             | -0.98                                | **                                     |  |  |  |
| Combination 4  | 67.15%       | 70.07%          | 71.29%             | +1.22                                | ***                                    |  |  |  |
| Combination 5  | 58.15%       | 57.66%          | 61.56%             | +3.90                                | ***                                    |  |  |  |
| Combination 6  | 38.69%       | 38.93%          | 37.71%             | -1.22                                | **                                     |  |  |  |
| Combination 7  | 54.74%       | 55.96%          | 61.56%             | +5.60                                | ***                                    |  |  |  |
| Combination 8  | 36.25%       | 38.20%          | 37.71%             | -0.49                                | **                                     |  |  |  |
| Combination 9  | 32.85%       | 31.63%          | 34.31%             | +2.68                                | ***                                    |  |  |  |
| Combination 10   | 30.66%       | 30.90%          | 34.31%             | +3.41                                | ***                                    |  |  |  |
| Well-Child Visits in the Fir   | st 15 Months | s of Life       |                    | -                                    |  |  |  |  |
| Six or More Visits   | 61.56%       | 66.67%          | 68.61%             | +1.94                                | ***                                    |  |  |  |
| Lead Screening in Children   | ı            |                 |                    |                                      |  |  |  |  |
| Lead Screening in<br>Children  | 78.86%       | 77.13%          | 81.51%             | +4.38                                | ****                                   |  |  |  |
| Well-Child Visits in the Th  | ird. Fourth. | Fifth. and Six  | th Years of Life   | ?                                    |  |  |  |  |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 73.21%       | 79.08%          | 77.37%             | -1.71                                | ***                                    |  |  |  |
| Adolescent Well-Care Visit   | <b>S</b>     | I               |                    |                                      | ·                                      |  |  |  |
| Adolescent Well-Care<br>Visits   | 54.74%       | 58.88%          | 63.26%             | +4.38                                | ****                                   |  |  |  |
| Immunizations for Adolesc  | ents         | 1               |                    |                                      | ·                                      |  |  |  |
| Combination 1  | 87.50%       | 85.40%          | 84.91%             | -0.49                                | ****                                   |  |  |  |
| Appropriate Treatment for  | Children Wi  | th Upper Resp   | piratory Infection | on                                   |  |  |  |  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 87.89%       | 89.46%          | 90.42%             | +0.96+                               | ***                                    |  |  |  |
| Appropriate Testing for Children With Pharyngitis                            |              |                 |                    |                                      |  |  |  |  |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 63.13%       | 71.07%          | 76.71%             | +5.64+                               | ***                                    |  |  |  |
| Follow-Up Care for Children Prescribed ADHD Medication <sup>3</sup>          |              |                 |                    |                                      |  |  |  |  |
| Initiation Phase   | 44.57%       | 41.48%          | 44.49%             | +3.01                                | **                                     |  |  |  |
| Continuation and<br>Maintenance Phase  | 59.46%       | 53.85%          | 58.02%             | +4.17                                | ***                                    |  |  |  |

#### Table B-10—UNI Trend Table

|  | Table D      | 10 01111      |                   |                                      |  |  |  |  |
|--|--------------|---------------|-------------------|--------------------------------------|--|--|--|--|
| Measure  |              | HEDIS 2017    | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|  | HEDIS 2010   | HEDIS 2017    | HEDIS 2018        | Companson-                           | Level-                                 |  |  |  |
| Women – Adult Care   |              |               |                   |                                      |  |  |  |  |
| Breast Cancer Screening <sup>4</sup>   |              |               |                   |                                      |  |  |  |  |
| Breast Cancer Screening  |              |               | 62.65%            | NC                                   | NC                                     |  |  |  |
| Cervical Cancer<br>Screening   |              |               |                   |                                      |  |  |  |  |
| Cervical Cancer<br>Screening   | 65.85%       | 69.10%        | 67.88%            | -1.22                                | ****                                   |  |  |  |
| Chlamydia Screening in W   | omen         |               |                   |                                      |  |  |  |  |
| Ages 16 to 20 Years  | 62.26%       | 66.04%        | 67.29%            | +1.25                                | ****                                   |  |  |  |
| Ages 21 to 24 Years  | 69.46%       | 71.37%        | 70.87%            | -0.50                                | ****                                   |  |  |  |
| Total  | 65.12%       | 68.21%        | 68.73%            | +0.52                                | ****                                   |  |  |  |
| Access to Care   | u            |               |                   |                                      |  |  |  |  |
| Children and Adolescents'  | Access to Pr | imary Care Pi | ractitioners      |                                      |  |  |  |  |
| Ages 12 to 24 Months   | 96.54%       | 96.20%        | 95.11%            | -1.09++                              | **                                     |  |  |  |
| Ages 25 Months to 6<br>Years   | 89.66%       | 89.27%        | 88.96%            | -0.31                                | ***                                    |  |  |  |
| Ages 7 to 11 Years   | 91.17%       | 91.77%        | 91.73%            | -0.04                                | ***                                    |  |  |  |
| Ages 12 to 19 Years  | 90.51%       | 91.88%        | 91.91%            | +0.03                                | ***                                    |  |  |  |
| Adults' Access to Preventiv  | e/Ambulator  | v Health Serv | ices              |                                      |  |  |  |  |
| Ages 20 to 44 Years  | 83.01%       | 81.34%        | 78.88%            | -2.46++                              | **                                     |  |  |  |
| Ages 45 to 64 Years  | 91.13%       | 89.97%        | 88.66%            | -1.31++                              | ***                                    |  |  |  |
| Ages 65+ Years   | 95.84%       | 94.79%        | 95.99%            | +1.20                                | ****                                   |  |  |  |
| Total  | 86.34%       | 84.82%        | 82.74%            | -2.08++                              | ***                                    |  |  |  |
| Avoidance of Antibiotic Tre  | eatment in A | dults With Ac | ute Bronchitis    |                                      | L                                      |  |  |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis                          | 24.42%       | 32.40%        | 33.20%            | +0.80                                | ***                                    |  |  |  |
| Obesity  |              |               |                   |                                      |  |  |  |  |
| Weight Assessment and Counseling for Nutrition and Physical Activity for<br>Children/Adolescents |              |               |                   |                                      |  |  |  |  |
| BMI Percentile—Total   | 71.05%       | 81.02%        | 85.89%            | +4.87                                | ****                                   |  |  |  |
| Counseling for<br>Nutrition—Total  | 68.86%       | 76.64%        | 77.86%            | +1.22                                | ****                                   |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup>   | 62.04%       | 62.53%        | 70.32%            | +7.79+                               | ****                                   |  |  |  |
| Adult BMI Assessment   |              |               |                   |                                      |  |  |  |  |
| Adult BMI Assessment   | 89.12%       | 85.40%        | 94.65%            | +9.25+                               | ****                                   |  |  |  |
|  |              |               |                   |                                      |  |  |  |  |





#### Table B-10—UNI Trend Table

| HEDIS 2016  | HEDIS 2017   | HEDIS 2018   | 2017–2018<br>Comparison <sup>1</sup>  | 2018 Performance<br>Level <sup>2</sup>   |  |  |  |  |
|---|--|--|---|--|--|--|--|--|
|   |  |  |   |  |  |  |  |  |
| Pregnancy Care Prenatal and Postpartum Care               |  |  |   |  |  |  |  |  |
| 76.03%  | 80.54%   | 78.83%   | -1.71   | **   |  |  |  |  |
| 52.06%  | 67.40%   | 67.15%   | -0.25   | ***  |  |  |  |  |
|   |  |  |   |  |  |  |  |  |
| are   |  |  |   |  |  |  |  |  |
| 86.81%  | 88.61%   | 89.29%   | +0.68   | ***  |  |  |  |  |
| 34.17%  | 32.50%   | 31.29%   | -1.21   | ****   |  |  |  |  |
| 54.58%  | 56.11%   | 57.29%   | +1.18   | ****   |  |  |  |  |
| 64.31%  | 65.14%   | 64.43%   | -0.71   | ****   |  |  |  |  |
| 93.06%  | 92.36%   | 94.43%   | +2.07   | ****   |  |  |  |  |
| 62.64%  | 62.08%   | 66.29%   | +4.21   | ***  |  |  |  |  |
| or People Wi  | th Asthma  |  |   | <u></u>  |  |  |  |  |
| 69.44%  | 67.42%   | 75.52%   | $+8.10^{+}$   | ****   |  |  |  |  |
| 45.00%  | 41.51%   | 57.49%   | +15.98+   | ****   |  |  |  |  |
|   |  |  |   | ·  |  |  |  |  |
| 64.68%  | 66.80%   | 62.26%   | -4.54++   | ***  |  |  |  |  |
| essure  |  |  |   | ·  |  |  |  |  |
| 52.32%  | 56.93%   | 64.48%   | +7.55+  | ***  |  |  |  |  |
| Medical Assistance With Smoking and Tobacco Use Cessation |  |  |   |  |  |  |  |  |
| 78.86%  | 82.17%   | 83.54%   | +1.37   | ****   |  |  |  |  |
| 59.35%  | 60.80%   | 61.27%   | +0.47   | ****   |  |  |  |  |
| 48.02%  | 50.56%   | 52.87%   | +2.31   | ****   |  |  |  |  |
| Managemen   | ut <sup>3</sup>  |  |   |  |  |  |  |  |
| 49.55%  | 59.84%   | 61.66%   | +1.82   | ****   |  |  |  |  |
|   | Tare         76.03%         52.06%         are         86.81%         34.17%         54.58%         64.31%         93.06%         62.64%         or People Wit         69.44%         45.00%         64.68%         essure         52.32%         noking and 2         78.86%         59.35%         48.02%         Management | 76.03%       80.54%         52.06%       67.40%         are       86.81%         86.81%       88.61%         34.17%       32.50%         54.58%       56.11%         64.31%       65.14%         93.06%       92.36%         62.64%       62.08% <i>pr People With Asthma</i> 69.44%       67.42%         45.00%       41.51%         64.68%       66.80%         essure       52.32%         56.93%       78.86%         82.17%       59.35%         60.80%       48.02%         50.56%       Management <sup>3</sup> | Care         76.03%       80.54%       78.83%         52.06%       67.40%       67.15%         are         86.81%       88.61%       89.29%         34.17%       32.50%       31.29%         54.58%       56.11%       57.29%         64.31%       65.14%       64.43%         93.06%       92.36%       94.43%         62.64%       62.08%       66.29%         or People With Asthma       69.44%       67.42%       75.52%         45.00%       41.51%       57.49%         64.68%       66.80%       62.26%         essure         52.32%       56.93%       64.48%         noking and Tobacco Use Cessation         78.86%       82.17%       83.54%         59.35%       60.80%       61.27%         48.02%       50.56%       52.87% | HEDIS 2016         HEDIS 2017         HEDIS 2018         Comparison <sup>1</sup> Care         76.03%         80.54%         78.83%         -1.71           52.06%         67.40%         67.15%         -0.25           are           86.81%         88.61%         89.29%         +0.68           34.17%         32.50%         31.29%         -1.21           54.58%         56.11%         57.29%         +1.18           64.31%         65.14%         64.43%         -0.71           93.06%         92.36%         94.43%         +2.07           62.64%         62.08%         66.29%         +4.21           or People With Asthma           69.44%         67.42%         75.52%         +8.10 <sup>+</sup> 45.00%         41.51%         57.49%         +15.98 <sup>+</sup> of 44.68%         66.80%         62.26%         -4.54 <sup>++</sup> essure           52.32%         56.93%         64.48%         +7.55 <sup>+</sup> noking and Tobacco Use Cessation         78.86%         82.17%         83.54%         +1.37           59.35%         60.80%         61.27%         +0.47         48.02%         50.56% |  |  |  |  |

### Table B-10—UNI Trend Table

|   |                | 10 01111       |                  |                                      |  |
|---|----------------|----------------|------------------|--------------------------------------|--|
| Measure   | HEDIS 2016     | HEDIS 2017     | HEDIS 2018       | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Effective Continuation<br>Phase Treatment   | 31.59%         | 46.87%         | 46.89%           | +0.02                                | ****                                   |
| Diabetes Screening for Peo<br>Using Antipsychotic Medic   |                | nizophrenia or | r Bipolar Disora | ler Who Are                          |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | 85.54%         | 85.99%         | 85.33%           | -0.66                                | ****                                   |
| Diabetes Monitoring for Pe  | cople With D   | iabetes and S  | chizophrenia     | <b></b>                              |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | 74.48%         | 74.29%         | 71.10%           | -3.19                                | ***                                    |
| Cardiovascular Monitoring<br>Schizophrenia  | for People     | With Cardiovo  | ıscular Disease  | and                                  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | 80.00%         | 74.03%         | 75.38%           | +1.35                                | **                                     |
| Adherence to Antipsychotic  | c Medication   | s for Individu | als With Schizo  | phrenia                              |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 60.02%         | 60.59%         | 55.04%           | -5.55**                              | **                                     |
| Annual Monitoring for Pat   | tients on Pers | sistent Medica | tions            |                                      |  |
| ACE Inhibitors or ARBs  | 88.68%         | 89.75%         | 88.88%           | -0.87**                              | ***                                    |
| Diuretics   | 88.75%         | 89.19%         | 88.73%           | -0.46                                | ***                                    |
| $Total^4$   |                |                | 88.82%           | NC                                   | NC                                     |
| Health Plan Diversity <sup>5</sup>  |                |                |                  |                                      |  |
| Race/Ethnicity Diversity of   | Membership     | )              |                  |                                      |  |
| Total—White   | 50.65%         | 50.85%         | 51.27%           | +0.42                                | NC                                     |
| Total—Black or African<br>American  | 31.80%         | 30.38%         | 30.28%           | -0.10                                | NC                                     |
| Total—American-Indian<br>and Alaska Native  | 0.24%          | 0.26%          | 0.25%            | -0.01                                | NC                                     |
| Total—Asian   | 2.37%          | 2.11%          | 2.05%            | -0.06                                | NC                                     |



#### Table B-10—UNI Trend Table

|   | Table B    |            |            |                                      |  |
|---|------------|------------|------------|--------------------------------------|--|
| Measure   | HEDIS 2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.01%      | 0.01%      | 0.01%      | 0.00                                 | NC                                     |
| Total—Some Other Race                                       | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Two or More<br>Races                                  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Unknown   | 14.94%     | 16.40%     | 16.15%     | -0.25                                | NC                                     |
| Total—Declined  | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Hispanic or<br>Latino                                 | 5.30%      | 5.61%      | 5.60%      | -0.01                                | NC                                     |
| Language Diversity of Men                                   | nbership   |            |            | L                                    | <u></u>                                |
| Spoken Language<br>Preferred for Health<br>Care—English     | 95.33%     | 95.71%     | 95.63%     | -0.08                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 4.67%      | 4.28%      | 4.37%      | +0.09                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>English     | 95.33%     | 95.71%     | 95.63%     | -0.08                                | NC                                     |
| Preferred Language for<br>Written Materials—Non-<br>English | 4.67%      | 4.28%      | 4.37%      | +0.09                                | NC                                     |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>English                            | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>Non-English                        | 0.00%      | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>Unknown                            | 100.00%    | 100.00%    | 100.00%    | 0.00                                 | NC                                     |

### APPENDIX B. TREND TABLES

## Table B-10—UNI Trend Table

| Measure   | HEDIS 2016  | HEDIS 2017   | <b>HEDIS 2018</b> | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|---|---|--------------|-------------------|--------------------------------------|--|--|--|--|
| Other Language Needs—<br>Declined   | 0.00%   | 0.00%        | 0.00%             | 0.00                                 | NC                                     |  |  |  |
| Utilization <sup>5</sup>  |   |              |                   |                                      |  |  |  |  |
| Ambulatory Care—Total (   | Per 1,000 Me  | mber Months  | )                 |                                      |  |  |  |  |
| ED Visits—Total*  | 73.22   | 72.58        | 69.56             | -3.02                                | **                                     |  |  |  |
| Outpatient Visits—Total   | 367.42  | 368.15       | 380.46            | +12.31                               | NC                                     |  |  |  |
| Inpatient Utilization—Gen   | eral Hospital   | /Acute Care_ | -Total            |                                      |  |  |  |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                               | 6.59  | 5.59         | 6.33              | +0.74                                | NC                                     |  |  |  |
| Total Inpatient—<br>Average Length of<br>Stay—Total   | 4.23  | 4.33         | 4.18              | -0.15                                | NC                                     |  |  |  |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total                                      | 2.74  | 2.49         | 2.56              | +0.07                                | NC                                     |  |  |  |
| Maternity—Average<br>Length of Stay—Total   | 2.62  | 2.57         | 2.56              | -0.01                                | NC                                     |  |  |  |
| Surgery—Discharges<br>per 1,000 Member<br>Months—Total  | 1.61  | 1.37         | 1.49              | +0.12                                | NC                                     |  |  |  |
| Surgery—Average<br>Length of Stay—Total   | 6.76  | 6.56         | 6.74              | +0.18                                | NC                                     |  |  |  |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                                       | 3.06  | 2.44         | 3.00              | +0.56                                | NC                                     |  |  |  |
| Medicine—Average<br>Length of Stay—Total  | 3.92  | 4.37         | 3.91              | -0.46                                | NC                                     |  |  |  |
| Use of Opioids From Mult  | Use of Opioids From Multiple Providers (Per 1,000 Members)* |              |                   |                                      |  |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                            | —   | _            | 184.59            | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                             |   |              | 1.36              | NC                                   | NC                                     |  |  |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple Pharmacies |   | _            | 0.83              | NC                                   | NC                                     |  |  |  |

#### APPENDIX B. TREND TABLES



#### Table B-10—UNI Trend Table

| Measure                          | HEDIS 2016   | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |
|----------------------------------|--|------------|------------|--------------------------------------|--|--|--|--|
| Use of Opioids at High Do        | Use of Opioids at High Dosage (Per 1,000 Members)* |            |            |                                      |  |  |  |  |
| Use of Opioids at High<br>Dosage |  | _          | 35.33      | NC                                   | NC                                     |  |  |  |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star \star = 25$ th to 49th percentile

 $\star$  = Below 25th percentile





|  |             |               | enu rabie             |                         |                    |
|--|-------------|---------------|-----------------------|-------------------------|--------------------|
|  | HEDIS       |               |                       | 2017–2018               | 2018 Performance   |
| Measure  | 2016        | HEDIS 2017    | HEDIS 2018            | Comparison <sup>1</sup> | Level <sup>2</sup> |
| Child & Adolescent Care  |             |               |                       |                         |                    |
| Childhood Immunization St  | tatus       |               |                       |                         |                    |
| Combination 2  | 78.10%      | 73.24%        | 73.97%                | +0.73                   | **                 |
| Combination 3  | 73.24%      | 71.53%        | 70.56%                | -0.97                   | **                 |
| Combination 4  | 66.67%      | 65.21%        | 67.40%                | +2.19                   | **                 |
| Combination 5  | 55.47%      | 54.99%        | 56.93%                | +1.94                   | **                 |
| Combination 6  | 43.55%      | 42.09%        | 48.18%                | +6.09                   | ****               |
| Combination 7  | 52.07%      | 51.58%        | 55.23%                | +3.65                   | **                 |
| Combination 8  | 41.61%      | 39.17%        | 47.20%                | $+8.03^{+}$             | ****               |
| Combination 9  | 37.23%      | 34.55%        | 41.85%                | +7.30+                  | ****               |
| Combination 10   | 36.01%      | 32.85%        | 41.61%                | +8.76+                  | ****               |
| Well-Child Visits in the First   | st 15 Monti | hs of Life    |                       |                         |                    |
| Six or More Visits   | 74.21%      | 74.21%        | 72.75%                | -1.46                   | *****              |
| Lead Screening in Children   |             |               |                       |                         |                    |
| Lead Screening in<br>Children  | 88.56%      | 82.43%        | 82.73%                | +0.30                   | ****               |
| Well-Child Visits in the Thi   | rd, Fourth, | Fifth, and Si | xth Years of L        | ife                     |                    |
| Well-Child Visits in the<br>Third, Fourth, Fifth, and<br>Sixth Years of Life | 69.59%      | 73.97%        | 75.18%                | +1.21                   | ***                |
| Adolescent Well-Care Visits  |             |               |                       |                         |                    |
| Adolescent Well-Care<br>Visits   | 42.09%      | 44.50%        | 47.93%                | +3.43                   | **                 |
| Immunizations for Adolesce   | ents        |               |                       |                         | . <u> </u>         |
| Combination 1  | 81.75%      | 80.90%        | 80.78%                | -0.12                   | ***                |
| Appropriate Treatment for  | Children W  | ith Upper Res | spiratory Infec       | tion                    | I                  |
| Appropriate Treatment<br>for Children With Upper<br>Respiratory Infection    | 90.27%      | 91.15%        | 93.59%                | +2.44+                  | ****               |
| Appropriate Testing for Chi  | ldren With  | Pharyngitis   |                       |                         |                    |
| Appropriate Testing for<br>Children With<br>Pharyngitis                      | 68.97%      | 63.09%        | 80.16%                | +17.07+                 | ***                |
| Follow-Up Care for Childre   | n Prescrib  | ed ADHD Me    | dication <sup>3</sup> |                         |                    |
| Initiation Phase   | 53.16%      | 42.98%        | 48.24%                | +5.26                   | ***                |
| Continuation and<br>Maintenance Phase  | 57.65%      | 45.36%        | 52.43%                | +7.07                   | **                 |

| <b>B</b> <i>A</i> <b>-------------</b>   | HEDIS       |                   |                | 2017–2018               | 2018 Performance   |  |  |  |
|--|-------------|-------------------|----------------|-------------------------|--------------------|--|--|--|
| Measure  | 2016        | <b>HEDIS 2017</b> | HEDIS 2018     | Comparison <sup>1</sup> | Level <sup>2</sup> |  |  |  |
| Women – Adult Care   |             |                   |                |                         |                    |  |  |  |
| Breast Cancer Screening <sup>4</sup>   |             | 1                 |                |                         |                    |  |  |  |
| Breast Cancer Screening  | —           |                   | 64.08%         | NC                      | NC                 |  |  |  |
| Cervical Cancer Screening  |             |                   |                | I                       | 1                  |  |  |  |
| Cervical Cancer<br>Screening   | 62.53%      | 67.15%            | 63.02%         | -4.13                   | ***                |  |  |  |
| Chlamydia Screening in Wo  | omen        |                   |                |                         |                    |  |  |  |
| Ages 16 to 20 Years  | 46.95%      | 44.93%            | 46.17%         | +1.24                   | *                  |  |  |  |
| Ages 21 to 24 Years  | 56.06%      | 58.75%            | 60.71%         | +1.96                   | **                 |  |  |  |
| Total  | 50.96%      | 51.13%            | 52.28%         | +1.15                   | **                 |  |  |  |
| Access to Care   |             |                   |                |                         |                    |  |  |  |
| Children and Adolescents' A  | Access to P | rimary Care I     | Practitioners  |                         |                    |  |  |  |
| Ages 12 to 24 Months   | 97.65%      | 97.26%            | 97.15%         | -0.11                   | ****               |  |  |  |
| Ages 25 Months to 6<br>Years   | 90.18%      | 90.64%            | 89.84%         | -0.80                   | ***                |  |  |  |
| Ages 7 to 11 Years   | 90.60%      | 91.82%            | 92.15%         | +0.33                   | ***                |  |  |  |
| Ages 12 to 19 Years  | 92.33%      | 91.60%            | 92.03%         | +0.43                   | ***                |  |  |  |
| Adults' Access to Preventive   | e/Ambulato  | ry Health Ser     | vices          |                         |                    |  |  |  |
| Ages 20 to 44 Years  | 86.23%      | 84.99%            | 82.87%         | -2.12++                 | ***                |  |  |  |
| Ages 45 to 64 Years  | 88.42%      | 87.55%            | 87.40%         | -0.15                   | ***                |  |  |  |
| Ages 65+ Years   | 86.44%      | 91.18%            | NA             | NC                      | NC                 |  |  |  |
| Total  | 87.10%      | 86.02%            | 84.66%         | -1.36++                 | ***                |  |  |  |
| Avoidance of Antibiotic Tre  | atment in 2 | Adults With A     | cute Bronchiti | s                       |                    |  |  |  |
| Avoidance of Antibiotic<br>Treatment in Adults With<br>Acute Bronchitis                          | 43.48%      | 25.77%            | 25.24%         | -0.53                   | **                 |  |  |  |
| Obesity  |             |                   |                |                         |                    |  |  |  |
| Weight Assessment and Counseling for Nutrition and Physical Activity for<br>Children/Adolescents |             |                   |                |                         |                    |  |  |  |
| BMI Percentile—Total   | 91.97%      | 88.81%            | 89.78%         | +0.97                   | ****               |  |  |  |
| Counseling for<br>Nutrition—Total  | 65.94%      | 67.40%            | 72.26%         | +4.86                   | ***                |  |  |  |
| Counseling for Physical<br>Activity—Total <sup>4</sup>   | 64.23%      | 64.96%            | 70.80%         | +5.84                   | ****               |  |  |  |
| Adult BMI Assessment   |             |                   |                |                         |                    |  |  |  |
| Adult BMI Assessment   | 95.62%      | 95.38%            | 96.84%         | +1.46                   | ****               |  |  |  |
|  | •           |                   |                |                         | •                  |  |  |  |





| Table  | B-11-        | UPP      | Trend    | Table |
|--------|--------------|----------|----------|-------|
| i unic | <b>D I I</b> | <b>U</b> | i i ciia | TUNIC |

|   |            | 11—UPP II       |            |                         |                    |
|---|------------|-----------------|------------|-------------------------|--------------------|
|   | HEDIS      |                 |            | 2017–2018               | 2018 Performance   |
| Measure                                       | 2016       | HEDIS 2017      | HEDIS 2018 | Comparison <sup>1</sup> | Level <sup>2</sup> |
| Pregnancy Care                                |            |                 |            |                         |                    |
| Prenatal and Postpartum C                     | are        |                 |            |                         |                    |
| Timeliness of Prenatal<br>Care                | 86.13%     | 91.48%          | 92.94%     | +1.46                   | ****               |
| Postpartum Care                               | 71.78%     | 72.75%          | 73.72%     | +0.97                   | ****               |
| Living With Illness                           |            |                 |            |                         |                    |
| Comprehensive Diabetes Co                     | ıre        |                 |            |                         |                    |
| Hemoglobin A1c (HbA1c)<br>Testing             | 91.61%     | 91.04%          | 92.32%     | +1.28                   | ****               |
| HbA1c Poor Control (>9.0%)*                   | 28.65%     | 24.73%          | 30.00%     | +5.27**                 | ****               |
| HbA1c Control (<8.0%)                         | 58.21%     | 59.14%          | 60.00%     | +0.86                   | *****              |
| Eye Exam (Retinal)<br>Performed               | 66.06%     | 67.56%          | 71.25%     | +3.69                   | ****               |
| Medical Attention for<br>Nephropathy          | 91.97%     | 92.11%          | 91.07%     | -1.04                   | ***                |
| Blood Pressure Control (<140/90 mm Hg)        | 75.73%     | 76.70%          | 77.50%     | +0.80                   | ****               |
| Medication Management fo                      | r People W | ith Asthma      |            |                         |                    |
| Medication Compliance<br>50%—Total            | 53.63%     | 66.08%          | 71.01%     | +4.93                   | ****               |
| Medication Compliance<br>75%—Total            | 22.71%     | 38.11%          | 46.56%     | +8.45+                  | ****               |
| Asthma Medication Ratio                       |            |                 |            |                         |                    |
| Total   | 64.55%     | 58.44%          | 59.92%     | +1.48                   | **                 |
| Controlling High Blood Pre                    | essure     |                 |            | <u> </u>                | #                  |
| Controlling High Blood<br>Pressure            | 63.99%     | 71.05%          | 72.75%     | +1.70                   | ****               |
| Medical Assistance With Sm                    | noking and | Tobacco Use     | Cessation  |                         |                    |
| Advising Smokers and<br>Tobacco Users to Quit | 79.43%     | 79.18%          | 77.95%     | -1.23                   | ***                |
| Discussing Cessation<br>Medications           | 55.95%     | 56.90%          | 56.82%     | -0.08                   | ****               |
| Discussing Cessation<br>Strategies            | 45.39%     | 45.57%          | 46.65%     | +1.08                   | ***                |
| Antidepressant Medication                     | Manageme   | nt <sup>3</sup> |            |                         |                    |
| Effective Acute Phase<br>Treatment            | 61.13%     | 59.86%          | 59.84%     | -0.02                   | ****               |

| Measure   | HEDIS<br>2016  | HEDIS 2017     | HEDIS 2018     | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |  |  |  |  |
|---|--|----------------|----------------|--------------------------------------|--|--|--|--|--|
| Effective Continuation<br>Phase Treatment   | 40.34%   | 42.69%         | 41.41%         | -1.28                                | ****                                   |  |  |  |  |
| Diabetes Screening for Peop<br>Using Antipsychotic Medica   | Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are |                |                |                                      |  |  |  |  |  |
| Diabetes Screening for<br>People With<br>Schizophrenia or Bipolar<br>Disorder Who Are Using<br>Antipsychotic<br>Medications | 87.20%   | 88.18%         | 87.97%         | -0.21                                | ****                                   |  |  |  |  |
| Diabetes Monitoring for Pe  | ople With I  | Diabetes and S | Schizophrenia  | п                                    |  |  |  |  |  |
| Diabetes Monitoring for<br>People With Diabetes<br>and Schizophrenia  | NA   | NA             | NA             | NC                                   | NC                                     |  |  |  |  |
| Cardiovascular Monitoring<br>Schizophrenia  | for People   | With Cardiov   | ascular Disea  | se and                               | <u> </u>                               |  |  |  |  |
| Cardiovascular<br>Monitoring for People<br>With Cardiovascular<br>Disease and<br>Schizophrenia                              | NA   | NA             | NA             | NC                                   | NC                                     |  |  |  |  |
| Adherence to Antipsychotic  | Medicatio  | ns for Individ | uals With Schi | zophrenia                            |  |  |  |  |  |
| Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia                                       | 60.22%   | 82.18%         | 82.24%         | +0.06                                | ****                                   |  |  |  |  |
| Annual Monitoring for Pat   | ients on Pe  | rsistent Medic | cations        |                                      |  |  |  |  |  |
| ACE Inhibitors or ARBs  | 87.49%   | 87.60%         | 87.50%         | -0.10                                | **                                     |  |  |  |  |
| Diuretics   | 89.29%   | 88.64%         | 87.53%         | -1.11                                | **                                     |  |  |  |  |
| $Total^4$   | —  |                | 87.51%         | NC                                   | NC                                     |  |  |  |  |
| Health Plan Diversity <sup>5</sup>  |  |                |                |                                      |  |  |  |  |  |
| Race/Ethnicity Diversity of   | Membersh   | ip             |                |                                      |  |  |  |  |  |
| Total—White   | 87.07%   | 87.04%         | 87.26%         | +0.22                                | NC                                     |  |  |  |  |
| Total—Black or African<br>American  | 1.41%  | 1.46%          | 1.54%          | +0.08                                | NC                                     |  |  |  |  |
| Total—American-Indian<br>and Alaska Native  | 2.53%  | 2.41%          | 2.30%          | -0.11                                | NC                                     |  |  |  |  |
| Total—Asian   | 0.28%  | 0.26%          | 0.24%          | -0.02                                | NC                                     |  |  |  |  |



| Measure   | HEDIS<br>2016 | HEDIS 2017 | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
|---|---------------|------------|------------|--------------------------------------|--|
| Total—Native Hawaiian<br>and Other Pacific<br>Islander      | 0.06%         | 0.05%      | 0.05%      | 0.00                                 | NC                                     |
| Total—Some Other Race                                       | 1.39%         | 1.49%      | 1.64%      | +0.15                                | NC                                     |
| Total—Two or More<br>Races                                  | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Unknown   | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Total—Declined  | 7.25%         | 7.30%      | 6.96%      | -0.34                                | NC                                     |
| Total—Hispanic or<br>Latino                                 | 1.39%         | 1.49%      | 1.64%      | +0.15                                | NC                                     |
| Language Diversity of Mem                                   | bership       |            |            |                                      |  |
| Spoken Language<br>Preferred for Health<br>Care—English     | 99.93%        | 99.94%     | 99.95%     | +0.01                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Non-English | 0.04%         | 0.03%      | 0.03%      | 0.00                                 | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Unknown     | 0.03%         | 0.03%      | 0.02%      | -0.01                                | NC                                     |
| Spoken Language<br>Preferred for Health<br>Care—Declined    | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>English     | 99.93%        | 99.94%     | 99.95%     | +0.01                                | NC                                     |
| Preferred Language for<br>Written Materials—Non-<br>English | 0.04%         | 0.03%      | 0.03%      | 0.00                                 | NC                                     |
| Preferred Language for<br>Written Materials—<br>Unknown     | 0.03%         | 0.03%      | 0.02%      | -0.01                                | NC                                     |
| Preferred Language for<br>Written Materials—<br>Declined    | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>English                            | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>Non-English                        | 0.00%         | 0.00%      | 0.00%      | 0.00                                 | NC                                     |
| Other Language Needs—<br>Unknown                            | 100.00%       | 100.00%    | 100.00%    | 0.00                                 | NC                                     |

|   | Table b       | 11—UPP II      | end rable  |                                      |  |
|---|---------------|----------------|------------|--------------------------------------|--|
| Measure   | HEDIS<br>2016 | HEDIS 2017     | HEDIS 2018 | 2017–2018<br>Comparison <sup>1</sup> | 2018 Performance<br>Level <sup>2</sup> |
| Other Language Needs—<br>Declined   | 0.00%         | 0.00%          | 0.00%      | 0.00                                 | NC                                     |
| Utilization <sup>5</sup>  |               |                |            |                                      |  |
| Ambulatory Care—Total (P  | er 1,000 M    | ember Month    | es)        |                                      |  |
| ED Visits—Total*  | 64.81         | 66.21          | 61.07      | -5.14                                | ***                                    |
| Outpatient Visits—Total   | 334.91        | 341.01         | 339.03     | -1.98                                | NC                                     |
| Inpatient Utilization—Gene  | ral Hospita   | al/Acute Care  | —Total     |                                      |  |
| Total Inpatient—<br>Discharges per 1,000<br>Member Months—Total                               | 6.34          | 6.54           | 6.26       | -0.28                                | NC                                     |
| Total Inpatient—Average<br>Length of Stay—Total   | 3.60          | 3.79           | 3.98       | +0.19                                | NC                                     |
| Maternity—Discharges<br>per 1,000 Member<br>Months—Total                                      | 2.05          | 2.61           | 2.42       | -0.19                                | NC                                     |
| Maternity—Average<br>Length of Stay—Total   | 2.72          | 2.80           | 2.77       | -0.03                                | NC                                     |
| Surgery—Discharges per<br>1,000 Member Months—<br>Total                                       | 1.63          | 1.95           | 1.81       | -0.14                                | NC                                     |
| Surgery—Average Length<br>of Stay—Total   | 4.69          | 5.42           | 5.67       | +0.25                                | NC                                     |
| Medicine—Discharges<br>per 1,000 Member<br>Months—Total                                       | 3.20          | 2.66           | 2.65       | -0.01                                | NC                                     |
| Medicine—Average<br>Length of Stay—Total  | 3.46          | 3.32           | 3.66       | +0.34                                | NC                                     |
| Use of Opioids From Multi   | ple Provide   | ers (Per 1,000 | Members)*  |                                      |  |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers                            | _             |                | 237.61     | NC                                   | NC                                     |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Pharmacies                             |               |                | 92.79      | NC                                   | NC                                     |
| Use of Opioids From<br>Multiple Providers—<br>Multiple Prescribers<br>and Multiple Pharmacies | _             |                | 65.73      | NC                                   | NC                                     |





| Measure                          | HEDIS<br>2016 | HEDIS 2017  | HEDIS 2018 |    | 2018 Performance<br>Level <sup>2</sup> |
|----------------------------------|---------------|-------------|------------|----|--|
| Use of Opioids at High Dos       | age (Per 1,   | 000 Members | *)*        |    |  |
| Use of Opioids at High<br>Dosage |               | —           | 30.99      | NC | NC                                     |

<sup>1</sup> HEDIS 2017 to HEDIS 2018 comparisons were based on a Chi-square test of statistical significance with a p value of <0.05. 2017–2018 Comparisons shaded green with one cross (+) indicate statistically significant improvement from the previous year. 2017–2018 Comparisons shaded red with two crosses (++) indicate a statistically significant decline in performance from the previous year.

<sup>2</sup> 2018 Performance Levels were based on comparisons of the HEDIS 2018 measure indicator rates to national Medicaid Quality Compass HEDIS 2017 benchmarks, with the exception of the Medications Management for People With Asthma—Medication Compliance 50%—Total measure indicator rate, which was compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmark.

<sup>3</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when trending rates between 2018 and prior years.

<sup>4</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, NCQA does not recommend trending between 2018 and prior years; therefore, prior year rates are not displayed and comparisons to benchmarks are not performed for this measure.

<sup>5</sup> Significance testing was not performed for utilization-based or health plan description measure indicator rates and any Performance Levels for 2018 or 2017–2018 Comparisons provided for these measures are for information purposes only.

\* For this indicator, a lower rate indicates better performance.

— indicates that the rate is not presented in this report as the measure is a first-year measure; therefore, no trending information is available. This symbol may also indicate that NCQA recommended a break in trending; therefore, no prior year rates are displayed.

*NC* indicates that a comparison is not appropriate or the measure did not have an applicable benchmark. *NA* indicates that the MHP followed the specifications, but the denominator was too small (<30) to report a valid rate.

2018 Performance Levels represent the following percentile comparisons:

 $\star \star \star \star \star = 90$ th percentile and above

 $\star \star \star \star = 75$ th to 89th percentile

 $\star \star \star = 50$ th to 74th percentile

 $\star$  = 25th to 49th percentile

 $\star$  = Below 25th percentile



## **Appendix C. Performance Summary Stars**

# Introduction

This section presents the MHPs' performance summary stars for each measure within the following measure domains:

- Child & Adolescent Care
- Women—Adult Care
- Access to Care
- Obesity
- Pregnancy Care
- Living With Illness
- Utilization

Performance ratings were assigned by comparing the MHPs' HEDIS 2018 rates to the HEDIS 2017 Quality Compass national Medicaid benchmarks (from **\*** representing *Poor Performance* to **\*\*\*\*\*\*** representing *Excellent Performance*). Please note, HSAG assigned performance ratings to only one measure in the Utilization measure domain, *Ambulatory Care—Total (Per 1,000 Member Months)— Emergency Department Visits*. Measures in the Health Plan Diversity domain and the remaining utilization-based measure rates were not evaluated based on comparisons to national benchmarks; however, rates for these measure indicators are presented in Appendices A and B. Due to changes in the technical specifications for *Breast Cancer Screening* and *Annual Monitoring for Patients on Persistent Medications—Total* in HEDIS 2018, NCQA does not recommend comparing these measures' rates to national Medicaid benchmarks; therefore, these measures are not displayed in this appendix. Additional details about the performance comparisons and star ratings are found in Section 2.



# **Child & Adolescent Care Performance Summary Stars**

| МНР | Childhood<br>Immunization<br>Status—<br>Combination 2 | Childhood<br>Immunization<br>Status—<br>Combination 3 | Childhood<br>Immunization<br>Status—<br>Combination 4 | Childhood<br>Immunization<br>Status—<br>Combination 5 | Childhood<br>Immunization<br>Status—<br>Combination 6 | Childhood<br>Immunization<br>Status—<br>Combination 7 |
|-----|---|---|---|---|---|---|
| AET | *   | *   | *   | *   | *   | *   |
| BCC | **  | ***   | ***   | ***   | ***   | ***   |
| HAR | *   | *   | *   | *   | *   | *   |
| MCL | **  | **  | **  | ***   | **  | ***   |
| MER | ***   | ***   | ***   | ***   | ***   | ****  |
| MID | NA  | NA  | NA  | NA  | NA  | NA  |
| MOL | ***   | ***   | ***   | ***   | **  | ***   |
| PRI | ****  | ****  | ****  | ****  | ****  | ****  |
| THC | **  | **  | **  | *   | **  | **  |
| UNI | ***   | **  | ***   | ***   | **  | ***   |
| UPP | **  | **  | **  | **  | ****  | **  |

## Table C-1—Child & Adolescent Care Performance Summary Stars (Table 1 of 3)

NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.



| МНР | Childhood<br>Immunization<br>Status—<br>Combination 8 | Childhood<br>Immunization<br>Status—<br>Combination 9 | Childhood<br>Immunization<br>Status—<br>Combination 10 | Well-Child Visits in<br>the First 15 Months<br>of Life—Six or More<br>Visits | Lead Screening<br>in Children | Well-Child Visits in<br>the Third, Fourth,<br>Fifth, and Sixth Years<br>of Life |
|-----|---|---|--|--|-------------------------------|---|
| AET | *   | *   | *  | *  | ***                           | **  |
| BCC | ***   | ***   | ***  | ***  | ***                           | **  |
| HAR | *   | *   | *  | *  | ***                           | *   |
| MCL | **  | **  | **   | ****   | ****                          | **  |
| MER | ***   | ***   | ***  | ****   | ****                          | ****  |
| MID | NA  | NA  | NA   | NA   | NA                            | *   |
| MOL | **  | **  | **   | ****   | ***                           | ***   |
| PRI | ****  | ****  | ****   | ****   | ****                          | ***   |
| THC | **  | **  | **   | ****   | **                            | ***   |
| UNI | **  | ***   | ***  | ***  | ****                          | ***   |
| UPP | ****  | ****  | ****   | ****   | ****                          | ***   |

## Table C-2—Child & Adolescent Care Performance Summary Stars (Table 2 of 3)

NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.



| МНР | Adolescent Well-Care<br>Visits | Immunizations for<br>Adolescents—<br>Combination 1<br>(Meningococcal,<br>Tdap) | Appropriate<br>Treatment for<br>Children With Upper<br>Respiratory Infection | Appropriate Testing<br>for Children With<br>Pharyngitis | Follow-Up Care for<br>Children Prescribed<br>ADHD Medication—<br>Initiation Phase <sup>1</sup> | Follow-Up Care for<br>Children Prescribed<br>ADHD Medication—<br>Continuation and<br>Maintenance Phase <sup>1</sup> |
|-----|--------------------------------|--|--|---|--|---|
| AET | ***                            | ***  | ***  | **  | *  | *   |
| BCC | ***                            | ****   | **   | ***   | ***  | ***   |
| HAR | *                              | **   | ****   | **  | NA   | NA  |
| MCL | **                             | ****   | *  | ****  | ***  | ***   |
| MER | ****                           | ***  | **   | ***   | **   | *   |
| MID | *                              | NA   | *  | NA  | NA   | NA  |
| MOL | ***                            | ****   | **   | **  | ***  | ***   |
| PRI | ****                           | ****   | ****   | ****  | *  | *   |
| THC | ***                            | ****   | ***  | **  | ****   | ****  |
| UNI | ****                           | ****   | ***  | ***   | **   | ***   |
| UPP | **                             | ***  | ****   | ***   | ***  | **  |

## Table C-3—Child & Adolescent Care Performance Summary Stars (Table 3 of 3)

*NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.* 

<sup>1</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when comparing rates between 2018 and prior years.



# Women—Adult Care Performance Summary Stars

| МНР | Cervical Cancer<br>Screening | Chlamydia Screening<br>in Women—Ages 16<br>to 20 Years | Chlamydia Screening<br>in Women—Ages 21<br>to 24 Years | Chlamydia Screening<br>in Women—Total |
|-----|------------------------------|--|--|---------------------------------------|
| AET | ***                          | ****   | ****   | ****                                  |
| BCC | ***                          | ****   | ***  | ****                                  |
| HAR | *                            | ****   | ****   | ****                                  |
| MCL | ***                          | ***  | **   | ***                                   |
| MER | ***                          | ****   | ***  | ****                                  |
| MID | **                           | NA   | *  | ***                                   |
| MOL | ****                         | ****   | ****   | ****                                  |
| PRI | ****                         | ****   | ***  | ****                                  |
| THC | ***                          | ****   | ****   | ****                                  |
| UNI | ****                         | ****   | ****   | ****                                  |
| UPP | ***                          | *  | **   | **                                    |

## Table C-4—Women—Adult Care Performance Summary Stars

NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.



# Access to Care Performance Summary Stars

| мнр | Children and<br>Adolescents' Access<br>to Primary Care<br>Practitioners—<br>Ages 12 to 24<br>Months | Children and<br>Adolescents' Access<br>to Primary Care<br>Practitioners—<br>Ages 25 Months<br>to 6 Years | Children and<br>Adolescents' Access<br>to Primary Care<br>Practitioners—<br>Ages 7 to 11 Years | Children and<br>Adolescents' Access<br>to Primary Care<br>Practitioners—<br>Ages 12 to 19 Years | Adults' Access to<br>Preventive⁄<br>Ambulatory Health<br>Services—Ages 20<br>to 44 Years | Adults' Access to<br>Preventive⁄<br>Ambulatory Health<br>Services—Ages 45<br>to 64 Years |
|-----|---|--|--|---|--|--|
| AET | *   | *  | *  | *   | *  | *  |
| BCC | **  | *  | **   | **  | **   | **   |
| HAR | *   | *  | *  | *   | *  | *  |
| MCL | *   | *  | **   | **  | **   | ***  |
| MER | ***   | ***  | ***  | ***   | ***  | ***  |
| MID | *   | *  | *  | *   | *  | ****   |
| MOL | **  | ***  | ***  | ***   | ***  | ***  |
| PRI | ***   | **   | **   | ***   | ***  | ****   |
| THC | *   | *  | **   | **  | **   | **   |
| UNI | **  | ***  | ***  | ***   | **   | ***  |
| UPP | ****  | ***  | ***  | ***   | ***  | ***  |

## Table C-5—Access to Care Performance Summary Stars (Table 1 of 2)



| МНР | Adults' Access to<br>Preventive⁄<br>Ambulatory Health<br>Services—Ages 65<br>Years and Older | Adults' Access to<br>Preventive⁄<br>Ambulatory Health<br>Services—Total | Avoidance of<br>Antibiotic Treatment<br>in Adults With Acute<br>Bronchitis |
|-----|--|---|--|
| AET | **   | *   | ****   |
| BCC | **   | **  | ***  |
| HAR | NA   | *   | ***  |
| MCL | **   | ***   | ***  |
| MER | ****   | ***   | ***  |
| MID | ***  | ***   | ****   |
| MOL | ****   | ***   | ***  |
| PRI | ****   | ***   | ****   |
| THC | *  | **  | ***  |
| UNI | ****   | ***   | ***  |
| UPP | NA   | ***   | **   |

## Table C-6—Access to Care Performance Summary Stars (Table 2 of 2)

NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.



# **Obesity Performance Summary Stars**

| МНР | Weight Assessment<br>and Counseling for<br>Nutrition and<br>Physical Activity for<br>Children/<br>Adolescents—<br>BMI Percentile<br>Documentation—<br>Total | Weight Assessment<br>and Counseling for<br>Nutrition and<br>Physical Activity for<br>Children/<br>Adolescents—<br>Counseling for<br>Nutrition—Total | Weight Assessment<br>and Counseling for<br>Nutrition and<br>Physical Activity for<br>Children/<br>Adolescents—<br>Counseling for<br>Physical Activity—<br>Total | Adult BMI<br>Assessment |
|-----|---|---|---|-------------------------|
| AET | ****  | ***   | ***   | ****                    |
| BCC | ****  | ***   | ***   | ****                    |
| HAR | **  | **  | *   | *                       |
| MCL | ****  | **  | **  | ****                    |
| MER | ****  | ***   | ***   | ****                    |
| MID | ***   | **  | **  | ****                    |
| MOL | ****  | ****  | ****  | ****                    |
| PRI | ****  | ****  | ****  | ****                    |
| THC | ***   | ***   | **  | **                      |
| UNI | ****  | ****  | ****  | ****                    |
| UPP | ****  | ***   | ****  | ****                    |

### Table C-7—Obesity Performance Summary Stars



# **Pregnancy Care Performance Summary Stars**

| МНР | Prenatal and<br>Postpartum Care—<br>Timeliness of<br>Prenatal Care | Prenatal and<br>Postpartum Care—<br>Postpartum Care |
|-----|--|---|
| AET | *  | *   |
| BCC | *  | **  |
| HAR | *  | *   |
| MCL | **   | ***   |
| MER | ***  | ***   |
| MID | *  | *   |
| MOL | *  | ****  |
| PRI | **   | ****  |
| THC | *  | *   |
| UNI | **   | ***   |
| UPP | ****   | ****  |

## Table C-8—Pregnancy Care Performance Summary Stars



# Living With Illness Performance Summary Stars

| МНР | Comprehensive<br>Diabetes Care—<br>Hemoglobin A1c<br>(HbA1c) Testing | Comprehensive<br>Diabetes Care—<br>HbA1c Poor Control<br>(>9.0%)* | Comprehensive<br>Diabetes Care—<br>HbA1c Control<br>(<8.0%) | Comprehensive<br>Diabetes Care—<br>Eye Exam (Retinal)<br>Performed | Comprehensive<br>Diabetes Care—<br>Medical Attention<br>for Nephropathy | Comprehensive<br>Diabetes Care—<br>Blood Pressure<br>Control (<140/90mm<br>Hg) |
|-----|--|---|---|--|---|--|
| AET | *  | **  | **  | **   | ***   | *  |
| BCC | **   | **  | **  | ***  | ***   | ***  |
| HAR | *  | *   | *   | *  | *   | *  |
| MCL | ****   | **  | **  | ****   | **  | ****   |
| MER | ***  | ***   | ***   | ****   | ***   | ***  |
| MID | **   | ***   | ***   | ***  | ****  | **   |
| MOL | ****   | ****  | ****  | ***  | ****  | *  |
| PRI | ****   | ****  | ****  | ****   | ****  | ****   |
| THC | *  | *   | *   | **   | **  | *  |
| UNI | ***  | ****  | ****  | ****   | ****  | ***  |
| UPP | ****   | ****  | ****  | ****   | ***   | ****   |

## Table C-9—Living With Illness Performance Summary Stars (Table 1 of 4)

\* A lower rate indicates better performance for this measure indicator.



| МНР | Medication<br>Management for<br>People With<br>Asthma—<br>Medication<br>Compliance 50%—<br>Total <sup>1</sup> | Medication<br>Management for<br>People With<br>Asthma—<br>Medication<br>Compliance 75%—<br>Total | Asthma Medication<br>Ratio—Total | Controlling High<br>Blood Pressure | Medical Assistance<br>With Smoking and<br>Tobacco Use<br>Cessation—<br>Advising Smokers<br>and Tobacco Users to<br>Quit | Medical Assistance<br>With Smoking and<br>Tobacco Use<br>Cessation—<br>Discussing Cessation<br>Medications |
|-----|---|--|----------------------------------|------------------------------------|---|--|
| AET | **  | **   | **                               | **                                 | ****  | ****   |
| BCC | ****  | ****   | **                               | *                                  | ***   | ***  |
| HAR | ****  | ***  | **                               | *                                  | ****  | ****   |
| MCL | ****  | ****   | ***                              | ***                                | **  | ***  |
| MER | ****  | ****   | **                               | ****                               | ****  | ***  |
| MID | ****  | ****   | *                                | **                                 | ****  | ****   |
| MOL | ***   | ***  | ***                              | **                                 | ****  | ****   |
| PRI | ****  | ****   | ****                             | ****                               | ****  | ****   |
| THC | ****  | ****   | *                                | *                                  | ***   | ****   |
| UNI | ****  | ****   | ***                              | ***                                | ****  | ****   |
| UPP | ****  | ****   | **                               | ****                               | ***   | ****   |

## Table C-10—Living With Illness Performance Summary Stars (Table 2 of 4)

<sup>1</sup> Indicates the HEDIS 2018 rates for this measure indicator were compared to the national Medicaid NCQA Audit Means and Percentiles HEDIS 2017 benchmarks.



| мнр | Medical Assistance<br>With Smoking and<br>Tobacco Use<br>Cessation—<br>Discussing Cessation<br>Strategies | Antidepressant<br>Medication<br>Management—<br>Effective Acute<br>Phase Treatment <sup>1</sup> | Antidepressant<br>Medication<br>Management—<br>Effective<br>Continuation Phase<br>Treatment <sup>1</sup> | Diabetes Screening<br>for People With<br>Schizophrenia or<br>Bipolar Disorder<br>Who Are Using<br>Antipsychotic<br>Medications | Diabetes Monitoring<br>for People With<br>Diabetes and<br>Schizophrenia | Cardiovascular<br>Monitoring for<br>People With<br>Cardiovascular<br>Disease and<br>Schizophrenia |
|-----|---|--|--|--|---|---|
| AET | ****  | *  | **   | ****   | *   | NA  |
| BCC | ***   | ****   | ****   | ***  | *   | **  |
| HAR | ****  | ****   | ****   | ***  | NA  | NA  |
| MCL | ***   | ****   | ***  | ***  | ****  | NA  |
| MER | ***   | ***  | **   | ****   | ***   | **  |
| MID | ***   | ***  | **   | *  | ***   | NA  |
| MOL | ***   | ***  | ***  | ****   | ***   | **  |
| PRI | ***   | ****   | ****   | ****   | *   | NA  |
| THC | ***   | ****   | ****   | ***  | *   | NA  |
| UNI | ****  | ****   | ****   | ****   | ***   | **  |
| UPP | ***   | ****   | ****   | ****   | NA  | NA  |

## Table C-11—Living With Illness Performance Summary Stars (Table 3 of 4)

*NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.* 

<sup>1</sup> Due to changes in the technical specifications for this measure in HEDIS 2018, exercise caution when comparing rates between 2018 and prior years.



| МНР | Adherence to<br>Antipsychotic<br>Medications for<br>Individuals With<br>Schizophrenia | Annual Monitoring<br>for Patients on<br>Persistent<br>Medications—<br>ACE Inhibitors or<br>ARBs | Annual Monitoring<br>for Patients on<br>Persistent<br>Medications—<br>Diuretics |
|-----|---|---|---|
| AET | *   | **  | **  |
| BCC | **  | **  | **  |
| HAR | NA  | *   | *   |
| MCL | ****  | *   | **  |
| MER | ****  | *   | *   |
| MID | ****  | *   | **  |
| MOL | ***   | ***   | ***   |
| PRI | ***   | ***   | **  |
| THC | *   | **  | **  |
| UNI | **  | ***   | ***   |
| UPP | ****  | **  | **  |

## Table C-12—Living With Illness Performance Summary Stars (Table 4 of 4)

NA indicates that the MHP followed the specifications but the denominator was too small (<30) to report a valid rate.



# **Utilization Performance Summary Stars**

| МНР | Ambulatory Care—Total<br>(Per 1,000 Member Months)—<br>Emergency Department<br>Visits—Total* |  |
|-----|--|--|
| AET | *  |  |
| BCC | **   |  |
| HAR | **   |  |
| MCL | *  |  |
| MER | *  |  |
| MID | **   |  |
| MOL | **   |  |
| PRI | **   |  |
| THC | **   |  |
| UNI | **   |  |
| UPP | ***  |  |

### Table C-13—Utilization Performance Summary Stars

\* A lower rate may indicate more favorable performance for this measure indicator (i.e., low rates of emergency department services may indicate better utilization of services). Therefore, Quality Compass percentiles were reversed to align with performance (e.g., the 10th percentile [a lower rate] was inverted to become the 90th percentile, indicating better performance).